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CHILDREN AND GENETIC RESEARCH ON STORED 
TISSUE SAMPLES. AN INTRODUCTION 
In history, children have long been seen as second-rate citizens, both in 
society in general as well as in medical research specifically. As they 
were often considered expendable, they were used as cheap labor 
forces and preferred research subjects, without much consideration for 
potentially negative outcomes. This has been changed during the last 
century. Clinical research on children has been the subject of ethical 
reflections which resulted in guidelines trying to define a balance 
between participation in research and protection against abuse.  
Recently there has been a rise in genetic research in general. Such 
research is supported by the availability of tissue collections, often 
referred to as biobanks. These were even quoted as number eight in 
the 10 ideas that changed the world list of the Time Magazine1. The 
establishment of such biobanks has given rise to certain ethical issues, 
which have been discussed in some depth in the ethical literature.  
Also research on stored tissue samples from children can yield valuable 
information. This raises specific ethical issues which are not completely 
analogous to the issues raised by the use of adult biological materials. 
Although much has been written about both the ethical issues related to 
pediatric clinical trials and those related to adult biobanks, much less 
has been written about the ethical issues related to pediatric biobanks, 
at the inception of this doctoral project. With this collection of papers we 
try to fill that void. 
 
In this chapter we shall first give an overview of existing thoughts on 
children in philosophy and ethics in general and children in medical 
research specifically. Then we shall describe the issues related to 
research on tissue samples from adults, as they appear in literature. 
Finally we shall describe the specific issues relating to research on 
stored tissue samples from children, and describe the rationale and 
outline of the doctoral thesis. 
                                               
 
 
 
 
 
 
1
 
http://205.188.238.181/time/specials/packages/article/0,28804,1884779_1884782_1884766,0
0.html 
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CHILDREN, ETHICS AND RESEARCH 
Children and Ethics  
In the last century the status of children has significantly changed. From 
second rate citizens, cheap and expendable work forces, children have 
now acquired specific rights. This culminated in the Convention on the 
Rights of the Child(1). This is a legally binding document containing 
principles founded on respect for the dignity and worth of each 
individual, regardless of race, color, gender, language, religion, 
opinions, origins, wealth, birth status or ability. It has as an aim to 
protect of children, to help meet their basic needs and to expand their 
opportunities to reach their full potential. 
Also, general philosophy and childhood did not go well together for quite 
some time. Philosophical works on children are still hard to find, and 
those that do exist either deal with techniques to do philosophy with 
children or the ideal way to raise children. However, the tide is 
changing. For example, Gareth Matthews investigates in The 
Philosophy of Childhood current ideas about childhood(2). Childhood is 
most often seen as a maturational process. And this ‘maturing’ takes 
place along identifiable stages. Seminal thinkers in this respect are 
Piaget(3) who described the psychological stages towards maturity and 
Kohlberg(4) who wrote about children’s moral development. Matthews 
argues that this is only one aspect of childhood. He takes examples 
from philosophical discussions he had with children and of children’s 
arts to demonstrate that children do not completely live in a prerational 
world or that they are amoral agents. Although they seem to live in a 
different ‘world’ from adults, this does not mean that this world is less 
valuable than adults’ or that the value of childhood only lies in what a 
child is yet to become. Children are persons; as such they deserve our 
respect. We should respect them not only for what they will become but 
also for what they are now. Not only should we consider children as 
soon-to-be adults but we should also take into account their current 
views and opinions, although these could change overtime.  
Children and Ethical Philosophy 
But also ethical philosophy and children have long been not ideal 
matches. Many ethical theories are based on a practical concept of 
personhood which is based on specific characteristics of human beings 
as moral agents. This is especially true for many biomedical ethical 
thoughts, in which autonomy is a key concept. And although one can 
appeal to a child’s sense of morals, as Matthews has argued, we feel 
that this is not completely analogous with how we would appeal to an 
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adult’s morality. A more metaphysical concept of personhood is based 
on the symbolic value of human beings, no matter what their capacity is. 
We feel that respect is due to less conscious persons, such as persons 
suffering from Alzheimer or persons in a coma and even to dead human 
bodies(5). This is the area of mercy rather than ethics in strict sense. But 
children do not easily fit in either of these two categories of personhood. 
On the one hand, in so far as they are moral agents, conventional ethics 
applies to them. But their moral sense and rationality is different from 
that of adults: as such, the metaphysical aspect of their personhood 
comes into play. Just as with the above quoted examples, we may owe 
them more respect, consideration and protection than adults. On the 
other hand, they are gradually developing into autonomous beings and 
learning to be autonomous beings and should be respected in this 
respect as well. 
Children and Their Parents 
Although some thinkers, notably Plato in The Republic(6), have stated 
that children should be brought up by the state, this is not a thought that 
is pursued frequently these days. Indeed, the Convention on the Rights 
of the Child clearly states that “Convinced that the family, as the 
fundamental group of society and the natural environment for the 
growth and well-being of all its members and particularly children, 
should be afforded the necessary protection and assistance so that it 
can fully assume its responsibilities within the community”(1) But the 
question which rights and duties parents have towards their children 
remains an interesting one. Whereas respect for an adult person is 
often framed in terms of his or her autonomy, with regard to children, 
this seems to be replaced by the ‘best interest’ doctrine. The autonomy 
of a child can be restricted if it is in his or her best interest(2). Still there is 
a tension between protection of the child and allowing her to develop 
her own autonomy. Indeed, as Jeffrey Blustein argues, parents have a 
duty to respect a child’s own desires and wants in matters that are not 
critical to protecting the child’s interest, and if they are not likely to 
impede the child’s development or harm others(7). If these three criteria 
are fulfilled, children should be given a kind of free playground to be 
able to develop autonomy. Still, this leaves open the question whether 
and to which degree parents can impose their own set of values on 
children. David Archard in this respect first mentions an approach of 
self-determination, where children should be brought up towards 
autonomous adults, constantly revising their own concept of the good 
life, and be given the knowledge of a manifold of choices that he or she 
may take later in life(8). The other option is that adults can and should 
choose paternalistically for their children, and bring them up with sets of 
believes the parents hold. There is indeed a balance to be found 
between sticking to parental values and allowing a child a great 
autonomy and between realizing a child’s particular nature and 
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safeguarding her open future(9). Particularly in our context, where we 
talk about research on tissue samples that can be stored over decades, 
this is a difficult exercise, but one that needs to be done.  
Children and Third Parties 
Next to the specific rights parents have regarding their children and the 
way they should educate them towards autonomy, there is the question 
when a third party can intervene to protect the child’s best interest. 
Typically, the third party is the state. However, this can be generalized 
towards any third party with a certain responsibility, such as medical 
personnel or policy makers with regard to research databases. On the 
one hand, Blustein acknowledges that family life offers necessary 
intimacy and diversity, but he is also pro greater collective assumption 
of responsibility. Along the same lines Archard believes in ‘a modest 
collectivism’. Although he also would not wish to abandon family life in 
favor of a state upbringing, he believes that state intervention and the 
need for just institutions that support child raising is justifiable. To 
illustrate an example of this thinking, recently some countries have 
issued laws against physical punishment of children, also by their 
parents. On the other hand, some, such as Lainie Friedmann-Ross(10), 
have advocated that parents should be left alone in their decisions, 
unless these decisions have grave consequences. As an example, 
Ross has argued that parents have the right to home educate children if 
they do not agree with sexual education in school or that they should be 
made aware by the respective GP of their children’s use of 
contraceptives. But even the best parents need and ask for third party 
reassurance and advice. It is important that parents raise their children 
with their own set of values. It is equally important that they are helped 
to make the right decisions even when these are sometimes counter to 
the wishes of the parents. We believe that educating children is not and 
never has been an entirely private matter. Various instances, such as 
the state and medical authorities and policy makers can help making 
the right decisions, although a parent’s values should also be 
respected. 
Children in Medical Research 
The history of children as medical research subjects has been 
characterized by malpractices, with little respect for understanding 
children’s rights and concerns. Lederer and Grodin describe the use of 
children as research subjects until the mid twentieth-century as largely 
one of child abuse: researchers would experiment with new vaccines on 
their own children, and especially institutionalized children were enrolled 
in sometimes questionable research projects(11). The atrocities of Nazi 
experimentation, which often involved research on children as well, are 
well-known. As a reaction to these aberrations, the Nuremberg Code(12) 
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laid down a series of research principles that stated that persons 
involved in medical research should have legal capacity to consent, 
thus effectively ruling out research on children. However, a complete 
ban on the use of children in research seems unacceptable as well. In 
this context the term therapeutic orphans was framed: not allowing 
children to participate in research because of a strict adherence to the 
informed consent doctrine would lead to the fact that children miss out 
certain therapies. Such therapies might only be tested on adults, or 
children might be prescribed drugs that are never tested on them(13,14,15). 
The Declaration of Helsinki(16), which was issued by the World Medical 
Association in 1964 and subsequently revised, therefore allows 
research on children, and formulates the conditions under which such 
research can be allowed. In its current revision (2008) the Declaration 
states that: 
When a potential research subject who is deemed 
incompetent is able to give assent to decisions about 
participation in research, the physician must seek that 
assent in addition to the consent of the legally 
authorized representative. The potential subject's 
dissent should be respected. 
And  
Research involving subjects who are physically or 
mentally incapable of giving consent, for example, 
unconscious patients, may be done only if the physical 
or mental condition that prevents giving informed 
consent is a necessary characteristic of the research 
population. 
Hence, the Declaration allows for specific types of research to be 
performed using vulnerable subjects such as minors. Similar principles 
are described in the CIOMS guidelines on biomedical research(17): 
before undertaking research involving children, the 
investigator must ensure that: the research might not 
equally well be carried out with adults; the purpose of 
the research is to obtain knowledge relevant to the 
health needs of children; a parent or legal 
representative of each child has given permission; the 
agreement (assent) of each child has been obtained to 
the extent of the child’s capabilities; and, a child’s 
refusal to participate or continue in the research will be 
respected. 
The Ramsey and McCormick Debate 
The debate between theologians Paul Ramsey and Richard McCormick 
in the seventies is exemplary of the different stances regarding children 
and non-therapeutic research. Ramsey thought children were 
vulnerable subjects because of their limited autonomy. Therefore they 
are in need for the utmost protection, should not be subjected to any 
risk, and therefore should not be used for research unless it has some 
Introduction 
12/233 
direct benefit for them (18). McCormick, however, thought that children 
are members of society, and growing towards more autonomy. 
Therefore, parents are allowed to make the decision to enroll them in 
non-therapeutic research, as a means to show their solidarity and to 
educate them to moral responsibility(19). Nowadays, most ethical 
literature on children in medical research seems to acknowledge that at 
least some non-therapeutic research that involves children’s 
participation is allowed, but that they are subjects in need of extra 
protection. Brown uses the principle of future independence: parents 
can consent to research on their children if the future independence of 
these children is not impaired (20). Other authors refer to the concept of 
minimal risk to set some standard on the type of non-therapeutic 
research that can be performed with children(21,22,13). This concept, 
together with its twin minimal burden, is also used in legal 
frameworks(23). In this respect, minimal risk is understood as no higher 
risk than encountered in everyday life. For children, this would include 
pain, blood taking and psychological risks such as separation from their 
parents. This risk is then measured against the direct benefits: if a 
participant receives much benefit from the procedure the risk that he or 
she is allowed to endure may be higher(24). Indeed, another concept 
frequently used, especially in the context of pediatric clinical trials, is 
that of benefit. For example, in the European legal frameworks for 
pediatric clinical trials, it is stated that research on minors can be done if 
there is a necessity to do so, either because there might be some direct 
benefit to the participant, or the research would aid children with the 
same condition(25).  
Children as Vulnerable Subjects 
The fact that children are in need of extra protection is not often further 
elaborated. Why are they in need of such protection? Children are 
considered vulnerable subjects. However, it is not easy to pinpoint 
exactly what is meant by this vulnerability. Bielby calls children 
cognitively vulnerable, which is in this case a temporary quality of the 
child’s mental state, rather than to specific circumstances(26). To begin 
with, vulnerability is often linked to their lack of or limited autonomy. As 
we do not know (with small children) what their choice would be, or as 
their current choice (as an older child) may not be their ‘definite’ one, 
children may seem vulnerable in their choices. Indeed we should 
prevent them from making choices that are too definite and that would 
close down other options later on(9). Related to this, children could be 
easily manipulated and are probably more gullible than adults. CIOMS 
in this respect refers to the incapability of protecting one’s own interests. 
However, the link between vulnerability and (lack of) autonomy is not as 
straightforward as one would assume. The need to make choices can 
also put pressure on people and in itself make them vulnerable. Even 
adults are insecure about their choices and can be unsure whether they 
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make the right ones or whether they would not regret them afterwards. 
Children have the option of delegating some of the more difficult 
choices to their parents. In that way, they operate in a kind of ‘autonomy 
playground’ and, one could say, have the luxury not to have to make 
certain choices. Next, vulnerability may refer to the fact that they would 
suffer more from certain procedures than adults, due to their lack of 
comprehension. Although this may be true in some cases (for example 
venepunctures) in other cases children may prove to be much more 
resilient than adults. Also, one could argue that they tend to forget more 
easily and be soothed by small rewards such as a sticker after a 
venepuncture. However, the idea of making them preferred research 
subjects for non-therapeutic research because of this resilience seems 
utterly unacceptable in present-day thinking. 
Children and Solidarity 
An often quoted example in the context of non-therapeutic research is 
given by Willard Gaylin(27), who describes a father of a ten-year old boy 
who gives permission, although his child refuses, that blood be taken 
from his son for research, under the motto ‘I’ll be damned if I was going 
to allow my child, because of some idiotic concept of children’s rights, to 
assume that he was entitled to be a selfish, narcissistic little bastard.’ 
Although this is an older quote, it shows resemblance with current 
thinkers, such as Ruth Chadwick and John Harris, who stress the need 
for solidarity for medical research to progress, rather than a stress on 
personal autonomy and the right to choose(28,29). However, can this duty 
really be generalized to children? Part of what it is to be a child lies in 
the fact that children are exempt from duties that adults have. Are they, 
along the same lines, then not exempt from non-therapeutic research? 
The problem here is that children could also benefit from research on 
(admittedly other) children. Plus, children are not exempt from all duties: 
they are increasingly expected to show some civilized behavior. To 
tackle the question to which extend children can contribute to non-
therapeutic research some middle ground between participation and 
protection should be found. The above mentioned John Harris admits 
that children are an exception to the principle of solidarity(30). He still 
believes that children are moral agents, and we should not assume that, 
only because they cannot consent they would not in principle like to 
participate (31). But he also states that one should be cautious about 
enrolling those who cannot consent and we should not force resisting 
incompetent individuals. Moreover, the incompetent should only be 
used where competent individuals cannot be research subjects because 
of the nature of the research itself. This criterion is similar to the 
restrictions posed by CIOMS and the Declaration of Helsinki quoted 
above.  
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BIOBANKS AND TISSUE SAMPLE COLLECTIONS 
Genetic research has taken a tremendous rise during the last decade. 
Such research tries to discover the functioning of genes in relation to 
certain conditions and traits. In order to effectively perform this 
research, collections of DNA are needed. Human biological material 
such as blood, extracted DNA and other tissue, often stored with 
medical data from the donor is an important source for genetic 
research. A collection of such material is referred to as a biobank, 
although opinions differ on the actual definition of biobank. For example, 
the Belgian law of 19 December 2008, regarding the procurement and 
use of human biological material for clinical or research purposes 
distinguishes between a bank of human biological samples and a 
biobank. The former is defined as an organized structure for each 
activity related to the procurement, testing, processing, preservation, 
storage or distribution, included the import or export of human biological 
material. A biobank is then defined as the structure that stores biological 
material and makes it available, solely for scientific research. In this text 
we shall take a functional approach: We shall use the term ‘biobank’ to 
refer to each collection of human biological materials and associated 
medical information that can or is used for non-therapeutic scientific 
research, and especially genetic research, as we believe that most 
ethical questions are related to the potential research use of such 
collections rather than to the modes of their inception. For example, the 
use of collections of blood spot cards for genetic non-therapeutic 
research would make them biobanks(32,33,34).  
Types of Collections 
Collections of human stored tissue samples exist in different forms. 
Some are founded with the study of one or some conditions in mind and 
contain tissue from patients with that disease. Or they contain materials 
originally gathered for diagnostic purposes and then secondarily used 
for non-therapeutic research. For example, collections of genetic 
material in the genetic centers in university hospitals contain diagnostic 
material, but could form a resource to study specific diseases. 
Population or cohort studies often also have an associated biobank. 
Such studies collect phenotypical information from a cohort or part of a 
population and try to link this information with genetic information. Such 
studies extend over different years and form a resource for further non-
therapeutic research, which is often not defined at the inception of the 
study. An example of such study is the UK Biobank. This project aims to 
store genetic and medical information of around 500,000 people aged 
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40-69 in the United Kingdom to study conditions such as cancer, heart 
diseases, diabetes, arthritis and forms of dementia(35). 
Biobanks and Risks 
There is consensus among scientists that collections of human tissue 
samples are an important resource for research(36). However, a number 
of ethical issues are linked with the storage and the use of such 
materials(37). To be able to answer these correctly, a risk assessment is 
necessary. These risks will differ whether the material was taken for 
other purposes (diagnostic or therapeutic) or whether it was taken 
specifically for non-therapeutic research. In the first case, no extra 
procedure is necessary. Admittedly, the procedure is often not invasive 
and will consist of a venepuncture or mouth swab. No substantial 
physical risks are associated with such research. Another type of 
‘intrinsic’ risk is related to the fact that certain research may not 
correspond to the participant’s values(38). But the risks most often 
quoted in the literature are consequentialist in nature and associated 
with breaches of privacy(39,38). In this respect, George J. Annas has 
framed the term ‘future diary’ with regard to genetic information(40). Fear 
exists that third parties, such as insurance companies, employers or the 
government would gain access to genetic information(41). There is also 
the possibility that participants that cooperate in research on a specific 
condition or diseases are automatically associated with this disease, 
even they do not have it. Next to this personal stigmatization, the 
literature mentions also group stigmatization(42). Research on 
populations could reveal that a certain gene mutation, associated with a 
specific condition occurs more frequent in a specific group or 
population. This could have implications for the insurance and 
employment of this group. Such risk is then no longer related to actual 
participation but also affects citizens that do not participate in the 
study(43). Potentially negative effects of genetic research are best 
countered through just policies and laws that prohibit genetic 
discrimination(44). However, the fact remains that rumors about the 
association of a gene mutation with a condition and a population are 
hard to extinguish. The risk of privacy breaches can be reduced through 
accurate security measures, which could prevent access by third 
parties. One option is to completely destroy the link between the patient 
or donor’s name and the sample(45,46,47). Such complete anonymization 
probably offers the highest form of security, but also has certain 
disadvantages. In many cases, researchers will want to recontact the 
patient or donor to get extra information(48). In genetic research, next to 
the raw data, demographic, lifestyle and medical information is often 
kept. Complete anonymization also makes it impossible to contact the 
donor if something relevant to his or her health is discovered. A coding 
system, in which a key is needed to link patient and data, is probably 
the best solution(49,50). This key could be stored in a different location 
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and managed by a third person. However, given that data and samples 
are more and more shared across country borders to jurisdictions where 
different legislation exist may further complicate the issue of privacy. 
Biobanks and Consent 
Probably most discussed in the ethical literature is the question of 
informed consent(51). Many agree that consent is needed for the use of 
tissue samples and medical data for non-therapeutic research, and 
preferably also for the use of existing collections(52). But what is exactly 
the task of informed consent(53)? Is its only task to allow donors or 
participants to assess the risk of participation in biobank research for 
themselves, and to show respect for their autonomous choice? Or is it 
to make extra clear to participants the difference between fundamental 
and non-therapeutic research and medical care, and hence to avoid the 
so-called therapeutic misconception(54)? The procedure of asking for 
consent can also aid in creating an atmosphere of trust in research and 
stress an active involvement in the progress of science(55). However, if 
consent procedures are too complex, the administrative overhead may 
jeopardize the research. Moreover, participants are often not interested 
in too detailed information(56,57,58), and an information overload could 
lead to anxiety(59). According to some, the stress that is put in the ethical 
literature on biobanks is based too much on an autonomy model. Some 
authors think that the duty to solidarity is more important(28): Sharing 
human tissue does not require much effort from the participants and 
may be of great importance for science and medical progress and 
contribute to the public good(60). But it has been argued that the direct 
association between medical science and public good, as is frequent in 
ethical discourse on biobanks, has gained too much emphasis. Indeed, 
one cannot just assume that every research type that can be performed 
on samples and information in a biobank is automatically contributing to 
the public good. Each appeal to solidarity must hence be accompanied 
with a reflection on the potential aims of medical science(43). The fact 
remains that people cannot be forced to cooperate; only in a climate of 
trust in the medical and research world will people be prepared to 
solidarity. Also, the question whether for certain forms of biobank 
research, consent can truly be informed is still open. Often such 
collections form a resource for research that extends itself over time 
and of which the content is not known at the point of gathering the 
samples. Is it ethical to ask for consent for research that is not yet 
specified(61,62,63)? Should participants be recontacted if a different type of 
research is performed on their samples? Empirical research suggests 
that people are prepared to give such ‘broad’ consent, as long as they 
are asked for consent, but opinions still vary(64,65,63). 
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Return of Individual Results 
Another question is whether researchers and scientists have the duty to 
share individual results of their investigation with donors or 
patients(66,67). Or is it sufficient to share general research results through 
a newsletter? The following arguments exist against returning individual 
results: It would be too resource-intensive for the researcher and 
require too much administrative overhead, which would lead the focus 
away from non-therapeutic research. It would also increase the chance 
of therapeutic misconception(68). Knowledge of inconclusive genetic 
findings may cause anxiety. The UK Biobank, for example, has a policy 
of not returning individual results(69). But it may be argued that 
participants in research have the right to know certain information about 
their health, especially in case of treatable or preventable 
conditions(70,71). Donors could be asked in the consent form whether and 
which information they would like to receive(72). In any case, the 
communication should happen through a medical person familiar with 
the subject, preferably accompanied by genetic counseling.  
Commercialization and Ownership 
Other ethical questions around biobank research are related to 
commercialization and ownership. Empirical research has shown that 
many people are prepared to donate tissue and medical data to 
‘science’, but people often do not want private companies to make profit 
with ‘their’ tissue(73). However, in the current health care system it is not 
unthinkable that scientific discoveries will ultimately lead to commercial 
products. To which extent should companies developing such products 
share their profit with the donors of the original material(74,75,76)? One 
could state that these donors did not do such great an effort and that 
they have the duty to solidarity with future generations(28). In this view, 
companies would not have duties towards specific individuals but 
towards society as a whole. The equity principle would then require that 
these companies would share their profit with the weakest members of 
society, a group not necessarily corresponding with the original donors 
of the tissue. The question about the ownership of tissue is related to 
this(77). Are the owners the original donors(78)? Or are the individual 
researchers working on the material the owners? Or is it the institution 
that houses the collection? Genetic information is also shared with 
family members; do they also have a right to decide? The discussion on 
commercialization and ownership is and interesting one and often also 
a legal one. We shall however, not focus on these two themes in this 
doctoral thesis. 
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CHILDREN AND BIOBANKS 
Most of the literature and guidelines in the context of medical research 
on children was written with clinical trials in mind. Much less is written 
about the use of stored tissues of children for fundamental research. In 
the remainder of this introduction we shall describe the need for 
pediatric stored tissue samples, and state that these generate ethical 
questions that are not covered by the discussion on biobanks with adult 
participants. But first, we need to answer the question whether the use 
of stored tissue samples from minors is necessary or useful. Would it 
not be possible to only store materials from adults? Indeed, most 
biobanks stock only samples from adults. Because DNA remains stable 
throughout a lifetime, one could say that there is no need for such 
material from children. Most genetic research, apart perhaps from some 
epidemiological studies investigating the prevalence of certain gene 
variants in a population, happens not in isolation but in combination with 
medical and lifestyle data. Nowadays, the influence of external factors 
(even in utero) on gene expression is commonly accepted. Conditions, 
such as allergies, asthma, food intolerances, diabetes and obesitas 
have, according to some, acquired epidemiological proportions amongst 
children. They are now commonly attributed to a combination of genetic, 
phenotypical and lifestyle factors. Large-scale systematic research 
using tissue samples can shed some light on the development of these 
conditions.  
 
There are several examples of large cohort studies following children 
from birth onwards to adulthood. The ‘Avon Longitudinal Study of 
Parents and Children (‘Children of the Nineties’)’ is an example of such 
study. This study collects detailed phenotypical and lifestyle data from 
14 000 children born in 1991-1992(79,80,81,82). These children are 
regularly followed and many of them are still in the study at the time of 
writing this chapter. A similar study is ‘Born in Bradford’, which 
examines environmental, psychological and genetic factors that impact 
on health and development perinatally, during childhood and 
subsequent adult life, and those that influence their parents' health and 
wellbeing. Recruitment started from March 2007 and continues until 
2010(83). Other similar studies are Generation R (Rotterdam, 
approximately 10000 babies enrolled)(84) and the Norwegian Mother and 
Child Cohort which aims to store 380,000 biological samples from 
pregnant women, their partners and their children for up to 100 years(85). 
 
Conditions that occur during childhood, such as childhood cancer and 
birth defects need to be studied using material from children that have 
this condition. For example, in the UK there is a ‘virtual’ tumor bank 
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which allows for easy sharing of tissue samples from cancer patients 
within the country(86). Another example of research of specific diseases 
that uses children’s tissue is the research of genetic factors of birth 
defects in the National Birth Defects Prevention Study, as described by 
Jenkins(87). And the Spanish HIV BioBank contains tissue samples, 
including extracted DNA, from HIV infected children to study the 
evolution of the disease in children(88). And of course there are many 
local initiatives in university and teaching hospitals to study the genetic 
component of a specific disease in affected children. Such studies 
typically enroll patients or ask participation from parents that seek 
genetic advice at genetic centers.  
 
Worldwide there is a large collection of existing blood samples from 
children, as in many countries babies are systematically screened for 
certain diseases through gathering of heel prick blood. This blood is 
gathered on cards together with a few demographic and other data. 
Such collections may potentially form a good resource for genetic 
epidemiological research and contain de facto material from children(89), 
but such research use is also the subject of a substantial amount of 
ethical literature(90,91,92,93,94). 
RATIONALE AND IMPLEMENTATION OF DOCTORAL 
THESIS 
Rationale 
Genetic research that uses tissue samples from children is necessary 
and useful. But it also raises a number of ethical issues that are not 
analogous to those raised by pediatric clinical trials or adult biobanks. 
Specifically the questions of risk, consent and return of results are 
complicated even more when children are concerned. With this doctoral 
thesis we aim to investigate the ethical issues related to genetic 
research on stored tissue samples from minors. Based on this 
investigation, we shall try to provide answers and draft 
recommendations that can be used by researchers, policy makers, 
ethics committees. Our focus will be on biological samples from living 
children between birth and the day they become legally competent. We 
shall not include a discussion on fetal tissue or post mortem tissue from 
children. 
 
In order to tackle biomedical ethical issues, and to define what is 
morally acceptable, Borry has described several approaches(95). First, a 
top-down method can be applied where moral argumentation is based 
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on a deductive process where ethical principles and theories are 
applied to practical cases, an approach where empirical research takes 
only a marginal position. In a bottom-up approach, it is the other way 
around: empirical research is the starting point from which to generate 
principles and norms. Hence, they follow moral practice. We have 
followed a third model, that of reflective equilibrium. In such an 
approach, a mutual adjustment among general principles and particular 
judgments occurs. We neither want to blindly apply models of risk, 
consent or solidarity to pediatric biobank research, or, alternatively, 
blindly follow ‘what the majority has to say’ but we want to test both 
theoretical and empirical findings against one another.  
 
The twentieth-century philosopher and ethicist Aural Kolnai has stated 
that “Moral evidence is neither logical or mathematical nor ‘plainly’ 
factual or empirical. It is ineluctably valuational; and all kinds of 
valuational evidences, moral and other, suffer from an additional 
element of ‘subjectivity’ or, in respect of the mode in which the object 
presents itself, of ‘opacity.’”(96) Indeed, to go from empirical facts to a 
theoretical/normative framework always presupposes a leap that can no 
longer, in itself, be defined or proven. A large part of this leap is based 
on the personality and values of the ethicist herself. We believe, 
however, that by doing empirical research, both qualitative and 
quantitative, the grounds from which to start this leap become more 
solid and the conclusions more valid. Therefore we have chosen, as an 
approach for this doctoral thesis, a combination of empirical study, part 
of which we did ourselves, and part of which was the result of literature 
study, and normative/theoretical reflections based on general concepts 
and principles governing bioethics and governing thinking about 
vulnerable subjects and children specifically. We admit that ethical 
conclusions can and will never be 100% evidence based, and always 
contain traces of the ethicist’s personal convictions and norms. We also 
believe that the conclusions we draw from this approach themselves 
can and perhaps should be subjected to new empirical research, and 
that they might need adaptations if times and cultural circumstances 
change. In this respect, ethical norms resulting from ethical research 
thus conceived is never final but should constantly be revisited and 
revised. 
Implementation 
Our ethical inquiry and subsequent recommendations are based on four 
steps. These steps are similar to the ethical reflection process as it is 
described by Paul Schotsmans(97). First, a state-of-the-art of the 
concepts and themes in current literature and guidelines about the issue 
under investigation is necessary. Second, the current ethos needs to be 
understood and checked against the theoretical state-of-the-art. Our 
investigation of the ethos is done through empirical research of opinions 
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of lay people and professionals. Third, concepts and themes that arose 
from the first and second part will be elaborated, investigated and 
checked for consistency in in-depth normative/theoretical reflections. 
Finally, based on the cumulative experiences from the previous parts, 
we shall formulate recommendations in the conclusion. These four parts 
form the backbone of this doctoral thesis. 
Part 1: State-of-the-art of the ethical aspects of genetic research 
on pediatric stored tissue samples 
In this part, we review existing guidelines and position papers and the 
ethical literature and distil themes and concepts from these papers. In 
order to meet this objective, we perform two reviews. With the first 
review we investigate guidelines and position papers on the topic of 
biobanks and biological sample collections to check what they 
recommend for pediatric participants. This study has the form of a 
systematic review. After finding the relevant documents, we extract 
themes and concepts. With the second review we investigate the 
existing ethical literature on the topic of research on stored tissue 
samples from minors. For the literature review we systematically 
retrieve documents from databases such as PubMed and CINAHL. 
Afterwards, these documents are thoroughly read and categorized 
according to concepts and themes.  
Part 2: Ethos: Empirical inquiries into the storage and use of 
pediatric tissue samples for genetic research 
In this part, our objective is to study the opinions of lay people and 
professionals on the topic of using stored tissue samples from minors 
for genetic research.  
To query the opinion of lay people we perform ten focus group 
discussions(98,99,100) (qualitative method), five with adults and five with 
young people (aged 15-19), with a total of 76 participants. These 
discussions are then analyzed using NVIVO 8(101) and categorized 
according to themes. We choose focus groups as our modus operandi 
for this part of our investigation of the ethos, as we believe this has 
several advantages. First, it is a relatively straightforward way to gather 
the opinions of many people on this topic. Second, our interest is not 
only to query opinions as such, but also to investigate the mechanisms 
behind certain reasoning. A group discussion allows for interaction 
between different members at the same time, hence inducing 
participants to explain reasons more clearly. Third, as we also want to 
find out the opinions of young people, we think that group discussions 
with peers would be less stressful and closer to their own experiences 
than one-to-one interviews.  
To query the opinion of professionals, we take a two step approach. We 
perform ten semi-structured interviews (qualitative method) with 
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professionals involved in genetic research on stored tissue samples 
from minors. These professionals are involved in different types of 
collections, such as collections linked to population-based studies, 
tumor banks and research on existing diagnostics collections. Some of 
these interviews are done during a research stay at the Ethox centre at 
the university in Oxford, during the summer of 2009. We choose this 
method to allow for in-depth exploration of ethical views and practices of 
the professionals. These interviews are analyzed and categorized with 
NVIVO8(101). We also do a small survey among Belgian geneticists. We 
choose a survey (quantitative method) for this part of the research to 
provide some numerical backbone to our previous findings. We use 
SPSS 16.0(102) to perform statistical analysis. 
Part 3: Normative and theoretical reflections  
Our objective in this part is to provide in-depth normative and theoretical 
reflections on three important topics with regard to the ethical use of 
stored tissue samples for genetic results (return of results/risk and 
benefit/consent), based on the findings from part one and two and 
supplemented by theoretical foundations. A first reflection questions 
whether the idea of ‘minimal risk’ is applicable to pediatric research on 
stored tissue samples, and formulates an alternative approach of 
‘burden and group benefit’. A second reflection deals with the scope of 
parental consent for non-therapeutic genetic research. Are parents 
allowed to give broad consent for any genetic research? Is the scope of 
their consent limited in time: should older children or adults be 
recontacted to assent or to reconsent to research on samples that were 
stored when they were small children? A third reflection deals with the 
question of the return of individual results in pediatric biobanks. 
Part 4: Conclusion: Recommendations on the storage and use of 
pediatric tissue samples for genetic research 
Our objective in this part is to formulate recommendations on the use of 
stored tissue samples from minors that can be used by researchers, 
ethics committees and policy makers. 
OUTLINE OF THE DOCTORAL THESIS 
The chapters that form the body of this thesis are composed of papers 
that have been published in or have been submitted to peer reviewed 
journals. Therefore, they may contain some repetition in the introductory 
paragraphs.  
 
In part I of this doctoral thesis we present the current state-of-the-art. In 
chapter 1 we provide a systematic review of international, European 
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and national guidelines on biobanks and stored tissue samples, 
especially with regard to stored tissue samples from minors. Chapter 2 
contains a literature review. We search for literature on the ethics of 
stored tissue samples from minors and on non-therapeutic research on 
blood spot cards and distill major themes and concepts.  
 
In part II we perform an investigation of the current ethos surrounding 
the topic of stored tissue samples from minors. In chapter 3 we 
describe the findings of a focus group study we perform among lay 
people. In chapter 4 we present the results of our analysis of in-depth 
interviews with professionals involved in non-therapeutic research on 
stored tissue samples from minors. Chapter 5 contains the results of a 
survey among Belgian geneticists.  
 
In part III we apply findings from part I and part II to generate a 
normative reflection based on empirical research and principles. In 
chapter 6 we discuss the issues of risk and benefits, based on the idea 
of limited solidarity. In chapter 7 we investigate the right of parents to 
give broad consent to the storage and use of samples of their children 
in a biobank. In chapter 8 we discuss the issue of the return of 
incidental findings and individual results when research participants are 
minors.  
 
In the summary and recommendations we present a summary of our 
findings, we provide recommendations for researchers and policy 
makers from professional organizations and give some suggestions for 
further research. 
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ABSTRACT 
Stored tissue samples are an important resource for epidemiological 
genetic research. Genetic research on biological material from minors 
can yield valuable information on the development and genesis of early-
onset genetic disorders and the early interaction of environmental and 
genetic factors. The use of such tissue raises some specific ethical and 
governance question which are not completely covered by the 
discussion on biological materials from adults. We have retrieved 29 
guidelines and position papers pertaining to the storage and use of 
biological tissue samples for genetic research, originating from 27 
different organizations. Five documents had an international scope, 
three a European scope and 21 a national scope. We discovered that 
11 of these documents did not contain a section on biological materials 
from minors. The content of the remaining 18 documents was 
categorized according to four themes: consent, principles of non-
therapeutic research on vulnerable populations, ethics committee 
approval and difference anonymous/identifiable samples. We found out 
that these themes are not consistently mentioned by each document, 
but that documents discussing the same themes were mostly in 
agreement with their recommendations. However, a systematic 
reflection on the ethical and policy issues arising from the participation 
of minors in biobank research is missing. 
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INTRODUCTION 
Stored tissue sample collections for genetic research exist in different 
forms. Some of these collections provide a resource for potentially 
unlimited genetic research, and gather samples and data from specific 
populations. An example is the “UK biobank”(1). Other collections are 
stored for research on a specific disease. Collections which were 
originally gathered for different purposes, for example blood spot cards 
for newborn screening, could be reused for genetic research(2). 
Genetic research on biological material from minors and the associated 
medical records can yield valuable information on the development and 
genesis of early-onset genetic disorders and the early interaction of 
environmental and genetic factors. For example, Rasmussen(3) 
describes the incorporation of DNA sample collections into the “National 
Birth Defects Prevention Study” in the United States to identify the risk 
factors for birth defects. Studies such as the “Avon Longitudinal Study 
of Parents and Children” in Bristol (‘Children of the nineties’) use 
genetic, phenotypic and environmental information of 14 000 babies 
from pregnancy onward to study the interaction between these data(4).  
An extensive ethical literature exists on the collection, storage and use 
of biological samples for genetic research. The overwhelming majority 
of these documents discuss issues of privacy, confidentiality, 
commercialization and consent(5,6,7,8,9,10,11,12,13,14,12). However, research 
on pediatric data raises specific ethical questions with regard to consent 
and privacy. For example, who should give consent to the inclusion of 
tissue and data from children? Is the general requirement that 
nontherapeutic research can only be done with children if it involves no 
more than minimal risk, applicable to biobank research? We shall 
review whether and how guidelines and policy documents discuss 
children in the context of storing biological samples and DNA for non-
therapeutic research. 
METHODS 
MedLine, Embase and Google Scholar were used as a primary source 
of information to identify relevant literature. Official websites of ethical 
committees, professional organizations and regulating bodies from the 
US and the European Union were equally searched (15,16). More 
information was gathered on the basis of the bibliographical data in 
these documents. We focused on documents about genetic databases 
(so-called ‘biobanks’) and about stored biological samples that 
mentioned genetic research. Documents discussing archived human 
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tissue without mentioning genetic research were discarded. General 
documents on genetic research were preserved, as long as they at least 
mention banking of data. Only documents in French, German, English 
or Dutch were preserved, that were no older than 1990. As the focus 
was on guidelines and recommendations, legally binding documents 
were not included.  
Some confusion may exist regarding the term ‘children’. We have 
included documents that mention ‘children’ or ‘minors’ and have 
covered the lifespan from birth till the age of majority. In the text, 
‘children’ and ‘minors’ will be used synonymously.  
RESULTS 
Guidelines and Position Papers 
We have retrieved 29 different guidelines and position papers (Table 1, 
numbered references to this table) pertaining to the storage and use of 
biological tissue samples for genetic research. The documents covered 
the period 1994-2007, with a peak in number of guidelines in 2002 (7 
out of 29 guidelines). The guidelines originated from 27 different 
organizations. Guidelines were issued by national bioethics committees 
[13], medical associations [6], genetic associations [5], other bioethical 
associations [1], UNESCO [1] and the Council of Europe [1]. Five 
documents had an international scope, three had a European scope 
and 21 had a national scope: United States of America [4], United 
Kingdom [3], Germany [2], Australia [1], Iceland [1], The Netherlands 
[1], Finland [1], Israel [1], Singapore [1], Canada [1], France [1], Ireland 
[1], Greece [1] and Austria [1].  
One international guideline (11) dealt with biomedical research in 
general, but as it contained a section on stored tissue samples, we 
included it as well. One document (4) dealt with clinical investigation, 
but was included because the document from the same organization 
(AMA) that deals with DNA databanks (16) explicitly refers to this 
document for vulnerable persons. 
At the moment of writing of this paper, the OECD (Organization of 
Economic Co-operation and Development) is working on a document 
provisionally titled “Guidelines for Human Biobanks and Genetic 
Research Databases”. As this is still open for comments, we have 
decided not to include the draft version of the document in our 
discussion. 
 
We first acknowledged whether the guidelines mentioned the use of 
tissue samples from minors. It turned out that 11 out of 29 documents 
did not mention such use. We then categorized the remaining 18 
documents according to the themes they discussed with regard to this 
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topic. We distilled four major themes: consent, principles of non-
therapeutic research on vulnerable populations, ethics committee 
approval and difference anonymous/identifiable samples (Table 2).  
Consent 
A major theme discussed is the issue of consent. The guidelines 
discuss first of all who should give consent to the donation, storage and 
use of tissue samples from children. Some guidelines also discuss the 
issue of a child’s assent (“permission) or dissent (“refusal”). A third 
question is whether and when a minor should be recontacted to give full 
consent. 
17 out of 18 documents state that a legal guardian should give consent. 
In this regard, a legal representative, guardian or legal proxy is named 
(1, 4, 6, 11, 14, 17, 19, 20, 22, 23, 26, 27, 28, 29), a parent (11, 23, 27, 
28, 29), someone with parental responsibility (2, 9), a relative (18, 28), 
someone designated to protect the interests of the subject (18). Four 
mention parents (9, 22, 27, 6). Only one guideline mentions that it must 
be both parents (6): “In general consent should be obtained from both 
parents”.  
Only four documents give further specification on the representative 
who gives consent. CIOMS (11) mentions that the parent or guardian 
who gives permission for a child to participate in research should be 
given the opportunity, to a reasonable extent, to observe the research 
as it proceeds, so as to be able to withdraw the child if the parent or 
guardian decides it is in the child’s best interest to do so. The Bioethics 
Advisory Committee Singapore (14) mentions that the extent and scope 
of a given legal proxy’s lawful authority to give consent may well depend 
on the particular circumstances and on the putative proxy’s legal 
relationship with the donor. The French Comité Consultatif National (18) 
stresses that although there is possibly no other solution than to gather 
consent from some trustworthy person,, one cannot “ignore that a 
collection based on samples from children necessarily carries 
knowledge about a whole lifetime”. Hence, they question the extent of 
such proxy consent. UNESCO (19) states that “the legal representative 
should have regard to the best interest of the person concerned”.  
 
Should a minor’s decision also be taken into account, next to the proxy 
consent by the parent(s) or legal guardian? 11 out of the 18 documents 
discuss the issue of assent (“permission”) and dissent (“refusal”). All 11 
agree that, when appropriate, the child should be consulted and their 
agreement obtained (2, 6, 9, 11, 17, 20, 19, 22, 23, 27, and 28). Some 
documents state that a procedure should not be performed if a child 
objects or appears to object to the procedures (2, 11, 17, 20, 22, 23, 27, 
and 28). In this respect, CIOMS (11) makes a distinction between the 
deliberate objection of an older child and “the behavior of an infant, who 
is likely to cry or withdraw in response to any stimulus”. Therefore, older 
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children, where an apparent objection can be more easily evaluated 
should be preferred over younger children. CIOMS also state “that a 
deliberate objection by a child to contribute to research should always 
be respected, even if the parents have given permission, unless the 
child needs treatment that is unavailable outside the context of 
research.” The Australian National Health and Medical Research 
Council (6) mentions the concept of the mature minor. If the child is a 
mature minor, his or her consent should be sought in addition to that of 
the parents or legal guardian. CIOMS (11) mentions that assent alone is 
insufficient to permit participation in research: additional consent from a 
legal guardian must be sought. 
 
Should children be recontacted to give their autonomous consent for 
research on their samples? Eight documents think so (1, 9, 23, 24, 6, 
11, and 29). The criterion when this should happen varies however. 
Two guidelines mention “when they are old enough to 
understand/comprehend or when they are capable of discernment” (1, 
9, 23, and 24). CIOMS (11) mentions “If such research subjects, 
including children, become capable of giving independent informed 
consent during the research, their consent to continued participation 
should be obtained”. They do not specify whether they mean a legal 
age or a level of maturity. Two documents (6, 29) specifically state that 
reconsent must occur when the child is legally capable of doing so.  
Principles of Nontherapeutic Research on Minors 
A second topic is the reference to general principles of non-therapeutic 
research on children. These principles include first the fact that such 
research should not entail more than minimal risk, second that it can 
only be done to benefit persons of the same age or condition, third that 
they should have some direct benefit to the participant, and fourth that 
they can only be performed if the same research cannot be done on 
adults.  
 
The first general principle with regard to non-therapeutic research on 
children that is quoted in the context of stored tissue samples is that of 
minimal risk. Eight documents mention this risk (2, 11, 17, 20, 21, 22, 
23, and 27). MRC (9) does not explicitly mention the principle but states 
that “Tests of known predictive value for adult onset diseases should 
not be done for research purposes on individually identifiable samples 
from children”, thus quoting a specific interpretation of risk. CIOMS (11) 
gives a definition of what minimal risk might entail: “the risk from 
research interventions that do not hold out the prospect of direct benefit 
for the individual subject should be no more likely and not greater than 
the risk attached to routine medical or psychological examination of 
such persons.” They make a distinction between the experiences of 
healthy children and those with a condition that would already require 
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interventions as lumbar punctures or bone-marrow aspirations. Those 
would be ruled out for healthy children. Nationaler Ethikrat (22) 
mentions residual material from therapy or diagnosis: as research on 
such material does not require extra bodily interventions, the risk is 
considered minimal.  
 
The next three principles are a reflection of the WMA’s Declaration of 
Helsinki (1964)(17), that states that “these groups should not be included 
in research unless the research is necessary to promote the health of 
the population represented and this research cannot instead be 
performed on legally competent persons”. 
 
The second principle states that research should be beneficial to minors 
with the same age or same condition. This principle is quoted by five 
documents (11, 17, 20, 22, 23). The WHO (20) states however that data 
should be coded to prevent identifiable links being made, and that “such 
permissions would only normally be granted to the direct clinical benefit 
of the child.” Nationaler Ethikrat (22) quotes a controversy surrounding 
the concept of ‘group benefits’. They state that “some hold that, if 
research is minimal risk and done on residual material from therapy or 
diagnosis, non-therapeutic research can be done on subjects incapable 
of giving consent for the benefit of fellow-sufferers. Others hold that 
consent is a personal matter and must be left to those concerned, and 
as it is impossible to determine whether risks are minimal, research on 
persons not able to consent should be prohibited”. The Nationaler 
Ethikrat does not, however, give a definite solution to the controversy. 
  
A third principle, that research on subjects that cannot consent should 
only be done if there is any direct benefit to participants, is quoted by 
four guidelines (11, 17, 20, 22). For example, the Nationaler Ethikrat 
(22) states that “No one disputes that those incapable of giving consent 
may be involved in research from which they themselves are likely to 
benefit therapeutically”. None of the documents give examples as to 
how this can be interpreted in the context of stored tissue samples, as 
probably no such examples exist.  
 
A fourth principle of research on children is that it should only be done if 
it cannot be done on adults. This is mentioned by six documents (1, 2, 
4, 11, 22, 23). For example, the Irish Council of Bioethics states the 
condition that “the research relates directly to a clinical condition from 
which the minor concerned suffers and/or is of such a nature that it can 
only be carried out on minors.” The other five documents have similar 
provisions.  
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Ethics Committee Approval 
Seven guidelines mention the need for ethics committee approval for 
the inclusion of children in research (2, 11, 14, 20, 21, 29, and 27). The 
circumstances under which such approval is needed vary.  
Four guidelines mention the need for ethics committee approval in 
general for research involving children (2, 20, 21, and 27). CIOMS (11) 
mentions the need for such approval when there is a slight or minor 
increase above minimal risk. The Bioethics Advisory Committee 
Singapore (14) mentions that “the standard protocols and forms to be 
used in the taking of consent given on behalf of incompetent donors by 
their legal proxies should be reviewed and settled by the institution’s 
ethics board or institutional review board, acting with the advice of the 
institution’s legal advisors. The same ethics boards and legal advisors 
may also be consulted for a review of consent formalities in research 
projects for which it is anticipated that a significant proportion of the 
donors are or are likely to be legally incompetent”. NCI (19) mentions 
that the IRB should review reconsent issues when the child reaches the 
legal age to consent, at the time the board reviews the initial protocol.  
Difference Between Anonymous and Identifiable 
Three documents make a distinction between the use of anonymous 
and linked biological samples from children (9, 20, 29). MRC (9) states 
that “tests of known predictive value should not be done for research 
purposes on individually identifiable samples from children”, without 
further explanation. WHO (20) states that “some research will require 
the linking of clinical and genetic data in order to proceed and that the 
main beneficiaries of this research may be future children rather than 
the child who provides the sample. In such cases data should be coded 
to prevent identifiable links being made with access to the key to the 
code being restricted and subject to separate permission on each 
occasion”. The NCI (29) mentions the need for reconsent when a child 
reaches the legal age to consent if identifiable samples are used.  
DISCUSSION 
Of the 29 documents that mention stored tissue samples, 18 mention 
special provisions when these samples originate from children. These 
provisions include thoughts about consent, assent, reconsent, minimal 
risks, group or individual benefits, ethics committee revision and the 
difference between anonymous and identifiable stored samples. We 
have observed that these themes are not consistently mentioned by 
each document. Documents that discuss the same themes were mostly 
in agreement in their recommendations. The guidelines do not provide 
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specific recommendations regarding ownership of tissues, return of 
results or recommendations when minors are concerned, probably 
because they do not consider these different from issues regarding 
tissue from adults. 
Consent 
Most policies agree that an informed consent must be obtained when 
biological samples and genetic material are collected for research. 
Moreover, 15 documents state that this should be written (4, 5, 6, 7, 8, 
9, 10, 13, 17, 21, 25, 26, 27, and 28). When minors that are 
incompetent, be it through lack of maturity or because they do not have 
the legal age to consent, are concerned, this is problematic. 17 
guidelines mention that a legal guardian or parent is the most suitable 
person to consent. However, the nature of genetic material might 
suggest that, if possible, both parents should consent, as their genetic 
material is equally present in the child. This is suggested by Bauman(18). 
However, in a society where many children do not live with both 
(biological) parents, this may be not feasible(19).  
With regard to assent, guidelines remain vague as to as of which age a 
child should be asked for his or her assent and whether the criterion is 
one of maturity or age. Most guidelines use general terminology such as 
‘his or her opinion should be taken into account depending on age and 
maturity’ (28). Only one document mentions the age of 12 or 13 years 
old, in its general section on biomedical research involving minors (11). 
This uncertainty is reflected in the literature on assent: there is no 
consensus at which age a child should be allowed to assent for non-
therapeutic research, and whether this age should be fixed(20), or is 
dependent on social context and personal experience(21). Moreover, 
Alderson has shown that already very small children are able to show 
objections to certain practices(22). It is fruitful to look at the United 
Nations Convention on the Rights of the Child, that asserts that children 
have a right to say what they think should happen when adults make 
decisions that affect them (Article 12) and have the right to get and 
share information (Article 13). As this is a legally binding document for 
most countries, it makes sense that in longitudinal genetic research, 
also small children are given appropriate information and their opinions 
are taken into account. 
What should be the scope of parental consent in time and in content? 
Literature supports that it is reasonable to recontact minors when they 
are able to do so and give them the opportunity to withdraw their data, 
which is there only by proxy consent(23). However, none of the 
guidelines studied is explicit about at which age this should happen: 
should this happen when they are able to understand the impacts of 
research or when they reach a certain age? An overview of legal 
regulations regarding the position of minors in a health care setting in 
the EU member states has shown that age and circumstances under 
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which minors are allowed to take health care decisions vary in different 
countries(24). In some countries, the age of medical majority is the same 
as the legal age of majority (Cyprus, Greece and Slovakia). Others 
distinguish between the medical and legal majority (Portugal, Slovenia, 
Lithuania and Spain). The Czech Republic and Estonia consider 
medical majority on a case-by-case basis, dependent on age and 
maturity.  
Another aspect of the scope of consent is the question of content of the 
consent. Are parents allowed to consent to any future genetic research 
on their children’s DNA? This is called broad consent(25). Or can they 
only give specific consent to research on specific genes and diseases? 
Most biobanks have as an aim the accommodation of future research, 
the nature of which is undetermined at the moment of storage. Hansson 
has argued that broad consent at the time of storage is sufficient to 
keep the data available for research for a long period of time(26). In the 
case of children, however, it is not the donor herself who has consented 
and it may seem fair to restrict proxy consent only to specific research 
protocols or research on certain genes or diseases. 
Principles of Research on Children 
Most would consider biobank research in general as minimal risk(9). 
There is probably very little harm involved in the taking of a sample of 
blood of an adult to be included in a biobank. The harm is mostly 
situated in the area of possible stigmatization of certain groups through 
genetic research and the risk of loss of privacy(9). However, for children, 
procedures such as having blood taken and visiting a hospital or 
research center may well be frightening. The amount of anxiety that 
such procedures cause is probably also dependent on the personality of 
each individual child, and the question whether a child should be 
enrolled or not in nontherapeutic research is hence one that has to be 
made on a case-by-case basis. 
The issue of privacy, which is often quoted with regard to biobanks in 
general, is a difficult one when children are concerned. It can be argued 
that the privacy of an infant is not that important and that his or her 
medical information is more or less public property. Most parents 
discuss a variety of health related issues about their baby with different 
people; they would probably refrain from doing this if an older child was 
concerned. Indeed, the need for privacy grows as the child grows older, 
and what a child considers private is in many cases different from what 
an adult would be sensitive about(27). Some consider genetic data as a 
‘future diary’, a term framed by Annas(28): we would not find it 
acceptable to publish a diary of a ten year old. Moreover, the DNA of 
the child is the same as the DNA of the adult it is to become. The 
combination of the static characteristics of genetic information together 
with the evolution of the child towards maturity makes the question of 
privacy and minimal risk in biobanks that store pediatric samples a 
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difficult one to answer. The topic of privacy and children was not 
explored further by any of the guidelines under consideration. 
A next requirement is that of who should benefit from non-therapeutic 
research on tissue from children. Although some people acknowledge 
that there could be benefits from being enrolled in biobank research, 
such as benefits from regular health checkups(29), this is not the primary 
aim of the research. Therefore it is difficult to envisage what direct 
benefit would mean in this respect. On the criterion of group benefits, 
Holm(23) has argued that group benefits are too restrictive and not well 
founded as criterion, and that parents should be allowed to consent to 
participation of their children regardless of these benefits. However, in 
the context of proxy consent and broad versus specific consent, it may 
seem reasonable that proxy consent is not given for research on the 
entire genome of a child, but restricted to research on specific genes or 
conditions, which would satisfy the requirement of group benefits as 
well.  
Ethics Committee Review and Anonymization 
No consistent overview of the issues that an ethics committee should 
take into account when considering research on children could be 
found. Moreover, it is remarkable that only a subset of guidelines (7 out 
of 29) mentions this specifically with regard to research on minors, as it 
could be deemed good practice.  
 
The Declaration of Helsinki(17) considers research on identifiable human 
materials as human subject research, but can this be generalized to the 
use of anonymized samples? If research on anonymous samples is not 
considered human subject research, maybe the provisions that are put 
on research on tissue samples from children do not apply. In the context 
of risk, some authors in ethical literature have argued that the risk of 
privacy breaches is removed when anonymous samples are used(30,31). 
But others, such as Lysaught, point out to the possibility that genetic 
research may lead to group stigma, and hence indirectly may affect the 
individual(32). Moreover, subjects may feel strongly about the type of 
research that is done on their tissue, regardless of the level of 
identifiability, as mentioned by Trouet(33). 
 
The storage and use of biological samples from children for research 
poses some specific questions that are not covered by ethical 
reflections on the use of samples from human beings in general, such 
as the question who should give consent, whether the opinions of the 
minors matter, to which risks children can be exposed and who should 
benefit from such research. The majority of the 29 guidelines does 
reflect this distinction and mentions children in a separate section. 
However, a systematic reflection is missing and should be subject to 
further study. Such study could also shed some light on existing general 
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discussions with regard to the ethics of biobanks, most notably the 
issue of informed consent.
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Table 1: Overview of sources used 1 
# Year Scope Guideline 
developer 
Guideline 
title 
Composition of the 
group 
that authored the 
guideline 
Methods used 
1 1994 The 
Netherlands 
Gezondheidsraad: 
Commissie 
Lichaamsmateriaal 
voor bijzondere 
doeleinden.(34) 
Naar goed gebruik. 
Lichaamsmateriaal in 
de gezondheidszorg 
The ‘Commissie 
lichaamsmateriaal 
voor bijzondere 
doeleinden’ is 
composed of P. 
Hoedemaeker, I. de 
Beaufort, D. 
Bootsma, P. 
Breslau, H. Bruinse, 
J. Gevers, A. 
Gittenberg-de Groot, 
K. Hamenlynck, K. 
Jager, N. Mul, H. 
Roscam, A. 
Schreurs, P. 
Strengers, E. van 
Veen, J. Visser, E. 
Olsthoorn-Heim. 
They consulted two 
experts, P. 
Brombacher and J. 
Vandenbrouck 
The 
recommendations 
are based on a 
literature review, a 
questionnaire sent 
out to specialists 
and consultations of 
expert. The 
recommendations 
are the expert 
consensus. 
2 1995  United 
Kingdom 
Nuffield Council on  
Bioethics(35) 
Human tissue, ethical 
and legal issues 
The working group 
on human tissue 
was composed of R. 
Hurley, K. Baker, C. 
Berry, G. Dworkin, 
T. M. Jones, I. 
Kennedy, K. 
Mooney, O. O'Neill. 
The 
recommendations 
are the expert 
consensus. 
3 1998 International Human Genome 
Organization 
(HUGO)(36) 
Statement on DNA 
sampling: Control and 
access 
HUGO Ethics 
Committee. Its 
current members 
are R. Chadwick, K. 
Berg, A. Daar, K. 
Kato, D. Macer, T. 
Murray, I. Verma, 
J.J. Mulvihill 
The 
recommendations 
are the expert 
consensus. 
4 1998 United States 
of America 
American Medical 
Association(37) 
E-2.07 Clinical 
Investigation 
/ / 
5 1999 United States 
of America 
National Bioethics 
Advisory 
Research involving 
human biological 
The advisory 
commission is 
The group has 
consulted scientists, 
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Committee(38) materials: Ethical 
issues and policy 
guidelines 
composed of H.T. 
Shapiro, P. Backlar, 
A. Brito, A.M. 
Capron, E.J. 
Cassell, R.A. Charo, 
J.F. Childress, D.R. 
Cox, R.G. Dumas, 
L.M. Flynn, C.W. 
Greider, S.H. 
Holtzman, B.O. 
Kramer, B. Lo, L.H. 
Müke, T.H. Murray, 
D. Scott-Thomas 
research 
administrators and 
the public. The 
recommendations 
are the expert 
consensus. 
6 2000 Australia National Health and 
Medical Research 
Council(39) 
Guidelines for genetic 
registers and 
associated genetic 
material 
NHMRC documents 
are prepared by 
panels of experts 
drawn from 
appropriate 
Australian 
academic, 
professional, 
community and 
government 
organizations. 
The 
recommendations 
are the expert 
consensus. 
7 2000 Iceland Visindasidanefnd(40) 
 
Biological Samples / / 
8 2001 Europe European Society of 
Human Genetics 
(ESHG) (41,40,42) 
DNA storage and 
DNA banking for 
biomedical research: 
technical, social and 
ethical issues 
Public and 
Professional Policy 
Committee of the 
ESHG (PPPC). 
Members of the 
PPPC were S. 
Aymé, M. Bobrow, 
J. 
Cassiman, G. 
Evers-Kiebooms, P. 
Farndon, H. 
Kääriäinen, U. 
Kristoffersson,  M. 
Pembrey,  S. 
Raeburn, Jörg 
Schmidtke, L. ten 
Kate, L.  
Tranebjaerg. 
The 
recommendations 
are the expert 
consensus. 
9 2001 United 
Kingdom 
Medical Research 
Council(43) 
Human tissue and 
biological samples for 
use in research – 
Operational and 
The working group 
was composed of E. 
Johnstone, L. Doyal, 
A. Grubb, S. Povey, 
Working drafts of 
the guidelines were 
sent out for 
consultation to a 
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ethical guidelines P. Quirke, S. 
Sadeque, A. Silman, 
G. Stamp. 
wide range of 
organizations and 
individual scientists 
with an interest in 
the use of human 
material in research. 
Their comments 
were taken into 
account in 
developing an 
interim version, 
which was then 
published, together 
with a more detailed 
report of the 
working group’s 
discussions, for 
wider public 
consultation and 
input. Comments 
were received from 
Research Ethics 
Committees, from 
researchers, patient 
and consumer 
groups, and from 
the MRC’s 
Consumer Liaison 
Group. The 
recommendations 
are the expert 
consensus.   
 
10 2002 Finland  The Sub-Committee 
on Medical Research 
Ethics (TUKIJA) of the 
National Advisory 
Board on Health Care 
Ethics(44) 
DNA samples in 
epidemiological 
research 
Working group on 
DNA and 
Epidemiology was 
composed of A. 
Aromaa, V. Launis, 
S. Lötjönen. 
The 
recommendations 
are the expert 
consensus. 
11 2002 International Council for 
International 
Organizations of 
Medical Sciences 
(CIOMS)(45) 
International ethical 
guidelines for 
biomedical research 
involving human 
subjects 
The group 
responsible of 
drafting the various 
drafts was 
composed of F. L. 
Stepke, J. Bryant, L. 
de Castro, R. 
Levine, R. Macklin,  
G. Tangwa, F. Luna,  
The group held a 
set of workshops 
and meetings. The 
report was written 
based on 
information and 
comments from 
different experts 
and institutions.  
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R. Saracci 
12 2002 International Human Genome 
Organization 
(HUGO)(46) 
Statement on human 
genomic databases 
HUGO Ethics 
Committee 2002 
B.M. Knoppers, R. 
Chadwick, I. Verma, 
K. Berg, J.M. Cantu, 
A. Daar, E. Engels, 
K. Kato, M. Kirby, D. 
Macer, T. Murray, 
R.Z. Qiu, D.C. 
Wertz, J. 
Bovenberg, R. 
Cotton 
The 
recommendations 
are the expert 
consensus. 
13 2002 Israel Bioethics Advisory 
Committee of the 
Israel Academy of 
Sciences and 
Humanities(47) 
Population-based 
large-scale 
collections of DNA 
samples and 
databases of genetic 
information 
The Bioethics 
Advisory Committee 
is composed of R. 
Arnon, G. Ben-Or, 
S. Berman, M. 
Halperin, D. Heyd, 
A. Kasher, A. 
Keynan, R. Ishay, E. 
Levy-Lahad, M. 
Revel, A. Shapira, 
H. Soreq, Y. Segal 
The 
recommendations 
are the expert 
consensus. 
14 2002 Singapore Bioethics Advisory 
Committee 
Singapore(48) 
Human tissue 
research 
The Bioethics 
Advisory Committee 
is composed of L. 
Pin, D. Chan Kum 
Wah, C. Wah Teck, 
C. Yip Seng, J. 
Elliott, T. Kaan, L. 
Lim, L. Soo Hoon, 
R. Magnus, O. Yong 
Yau, T. Chorh 
Chuan, Z. Abidin 
Rasheed. 
The 
recommendations 
are the result of a 
review of existing 
publications and a 
public consultation 
process and are the 
expert consensus.  
15 2002 United 
Kingdom 
Human Genetics 
Commission(49) 
Inside information The Human 
Genetics 
Commission is 
composed of J. 
Sulston, B. Almond, 
S. Bain, C. Brazell, 
S. Cunningham-
Burley, P. 
Debenham, F. 
Flinter, R. Gardner, 
J. Harris, M. 
Harrison, C. 
The group has 
consulted key 
national and 
international 
organizations to 
discuss relevant 
areas of concern 
and drew on the 
work of the Science 
and Technology 
Committees of the 
House of Commons 
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Higgins, A. Kent, R. 
Leonard, A. 
Maynard, L. Oni, C. 
Patch, P. Sayers. 
and the House of 
Lords. The 
recommendations 
are the expert 
consensus. 
16 2002 United States 
of America 
American Medical 
Association(50) 
E-2.079 Safeguards 
in the use of DNA 
databanks in genomic 
research 
  
17 2003 Canada Commission de 
l’éthique de la science 
et de la technology(51) 
Les enjeux éthiques 
des banques 
d’information 
génétique: pour un 
encadrement 
démocratique et 
responsable 
The working group 
was composed of J. 
Patenaude, L. 
Barbeau, A. 
Beauchamp, 
D.Boucher, J. de 
Champlain, E. 
Deleury, P. 
Deschaies, J. 
Guédon, M. Jean, 
M. Prémont, G. 
Tincotte, D. Duquet 
The 
recommendations 
are the expert 
consensus. 
18 2003 France Comité consultatif 
national d’éthique 
pour les sciences de 
la vie et de la santé(52)  
Avis n 77, Problèmes 
éthiques poses par 
les collections de 
materiel biologiqueet 
les données 
d’information 
associées: 
“biobanques” 
“biotheques 
The working group 
was composed of N. 
Baumann, A. 
Cambin-Thomsen, 
M. Canto-Sperber, 
H. Gaumont-Prat, B. 
Kriegel, M. Loizeau, 
N. Questiaux, S. 
Beloucif, G. Bréart, 
G. Orth 
The 
recommendations 
are the expert 
consensus. 
19 2003 International United Nations 
Educational, Scientific 
and Cultural 
Organization 
(UNESCO)(53) 
International 
declaration on human 
genetic data 
The group 
responsible for 
drafting the 
declaration was 
composed of R.L. 
Andorno, L. 
DeCastro, H. 
Galjaard, M. 
Hamdan, R. Ida, 
D.A. Iljalye, G. 
Kosztolányi, G.B. 
Kutukoljian, P.P. 
Majumder, A. 
McCall Smith, N. 
Questiaux, M. 
Revel, S. Rumball, 
J. Sandor , P. 
The group drafted 
the first draft, which 
was then revised by 
international 
organizations, 
specialists and 
special-interest 
groups 
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Robinson 
20 2003 International World Health 
Organization 
(WHO)(54)  
Genetic databases. 
Assessing the 
benefits and the 
impact on human & 
patient rights 
The report has been 
prepared under the 
auspices of the 
WHO’s European 
Partnership on 
Patients’ Rights and 
Citizens’ 
Empowerment. The 
group preparing the 
report consisted of 
F. Dekkers, A. Kent, 
G. Laurie, C. Shalev 
The 
recommendations 
are the expert 
consensus. 
21 2004 Germany Deutsche Gesellschaft 
für Humangenetik(55) 
DNA-banking and 
personenbezogene 
Daten in der 
biomedizinischen 
Forschung: 
Technische, soziale 
und ethische Frage 
G. Wolff, W. Henn, 
J. Schmidtke, W. 
Vogel, K. Zerres, I. 
Nippert, P. 
Propping, C. R. 
Bartram 
The 
recommendations 
are the expert 
consensus. 
22 2004 Germany Nationaler Ethikrat(56) Biobanks for research The committee is 
composed of S. 
Simitis, R. Kollek, E. 
Nagel, H. Barth, W. 
van den Daele, H. 
Dreier, E. Engels, G. 
Fürst, D. Ganten, V. 
Gerhardt, C. 
Lohkamp, M. J. 
Lohse, T. Neuer-
Miebach, C. 
Nüsslein-Volhard, P. 
Propping, H. 
Putzhammer, P. 
Radtke, J.  Reich, E. 
Schockenhoff, B. 
Schöne-Seifert, R. 
Schröder, J. 
Taupitz, H. Vogel, K. 
Weber-Hassemer, 
C. Woopen 
The 
recommendations 
are the expert 
consensus. 
23 2005 Ireland Irish Council for 
Bioethics(57) 
Human Biological 
Material: 
Recommendations for 
Collection, Use and 
Storage in Research 
The Irish Council for 
Bioethics is 
composed of D. 
Gleeson, P. 
Whittaker, P. 
Cunningham, M. 
Dempsey, D. 
The 
recommendations 
are the result of 
evaluation of 
international best 
practice and wide-
ranging discussions 
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Dooley, M. 
Fitzgerald, P. 
Flanagan, P. 
Hannon, K. Kearon, 
C. Kelleher, M. 
Lawler, T. 
McGleenan, P. 
McKenna, M. 
Mulvihill, N. O'Brien, 
F. O'Gara, R. 
O'Regan, A. Scott, 
A.A. Sheikh, S. 
Strain. 
by the working 
group and are the 
expert consensus. 
24 2006 Europe Council of Europe(58) Recommendation 
REC (2006)4 of the 
Committee of 
Ministers to member 
states on biological 
materials of human 
origin 
/ / 
25 2006 Greece National Bioethics 
Commission(38) 
Recommendation on 
banks of biological 
material of human 
origin (biobanks) in 
biomedical research 
The National 
Bioethics 
Commission is 
composed of 
G..Maniatis, S. 
Agouridis, M. 
Dragona-Monachou, 
C. B. Krimbas, D. 
Roupakias, P. 
Sourlas, C. 
Tsoukalas, J. 
Vlahoyiannis 
The 
recommendations 
are the expert 
consensus. 
26 2006 Switzerland Swiss Academy of 
Medical Sciences(59) 
Biobanks: 
Obtainment, 
preservation and 
utilization of human 
biological material. 
Medical-ethical 
guidelines and 
recommendations 
The subcommittee 
appointed to draw 
up guidelines was 
composed of V. 
Dittmann, M. 
Bargetzi, A. 
Bondolfi, B. Elger, 
M. Gersbach-Forrer, 
H. Kurz, W. 
Pletscher, M. 
Salathé, H. 
Schneider, D. 
Sprumont, E. 
Stauffer, M. 
Vallotton. Experts 
consulted are R. 
The 
recommendations 
are the expert 
consensus. 
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Bühlmann, L. 
Bühler, W. 
Holzgreve, V. 
Schwander 
27 2007 Austria Austrian Bioethics 
Commission(60) 
Biobanken für die 
medizinische 
Forschung 
/ / 
28 2007 European The European 
Nutrigenomics 
Organisation 
(NuGO)(61)  
Bioethics guidelines 
on human studies 
The NuGO Bioethics 
Working Group is 
composed of M.M. 
Bergmann, M. 
Bodzioch, L. Bonet; 
C. Defoort, G. Lietz. 
Experts involved in 
the generation of the 
NuGO Guidelines 
are D. Castle, A. 
Cutter; E. Engels, G. 
Javashvili, H. 
Roscam Abbing, U. 
Görman 
The 
recommendations 
are the expert 
consensus. 
29 2007 United States 
of America 
National Cancer 
Institute(62) 
Best practices of 
biospecimen 
resources 
The Biorepository 
Coordinating 
Committee (BCC) is 
composed of A.D. 
Barker, L.M. 
Bennett, C.D. Berg, 
C.C. Compton, H. 
Erickson, I. Fore, 
D.S. Gerhard, J. 
Gillespie, M.K. 
Henderson, A. 
Hruszkewycz, J.M. 
Jessup, P. Kim, S. 
M. Lemrow, J. 
Levine, N.C. 
Lockhart, I.A. 
Lubensky, H.M. 
Moore, K. Pitt, J.A. 
Schneider, D. 
Seminara, S.E. 
Taube, J.W. 
Thomas, A. Umar, J. 
Vaught, L. Weiss, R. 
Yassin. The Office 
of Biorepositories 
and Biospecimen 
Research is 
The guidelines were 
laid down by 
surveys and 
community forums, 
and two workshops 
attended by ethical, 
legal and policy 
experts and cancer 
research experts. 
The 
recommendations 
are the expert 
consensus. 
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composed of C. 
Compton, N. 
Lockhart, H. Moore, 
J. Vaught. 
 1 
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Table 2: Content analysis 1 
Consent Principles of -n-therapeutic  
research with children 
Nr. Year Organization Mention 
Children Legal
 g
ua
rdia
n
 
B
oth
 pa
re
nts
 
Asse
nt M
inim
al
 ha
rm
 
B
e
nefit
 to
 pe
rso
ns
 
sa
m
e
 age
 
B
e
nefit
 to
 pe
rso
ns
 
with
 sa
m
e
 co
nditio
n
 
B
e
nefits
 to
 
pa
rticipa
nts
 
O
nly
 if
 it
 ca
n
-t
 be
 
d
o
ne
 o
n
 ad
ults
 
Ethics 
comm. 
approval 
needed 
Difference 
anonym./ 
linked 
wrt 
samples 
from 
children 
Recontact 
children 
when they 
are able to 
understnd 
Recontact 
children 
when they  
reach 
legal age 
to consent 
1 1994 Gezondheidsraad + + - - - - + - - + - 
2 1995 Nuffield Council on 
Bioethics 
+ + - + + - + + - - - 
3 1998 Human Genome 
Organization 
(HUGO) 
- - 
4 1998 American Medical 
Association (AMA) 
+ + - - - + - - - - 
5 1999 National Bioethics 
Advisory 
Committee (NBAC) 
-
ii
 - 
6 2000 National Health 
and Medical 
Research Council 
+ + + + - - - - + 
7 2000 Visindasidanefnd 
 
- - 
8 2001 European Society 
of Human Genetics 
(ESHG) 
-
iii
 - 
                                               
 
 
 
 
 
 
ii
 Does not explicitly mention children in its recommendations  but does so briefly in appendices 
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9 2001 Medical Research 
Council 
+ + +iv + +
v
 
- - + + - 
10 2002 The Sub-
Committee on 
Medical Research 
Ethics (TUKIJA) of 
the National 
Advisory Board on 
Health Care Ethics 
- - 
11 2002 Council for 
International 
Organizations of 
Medical Science 
(CIOMS) 
+vi + - + + + + + + + - + + 
12 2002 Human Genome 
Organization 
(HUGO) 
- - 
13 2002 Bioethics Advisory 
Committee of the 
Israel Academy of 
Sciences and 
Humanities 
- - 
14 2002 Bioethics Advisory 
Committee 
Singapore 
+ + - - - + - - - 
                                                                                                                                                                                                                     
 
 
 
 
 
 
iii
 With regard to new collections it is stated that “Consent should be written and specific procedures should be provided for vulnerable subjects and 
vulnerable populations, based on the general principle of acting in their best interest.” 
iv
 Does not specify whether this has to be both parents 
v
 “Tests of known predictive value for adult onset diseases should not be done for research purposes on individually identifiable sample from children  
vi
 Contains some information about biological samples, but not from children. Contains general information about children in research.  
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15 2002 Human Genetics 
Commission 
-
vii
 - 
16 2002 American Medical 
Association (AMA) 
- -, refers to opinion 2.07 for informed consent (4) 
17 2003 Commission de 
l’éthique de la 
science et de la 
technologie 
+ + - + + + + + - - N:M - - 
18 2003 Comité consultatif 
national d’éthique 
pour les sciences 
de la vie et de la 
santé  
+viii + - 
19 2003 United Nations 
Educational, 
Scientific and 
Cultural 
Organization 
(UNESCO) 
+ + - +ix - 
20 2003 World Health 
Organization 
(WHO) 
+ + - + + + + + - + +x - - 
21 2004 Deutsche 
Gesellschaft für 
Humangenetik 
+ - - + - + - 
                                               
 
 
 
 
 
 
vii
 Only mentions children with regard to genetic testing 
viii
 Specifies that regulating offices should set out how informed consent on behalf of a child will be guaranteed. Points out that collections based on 
samples from children carry knowledge about a whole future lifetime.  
ix
 “The opinion of a minor should be taken into consideration as an increasingly determining factor in proportion to age and degree of maturity.” 
x
 Data from children used for non-therapeutic research must be coded 
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22 2004 Nationaler Ethikrat + + +xi + + + + + + - N - - 
23 2005 Irish Council for 
Bioethics 
+ + - + + + + - + - - + - 
24 2006 Council of Europe -xii - +xiii - 
25 2006 National Bioethics 
Commission 
- - 
26 2006 Swiss Academy of 
Medical Sciences 
+ + - - - - - + - 
27 2007 Austrian Bioethics 
Commission 
+ + +
xiv
 
+ + - + - 
28 2007 European 
Nutrogenomics 
Organization 
(NuGO) 
+ + - + - 
29 2007 National Cancer 
Institute 
+ + - - - - - - - + + - + 
                                               
 
 
 
 
 
 
xi
 Does not mention whether this has to be both parents 
xii
 Does not mention children explicitly: “Where authorization has been given on behalf of a person not able to consent, the representative, authority, 
person or body provided for by law should have the rights referred to in paragraph 1 above”. 
xiii
 3. Where a person on whose behalf authorization has been given attains the capacity to give consent, that person should have the rights referred 
to in paragraph 1 above. 
xiv
 Does not specify whether this has to be both parents 
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APPENDIX 
After the publication of this paper two guidelines were published that 
have separate provisions for minors. The first is the advice of the 
Belgian Raadgevend Comité voor Bioethiek: Advies nr. 45 van 19 
januari 2009 betreffende de banken van menselijk lichaamsmateriaal 
bestemd voor het onderzoek(63). This advice was prepared by the 
members of the committee E. Heinen, E. De Groot, G. Rorive, P. Cras, 
L. Michel, J.-N. Missa, S. Sterckx, G. Verdonck, J.-A. Stiennon, M. 
Bosson after hearing the following experts: Y. Gillerot, L. Van 
Maldergem, A. Cambon-Thomsen, N. Van Regemorter, E. Legius. It 
mentions the need for consent of a legal guardian (with a reference to 
the Belgian patients’ law of 2002), and reconsent when a minor reaches 
the age of majority. It also mentions benefits to persons with same 
age/condition (‘Anderen dringen erop aan dat de inzameling van 
materiaal en gegevens bij deze patiënten die niet in staat zijn om een 
geïnformeerde toestemming te geven, beperkt is tot aandoeningen die 
zich niet voordoen bij de wilsbekwame persoon of die enkel kunnen 
worden gedaan op het materiaal dat door hem wordt geleverd. Dat geldt 
in het bijzonder voor de onderzoeken die worden gedaan op weefsels 
van foetussen’ – ‘Others insist that the collection of samples and data 
from these patients who are not capable to give informed consent, 
would be limited to conditions that do not occur with competent persons 
or that can only be done on samples provided by him. This is especially 
the case for research done on tissue from fetuses.’). There is also a 
reference to anonymous data (‘In dat geval zouden het materiaal en de 
gegevens meestal anoniem kunnen worden gemaakt’ – ‘In that case the 
samples and the data could in most cases be anonymized’). It is unclear 
to what ‘in that case’ refers, however.  
The second document is titled OECD Guidelines on Human Biobanks 
and Genetic Research Databases by the Organization for Economic Co-
operation and Development (OECD)(64). It is established based on 
expert consultation. With regard to minors, it refers mainly to local 
jurisdictions. In this respect it mentions legal guardians (‘in such 
circumstances, applicable law may permit that the informed consent be 
sought from the appropriate substitute decision-maker, who is 
authorized to consent in the place of the participant. In some 
jurisdictions, this may be permitted only in exceptional situations. The 
conditions under which a substitute decision-maker will be able to give 
consent on behalf of the participant are subject to applicable law and 
ethical principles pertaining to the protection of human subjects and will 
vary from jurisdiction to jurisdiction.’). It also mentions assent (‘The 
operators of HBGRDs involving participants who are minors should 
have a clearly articulated policy on whether, when and how the minor’s 
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assent will be obtained, in accordance with applicable law and ethical 
principles.’) and the need to recontact donors when they become legally 
competent (‘The operators of HBGRDs involving participants who are 
minors or with impaired decision-making capacity should have a clearly 
articulated policy on what steps will be taken, in accordance with 
applicable law and ethical principles, once such participants become 
legally competent to consent.’) 
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GENETIC RESEARCH ON STORED TISSUE 
SAMPLES FROM MINORS: A SYSTEMATIC REVIEW 
OF THE ETHICAL LITERATURE  
K. Hens, H. Nys, J-J. Cassiman, K. Dierickx 
Am J Med Genet Part A 2009;149A, 2346-2358. 
 
ABSTRACT 
The potential benefits of biobank research are well-known. Also, the 
ethical implications of genetic research on stored tissue samples are 
well discussed in existing literature. The inclusion of tissue samples 
from minors may have significant scientific value. However, this 
inclusion raises specific ethical questions. We have performed a 
systematic search of the literature and found 20 theoretical and 
empirical articles dealing with the issue. After review, we distilled five 
clusters of themes: consent, risks, benefits, return of results and 
ownership. We have described the different components of these 
themes, as they occurred in the literature. We also provided a 
discussion on the argumentation and on any lacunae in the literature. 
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INTRODUCTION 
Collections of human biological samples, often called ‘biobanks’, exist in 
a variety of forms. They can differ in the method of collection, the source 
of the samples, the aim for which the collection was established and the 
type of research. In present-day medical research, genetics play an 
important role. Although the idea of genetic determinism, which is the 
belief that genes are solely responsible for physical and psychological 
traits, is somewhat obsolete, there is a rising interest to know the genes 
that influence these traits. Collections of stored ‘raw’ tissue (such as 
blood or bone marrow) or extracted DNA could form an excellent source 
for genetic epidemiological research, especially if these collections are 
linked with medical and environmental data.  
There is substantial literature on the ethical implications of genetic 
research using stored tissue samples. Most of this literature focuses on 
topics such as informed consent, privacy and confidentiality, 
commercialization and ownership, typically with adult donors in mind (see 
for example 1,2,3,4,5,6,7,8,8,9)
 
Children have long been seen as vulnerable subjects that should be 
exempt from non-therapeutic research(10).But this exemption can lead to 
the situation that children become ‘therapeutic orphans’: they miss out 
certain therapies that are only tested on adults, or are prescribed drugs 
that are never tested in children (11,10). Nowadays, most guidelines 
would formulate principles along the lines of those of the Declaration of 
Helsinki (12) and allow research on children under certain conditions. In 
the European Union, The European Directive 2001/20/EC of the 
European Parliament and of the Council of 4 April 2001 and the 
implementation by EMEA in its ‘Ethical considerations for clinical trials 
on medicinal products conducted with the pediatric population’ formulate 
similar principles(13). 
Many biobanks deliberately do not include tissue from children in their 
collection. This may be due to the fact that storage and use of human 
tissue in human biobanks has been largely framed in terms of the 
research subject’s rights, with a stress on informed consent(9). But not 
including children in biobank research poses different challenges. As we 
have already stated above for research in general, and as pointed out 
by Williams(9) for biobanks, this could lead to the situation that genetic 
research that may result in treatment is not done. Although some argue 
that genetic research could equally well be conducted on adults as on 
children(14) others claim that pediatric genetic research is necessary(9). 
For example, scientists now acknowledge the influence of early 
childhood and prenatal environmental factors on gene expression later 
in life. To study these factors, it can be argued that data and sample 
collection for research should start as early as possible. The 
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proliferation of diseases such as allergies, asthma, food intolerances, 
diabetes and obesity is attributed to a combination of genetic and 
environmental factors. To thoroughly understand this interaction, and to 
develop preventive measures, epidemiological research using genetic 
databases coupled with environmental and medical data may be 
appropriate. For more traditional purposes, such as the study of genetic 
factors of certain childhood cancers, DNA samples from children with 
that condition could be needed. It would stall research to have to collect 
these samples and store them until the child has reached the age to 
consent.  
Various child-cohort studies are already being done in different forms. 
For example, in Bristol the “Avon Longitudinal Study of Parents and 
Children” (‘Children of the nineties’) has collected detailed phenotypic 
and environmental information from pregnancy onwards on 
approximately 14 000 babies born in 1991-1992(15). A similar study is 
“Generation R”, which researches growth and health of 10 000 children 
from Rotterdam, starting from early pregnancy till the children reach 
adulthood, and “Born in Bradford”, which will follow the lives of over 
10,000 Bradford babies over the next 20 years. Rasmussen(16) has 
described the incorporation of DNA sample collection into the “National 
Birth Defects Prevention Study” (NBDPS) in the United States. The goal 
of the NBDPS is the identification of risk factors for birth defects. The 
biobank of the “Norwegian Mother and Child Cohort Study” (MoBa), 
holds more than 138,000 biological samples from pregnant women, 
their parents and their children in storage for over 100 years, thus 
providing samples for future research studies(17). An example of 
disease-specific use of pediatric tissue is given by Jenkins(18), who 
discusses a study to identify genetic and environmental risk factors for 
certain birth defects. Existing collections of tissue of children are also 
used. One example is the use of blood spot cards, which are taken from 
the vast majority of newborns over the Western world. Klotz(19) 
describes how these samples can be used for DNA extraction, to study 
cancer susceptibility genes. 
In this paper, we shall review the existing literature on ethical aspects of 
genetic research using stored tissue from children. We shall distil the 
main arguments from these papers and provide them in a descriptive 
text in the results section. In the discussion, we shall point out the gaps 
in the literature and provide a starting point for further reflection. We 
have used the broadest meaning of the term biobank: we have selected 
articles dealing with longitudinal biobank research, as well as the use of 
existing archives such as stored blood spot cards. 
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MATERIALS AND METHODS 
We have searched the following databases: Pubmed, Embase, 
Cochrane, Web of Science, CINAHL, Psychinfo, Sociological Abstracts, 
Social Sciences Citation Index and Philosopher’s Index. The following 
search terms were used: DNA database, stored DNA, archived DNA, 
DNA collection, biobank, biological sample collection, archived tissue, 
stored tissue, tissue sample, genetic database, genetic research, child, 
pediatric, minor, infant, proxy, parental consent, newborn, infant, 
embryo, preschool, ethics. We have left out articles dealing solely with 
genetic screening and articles discussing umbilical cord blood banking 
for transfusion, as well as articles that did not refer to ethical issues. Of 
the resulting set of articles, the reference list was checked for further 
relevant information, which resulted in the addition of three book 
chapters to our corpus. We also checked whether articles that cited the 
papers found yielded any additional information, which was not the 
case. We did not systematically discuss biobank guidelines, as there 
are no guidelines that deal with tissue from children alone. An overview 
of international and national guidelines with regards to this topic can be 
found in Hens et al.(20) and Samuël et al.(21). The article by Therrell(22) 
was included as it appeared in a peer-reviewed journal and its content 
surpasses that of mere guidelines.  
Newborns in many countries have a sample of blood taken a few days 
after birth, for newborn screening for treatable genetic, endocrinologic, 
metabolic and hematologic diseases, such as Phenylketonuria and 
sickle cell anemia. This blood sample is stored on so-called ‘Guthrie 
cards’, filter paper cards containing the blood and some extra 
information about the infant. These cards are kept for various lengths of 
time, depending on facility that stores them(23). It is possible to extract 
DNA from these samples(24). Hence, blood spot card samples can be 
considered ‘inchoate DNA banks(23)’. They form a possibly huge 
potential resource for genetic research, although they were originally 
gathered for diagnostic purposes(19). As they contain de facto material 
from children, we have included papers that deal with ethical issues in 
the storage and use of blood spot cards for genetic research. Some 
confusion may exist regarding the term ‘children’. We have included 
documents that mention ‘children’ or ‘minors’ and have covered the 
lifespan from birth till the age of majority. In the text, ‘children’ and 
‘minors’ will be used synonymously. 
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RESULTS 
The result of our search was 20 articles. One is an editorial, 3 are book 
chapters from edited volumes and 16 are papers from peer-reviewed 
journals. Of the latter 16, seven came from medical journals, six from 
ethical and law journals and three from journals dealing with genetics. 
Four papers contain empirical data with regard to people’s opinions on 
the participation of minors in biobank research, nine papers deal with 
theoretical-ethical issues regarding this participation. Eight papers deal 
with ethical and legal issues of the storage and use for further research 
of blood spot cards gathered for newborn screening.  
During our review of these papers, we have distilled five clusters of 
themes that have special relevance for research on tissue from minors. 
A theme that is prevalent in the general discussion on research on 
archived tissue samples, that of commercialization, was left out of the 
discussion as this was only marginally mentioned by the authors papers 
relating to pediatric biobanks, with no specific discussion on how this 
would affect or generate a special concern when participants are 
minors. The resulting five clusters are consent, risk, benefit, return of 
results and ownership. We shall now discuss our findings with regard to 
each cluster separately. We shall first give theoretical discussions and 
arguments on each topic, and then add empirical data, if any was found. 
In this section, we cite the claims and arguments as they were found in 
the literature. We shall elaborate on gaps and shortcomings in the 
discussion section.  
Consent 
The topic most broadly discussed is the one on consent. With regard to 
consent the following questions arose in the literature. Should consent 
be sought for further storage or use of pediatric tissue samples? Are 
parents allowed to consent to storage and use of materials from their 
children? And if yes, should this consent be supplemented by the 
assent of the minor? Are parents allowed to consent to any research on 
the genetic material of their children? Should minors be recontacted to 
obtain fully informed consent when they reach the legal age of 
competency? And should they have the right to withdraw from the 
study? 
Consent requirement 
In literature about biobank research, the need for consent for storage 
and further use is omnipresent. An issue that is especially linked to 
blood spot cards, which were originally gathered for newborn screening, 
is that for most of these cards, no consent for storage or use for 
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research purposes exists. In most countries, such as Canada, USA and 
UK, consent for newborn screening is presumed: often no written or oral 
consent is sought and many parents are unaware that they could refuse 
screening of their newborn(25). The nine articles we have found that 
discuss the storage and further use of blood spot cards agree that 
newborn screening for treatable disorders without consent can be 
defended because the benefits to the child are obvious. For example, 
early detection of Phenylketonuria (PKU) and preventive measures can 
substantially reduce neurological problems in affected babies. However, 
all authors discussing blood spot cards make a strong distinction 
between diagnostic use of the samples, for which consent may not be 
needed as this is considered part of routine care and use for further 
storage and non-therapeutic research for which consent is 
needed(22,24,26,27,28,29,30,25,31). 
Consent by whom 
The need for consent to storage and subsequent use in non-therapeutic 
research is not questioned by any author. In the case of tissue samples 
from legally incompetent minors, this means that consent must be given 
by proxy. Who should consent for minors who have not the legal 
capacity to do so? Most authors(22,24,26,27,32,30,25,31,33,34,35,36) acknowledge 
the fact that biobank storage and research on pediatric samples can be 
done under a regime of parental consent, where one of the parents or a 
legal guardian gives consent for the child. Holm(33) justifies this by 
stating that the enrolment of children in biobank research in most cases 
does not have demonstrable negative effects on the children. Only 
Baumann(14) thinks that parents or other individuals should not be 
allowed to consent to the inclusion of their children in such databank, at 
least until there are sound regulations about genetic discrimination. She 
thinks the risks for such discrimination are too high. Moreover, she 
claims that if inclusion of pediatric samples in a biobank is done 
nonetheless, both parents should consent. She gives two arguments: 
first, she considers DNA sampling to be more than minimal risk, and 
second, each parent’s genetic material is present in the child, so each 
parent faces equal risk of genetic discrimination. Avard and Knoppers 
(28)
 think that the whole family should be involved in the information 
process, as genetic information affects also the family members. These 
authors do not specify whether this means that all family members 
should give their explicit consent. 
Empirical research by Goodenough et al.(37) suggest that children seem 
not to question their parents’ decision to enroll them in a longitudinal 
genetic and environmental study, and most of the children would join 
again if given the choice. In a study by Neidich et al.(38), almost half of 
the women interviewed would be willing to enroll their children in a 
hypothetical pediatric biobank (47%) and 28% were unsure. Williamson 
et al.(39) found that when parents did refuse to consent this was due to 
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their own fears and concerns, and not due to the parents’ questioning 
their right to make such a decision on behalf of their child. Some focus 
group participants in the study by Kaufman et al.(40) regard a parent’s 
consent to be sufficient for a minor to participate. On the other hand, 
some did find pediatric enrolment problematic if consent of participants 
cannot be obtained, because the child is too young to consent. 
 
Related to the issue of parental consent is the question whether the 
opinions of the minors matter. These opinions can be expressed 
through assent (give permission) or dissent (refuse to give permission). 
Fisher(36), Avard and Knoppers(28), Knoppers et al.(32), Goodenough et 
al.(37), Holm(33), and Helgesson(34) believe that older children and 
adolescents should be asked to assent or dissent. Goodenough et al. 
(37)
 mention the age of 9-11 as the age where children are being used to 
being offered choices and are gradually making more choices for 
themselves. Helgesson(34) states that parents help children to become 
such autonomous persons by making decisions for them. But to develop 
autonomy also means being given the capacity to exercise it to the 
degree one is capable of. Hence information should be given to children 
according to their age and assent should be sought in addition to 
parental consent. McHale et al.(41) describes how, in a UK legal context, 
the age as of which a minor may autonomously consent may vary 
dependent on whether the consent is for surgery or for storage or 
further use of the tissue removed. Whether assent should always be 
sought, or starting from a fixed age, or whether a test for maturity should 
be used was not discussed in these papers. 
Empirical data from Williamson et al.(39) show that children thought of 
consent as an ongoing process in relation between themselves and 
their parents, and that they believed they would have more control when 
they grow older. Also, parents considered the fact that their children 
were informed during the process as positive. In practice, however, 
children sometimes felt that they did not have an option to dissent or not 
to participate with certain activities or assessments in longitudinal 
research(37,39). 
Scope of consent 
Another issue is the scope of such proxy consent. First, should a parent 
be allowed to consent to any study using the genetic material of their 
child? Second, should the minor be recontacted to obtain fully informed 
consent once he or she is of legal age to do so? And third, should 
minors be given the option to withdraw from the study. 
 
A first question is what parents should be allowed to consent to for their 
children. We found no theoretical discussion on this subject. In the 
empirical study by Neidich et al.(38) women who were willing to enroll 
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their child in a pediatric biobank put very few restrictions on the type of 
research that can be done on samples, with the exception of ‘cloning’. 
 
Secondly, an important question is whether children should be 
recontacted to give consent when they reach the age where they can 
legally do so. Burke and Diekema(35), although admitting that it is costly, 
are in favor of reconsent because this allows minors to participate more 
as they grow older, and to gain full consent from them when they reach 
adulthood. A second argument from Burke and Diekema is that the 
initial consent was not obtained from the participant him or herself. This 
second argument is acknowledged by Helgesson(34) and Fisher(36) who 
state that proxy consent and informed consent are fundamentally 
different: proxy consent does not express the autonomy of the person 
involved. So, consent should be obtained from participants when they 
reach the age that they legally can do so. A similar stance is taken by 
Elkin and Jones(26) who mention the age of 16 years in a New Zealand 
context.. Also Kaufman’s empirical research(40) describes that people 
thought children should be recontacted when they became old enough 
to understand the impact of genetic research or when they turn 18, 
hence referring to both maturity and a legal age of majority. 
 
The third aspect of scope of consent is the question to what extent 
children should have the right to withdraw from the study. No author 
claimed that children should not be given this right. Elkin and Jones(26), 
Pelias and Markward(27) Kharaboyan et al.(30), Goodenough et al.(37), 
Williamson et al.(39), Holm (33), Helgesson (34), Thomas (31) and Fisher (36), 
stress the importance of the possibility to withdraw. Holm (33) gives as an 
argument for this stance that, as children have not been able to 
autonomously consent and give up the right to withdraw at the moment 
of donation, the right to withdraw for children is more important than the 
right to withdraw for adult donors. In Kaufman’s focus group 
research(40), participants also expressed the opinion that children that 
reach the age of consent or a given level of understanding or maturity 
should be recontacted and given the possibility to withdraw. There was 
no further clarification on what this maturity would entail.  
Risk 
Which kinds of risk can children encounter when they are enrolled as 
participants in biobank research? Knoppers et al.(32), Avard and 
Knoppers(28), Williamson et al.(39), Holm (33) and Helgesson (34) refer to 
the idea that non-therapeutic research on tissue from minors can be 
done if there is no more than minimal risk. Empirical data from Neidich 
et al.(38) has shown that most women interviewed considered enrollment 
in a biobank as entailing no more than minimal harm. Three types of 
harm associated with storage and use of genetic research databases 
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are discussed: physical and emotional harm, breaches of confidentiality 
and group stigmatization. 
Physical and emotional harm 
A first type of risk is physical and emotional harm. With regard to 
biobanks Kaufman et al.(40) report that some participants mention that 
children might experience fear, for example of needles and the clinical 
environment, which would erode the trust between parents and child. 
Participants thought procedures should be minimally invasive and 
possibly conducted by a physician who is familiar with the child. Some 
participants thought that children would be overburdened by 
participation, as they had already a long list of activities. Also, 
Goodenough et al.(37) show that some children said they would not 
enroll in the research again if they were given the choice as they have 
already so much to do. Williamson et al.(39) point out that a parent’s view 
of what is personal information varies from the view of children. They 
believe that views of children should be respected: what is considered 
private and vulnerable information changes as the children grow older. 
Hence, children might feel uncomfortable about certain questions and 
knowledge which would pose no problems if adults were asked the 
same things. 
Confidentiality 
As the biobanks under discussion also contain genetic information, the 
risks quoted first and foremost are confidentiality related, such as 
access by third parties (e.g. insurance companies, employers, the 
government). This could lead to discrimination of the participants or to 
personal stigma(22,26,28,29,30,35,33,40). Burke and Diekema (35) and Holm (33) 
stress the need for privacy protection. Participants have a right to know 
how this will be protected. Because DNA-based identification 
procedures will increase of time, participants who enrolled as children 
have a right to know about privacy protections and risks as adults. 
Baumann (14) suggests the risks of biobank research far outweigh the 
benefits. She is of the opinion that a DNA sample can be used to 
identify every physical and mental characteristic of an individual and 
that the potential harm that can occur is genetic discrimination by 
employers and insurers. In her opinion it is still unsure what DNA will be 
able to reveal about the individual in the future. Hence, there is 
significant possible risk for genetic discrimination associated with 
genetic biobank research.  
There is also some potential harm when data is accessed by the 
parents. We shall discuss this when we discuss return of results. 
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Levels of identifiability 
Data and samples in biobanks can have different levels of identifiability. 
Data can be kept completely anonymized, which means there is no way 
to retrieve the donor’s identify with a reasonable amount of effort. They 
can be kept coded, where the identifying information can be retrieved 
using one or more keys. Or they can be completely identifiable. Some 
authors suggest that anonymization appears to remove the risks for 
privacy breaches(22,30,25). Others claim that even if the risk for personal 
harm is minimal after anonymization, the results of genetic research 
may lead to group stigma, and hence, indirectly may affect the 
individual(24,31,33,35,28). Avard and Knoppers (28) also prefer anonymization 
of the sample, but in any case the donor should be informed about the 
use of anonymized samples. Hence, some suggest that anonymization 
may be a solution for existing collections, but new donors should be 
able to decide whether their sample should be kept anonymous or not 
(24,27,32,36)
. 
Williamson et al.(39) describe how children perceive how their samples 
are kept: they think their name is on the sample and some children 
thought the samples would be returned to them after the study. 
Strikingly, some also thought that these could be used for other things 
such as police profiles. Parents, on the other hand, did not consider it 
appropriate that information gathered for one purpose would be used for 
another purpose.  
Personal and Group Benefit 
Who should benefit from research on stored tissue samples from 
minors? Different levels of benefit can be distinguished. First, research 
may directly benefit the participant. Second, it may benefit others who 
suffer from the same condition. And third, there may be a benefit to 
society as a whole. Avard and Knoppers(28), Knoppers et al.(32) and 
Helgesson(34) refer to general principles of non-therapeutic research on 
children. They mention that research on samples from minors can only 
be done if it is not possible to obtain the same results with participants 
that can consent, and that participants should either benefit directly, or 
children of the same age or with the same condition should benefit. In 
this respect, Holm(33) states three possible justifications for restricting 
research to benefits to the same group. First, it acts as an adequate 
protection, given the historical fact that vulnerable groups have been 
used in not so ethical research. Secondly, this requirement guarantees 
that the group of persons with a specific interest and the group of 
sufferers exist at the same time. However, if research is prospective, or 
if the group to which a participant belongs is transitory, such as ‘age’, 
there is a time lag: the sufferers will not directly benefit from research. 
Thirdly, some people consider all research on children unethical, but 
admit that this may stall research. They accept the group restrictions out 
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of pragmatic reasons. Holm considers all three justifications as 
insufficient, and states that it is much easier to justify a complete ban on 
research on children because they cannot give informed consent than to 
argument for this particular way of restricting research. This is a route 
he does not want to take. The requirement that such research should 
benefit participants directly is difficult to apply to biobank research, as 
this is typically non-therapeutic. But empirical research from Kaufman et 
al.(40) points out that participants believe that regular checkups might 
increase children’s health and that research might lead to more insight 
in familial genes. Participants of focus groups also recognized benefits 
to society as a whole. Besides, Goodenough et al.(37) and Williamson et 
al.(39) describe how many children said the purpose of the study they 
participated in was to help other children. In the Neidich et al. study (38) 
however, many women (69%) believed that the main goal of the 
research was helping their own child, but 88% also stated that one of 
the goals of the research would be to improve scientific knowledge for 
the benefit of future patients. 
Return of Results 
Genetic biobank research is primarily non-therapeutic and in most 
cases there is no direct benefit to participants. But in principle, when 
data is not kept in an anonymized way, some results could be returned 
to participants(30,25). Should results be returned and which ones should 
be returned? Should only results which may have an immediate benefit 
for the child be returned, or also results that might be useful at a later 
time (24,42)? Avard and Knoppers(28) and Burke and Diekema(35) state that 
the return of results of genetic analysis to parents can trigger anxiety 
and change the way in which parents treat their children. Burke and 
Diekema quote the recommendations from the US National Bioethics 
Committee (NBAC) that state that disclosure needs only occur if results 
can be used to improve health outcome, hence if there is direct 
beneficence. If genetic results without immediate medical value are 
disclosed to parents this is a breach of the autonomy principle, as this 
prevents the child from exercising the right not to know, a choice a child 
might make as an adult. Kaufman’s empirical data(40) show that many 
people thought results should be provided to parents, especially if the 
child was facing immediate risk. On the other hand, some thought that 
when findings are inconclusive the return of these findings might do 
more harm than good. Parents should be given the opportunity to opt 
out of learning such information. Focus group participants also thought 
that parents should have access to the data from their children, at least 
until they reach maturity. 
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Ownership 
Who is the owner of pediatric tissue residing in biobanks, and the 
associated medical data? At least five options exist: the institution 
where the collection is housed, the state, the researchers, the parents 
or the child. With regard to blood spot cards, Lysaught et al.(24) ask 
whether the owner is the state or the parents: if we consider the state to 
be the owner, can parents still express specifications about the 
disposition of the child’s sample? For example can they decide whether 
it should be destroyed rather than retained, which secondary uses are 
allowed, should it be anonymized or identifiable? Pelias and 
Markward(27) describe three aspects of full ownership: possession 
(physical dominion), enjoyment (having the benefit of what the thing 
may yield) and dispensing of the property (the right to sell, donate or 
destroy it). The authors state that for historical collections, the full 
ownership lies with the institutions where the collection is housed. For 
current and future collections ownership is shared between the 
institution and the donors: possession lies with the institution or hospital, 
enjoyment with the donor who may have a right to the information that is 
generated and with the researcher who can use it for research. The 
donor also has the right to dispense: to request withdrawal of his or her 
sample. Elkin and Jones (26) and Thomas(31) state that in New Zealand, 
referring to New Zealand Code of Health and Disability Services 
Consumers’ Rights, blood spot cards are the property of the individual, 
with the parents acting as surrogate until the child is competent. 
Williamson et al.(39) ask whether information about a child, given by the 
parent, belongs to the child or the parent. They also ask whether there 
is a difference between information in different ages: does ownership 
rights change if the information is about a baby’s feeding habits or about 
puberty? Williamson et al. mention genetic information from placental 
blood, which can contain DNA information on mother and child. Holm(33) 
thinks that disputes with regard to such information should be resolved 
in favor of the child, because its information is only there through proxy 
consent. Empirical research from Williamson et al.(39) shows that 
children enrolled in the ALSPAC study perceive the tissue belongs to 
them, although legally they are not the owners. The authors mentioned 
did not explicitly make a distinction between ownership of tissue and of 
derived or associated data and information. 
DISCUSSION 
We have reviewed 20 papers consisting of legal and ethical literature on 
stored tissue from minors and results from empirical studies. We 
distilled five major clusters from these studies: consent, risk, benefit, 
return of results and ownership. We shall now provide our own 
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comments on the findings on consent, risk, benefit and return of result 
and conclude by pointing out some gaps. We have left out a thorough 
discussion on ownership, as this is primarily a legal concept and hence 
is outside of the scope of this article. As some aspects of ownership are 
also ethically relevant, such as who has decision capacity over the 
tissue and information stored, we have included it in the analysis, but 
these aspects are discussed as part of other topics. 
Consent 
The majority of issues discussed were related to the issue of consent. 
All papers agreed that tissue should not be stored and used for 
research without written consent. This was stressed especially in the 
papers on blood spot cards: although taking and storing of blood 
samples of newborns without explicit written consent by the parents was 
considered acceptable in the context of diagnosis and treatment, it was 
not deemed acceptable that these would be reused for non-therapeutic 
genetic research. Minors and especially young children are not deemed 
legally competent to give fully informed consent. Who should then give 
consent for the inclusion of the tissue sample of the child? The validity 
of parents giving such consent is not questioned by most articles. This 
consent is then proxy consent, rather than an autonomous consent, as 
the decision was made on behalf of the child.  
We can discern three approaches to proxy consent: the theory of 
substituted judgment, that of best interest and an approach that 
stresses parental interest(43,44,45). First, the theory of substituted 
judgment states that a consent given by proxy aims at best representing 
what the incompetent patient would decide if he or she were competent. 
In the context of pediatric consent, substituted judgment is problematic, 
especially with babies and young children, as they have never been 
competent and their wishes have not yet known (44). The theory of best 
interest states that a decision is made on behalf of the incompetent 
person in his or her best interest. This is also problematic when applied 
to biobank research as most of this research has no direct benefit to the 
participants. What is best interest in non-therapeutic research? 
According to Ross(45), parental permission also serves to respect a 
legitimate parental interest in making decisions for their child: respect 
for children means respect for people they are becoming. Hence, to 
allow non-therapeutic research may mean respecting the child’s 
development and hope of the kind of person the parents want the child 
to become. In this context, parents may be allowed to consent to the 
enrolment of their children in biobank research, even if this type of 
consent does not fit into the scheme of substituted judgment or best 
interest.  
Should both parents consent to the enrolment of children in biobank 
research? As for pediatric participants of non-therapeutic research in 
general, Ross(42) suggests that when this research involves more than 
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minimal risk, the consent of two parents may ensure greater protection. 
On the other hand, she wonders whether this is truly feasible: not only 
must both parents consider the risks and benefits of the child’s 
participation, but they both must be able and willing to sign for his or her 
participation. In a society where many families do no longer consist of 
two parents with their (genetic) children this may be difficult. Does the 
fact that the research focuses on genetic information, which is shared 
with both parents, make a difference? In our opinion, consent from both 
parents should be seen as a best practice, rather than as an absolute 
requirement. This would correspond to for example the implementation 
of the European Clinical Trial Directive (2001/20/EC) in Belgian law. 
This law is applicable to clinical trials and states that in principle, 
parental consent is granted by both parents. However, as this may be 
difficult to achieve and in practice the consent of the second parent is 
assumed(46).  
 
Most authors we reviewed considered it to be good practice to ask for 
assent from the child, next to parental consent, when he or she is able 
to give such assent. The literature did not specify whether this should be 
done based on a fixed age or on maturity, and if the latter is the case, 
how this maturity should be assessed. However, there is no consensus 
or guideline as of which age children should be allowed to assent to 
non-therapeutic research. For example, Wendler and Shah(47) suggest a 
fixed threshold for assent at 14 years of age, but think a dissent 
requirement should be adopted for all children regardless of age in the 
context of non-beneficial research. On the other hand, Ashcroft et al.(48) 
stress maturity and argues that the capacity to assent is dependent on 
social context and personal experience, and hence such fixed age is not 
useful. Finally, Alderson(49) suggests that also very young children can 
express their opinions, and that these opinions are valuable in 
themselves. It is unclear how this should be seen in context of biobank 
research: should we disregard the fear of needles of a five year old and 
take a sample of her blood anyway, as long as the parents have 
consented? With regard to genetic research on biobank samples, these 
decisions should be supported by empirical research on children’s 
knowledge of the benefits and challenges of such research specifically 
Moreover, there is agreement that a child should be allowed to give 
consent for further research and storage when he or she reaches the 
legal age to do so. An overview of legal regulations regarding the 
position of minors in a health care setting in the EU member states 
shows that this position varies from country to country: the age and 
circumstances under which minors are allowed to take health care 
decisions vary in the different countries(50). For example, in countries 
such as Cyprus, Greece and Slovakia, the age of medical majority is the 
same as the legal age of majority (18 years in these cases). Some 
countries distinguish between the age of medical majority and that of 
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legal majority: the age of medical majority is 15 years in Denmark and 
Slovenia, 16 years in Lithuania and Spain, and 14 years in Portugal. 
The Czech Republic and Estonia do not have a fixed age, but consider 
this on a case-by-case basis, dependent on age and maturity.  
 
With regard to the scope of consent, most papers do not make a 
distinction between consent for storage and consent for subsequent 
genetic research. The nature of biobank research is such that samples 
are stored for several years, and that the types of research done may 
be unknown at the time of storage. Hence, people actually consent to 
different things: storage and further research use(51). This may also have 
legal implications which are not always fully understood(52). 
Furthermore, there is the question of the type of research parents 
should be allowed to consent to. Should they be allowed to consent for 
any study on the genetic material of their children, or only for specific 
studies? The former is called broad consent: a subject is asked to agree 
to any future research that can be done with his or her DNA. In the case 
of specific consent, this means that the donor is recontacted each time 
a new type of research is done on his or her material(53).In the case of 
pediatric biobanks this question becomes more complicated: should the 
parents be allowed to give broad consent for the use of genetic material 
of the children? Should they be recontacted or should the children be 
recontacted? Some suggest(54,55) that biobank participants should be 
allowed to give broad informed consent for unknown future research. 
For pediatric tissue sample storage, however the consent is done by 
proxy: and the minor participants’ ideas of what is good research might 
differ from what their parents consider so(33). A solution could be to allow 
parents to consent to storage of the tissue, and for research on specific 
genes or conditions that their child suffers from. This would correspond 
to the Helsinki guidelines on non-therapeutic research on minors, that 
such research would benefit other children of the same age or condition. 
When the minor reaches maturity, broad consent for further storage and 
research use could then be sought. On the other hand, one could argue 
that biobank research is much less ‘risky’ than for example clinical trials, 
and that in that respect, parents should be allowed to give broad 
consent for their children, for both storage and research, at least until 
the child is able to assent or consent. However, given the fact that DNA 
is stable throughout a lifetime, it may seem unfair for parents to give 
consent to any genetic research on their children’s DNA. Given the fact 
that such consent is given on behalf of the child, it may be reasonable to 
postpone the choice for ‘broad’ consent to any future genetic research 
until the minor reaches the age of majority.  
 
There was a consensus in all papers in our review that discuss 
withdrawal that minors should be given the option to withdraw from a 
study for which their parents consented. Again, no fixed age or criterion 
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of maturity was specified. An open question is also what this withdrawal 
should entail. Does this mean that they do not actively participate in 
activities surrounding the biobank, such as filling in questionnaires or 
providing extra medical information? Should the actual sample be 
destroyed or flagged ‘do not use’? Fact is that in many cases some 
results that use the minor’s data will already be published at the time of 
withdrawal. As such, a minor never has the capability of completely 
undoing his or her parent’s decisions.  
 
With regard to biobanks, often the discussion is between adherents of 
the doctrine of informed consent, who emphasize autonomy, and those 
who emphasize the duty for solidarity for the public good (1). Some take 
the middle ground that solidarity is not possible as long as there is not a 
feeling of trust from the public(56). Asking for consent is in this respect 
not so much an action to stress the participant’s autonomy, but a tool to 
generate trust(4). Although some papers reviewed mention the need for 
trust between researchers, the children and their families, this view on 
informed consent is not explored in depth with regard to children. 
However, to ensure support of research, it is imperative that such trust 
is gained also from the children participating in the research. This has 
been already pointed out for clinical trials involving children by 
Pinxten(10), but it is also applicable to longitudinal genetic research. A 
policy of ongoing information provisioning and assent helps to gain the 
trust from children in specific research and in science in general.  
 
There is agreement amongst the authors studied that consent is 
needed, and that in the case of minors, this consent can be given by a 
parent. No author doubted that it is good practice to obtain assent from 
the child as well. They also did not doubt that upon reaching the age of 
majority, the donor should be recontacted for consent and should be 
given the option to withdraw from the study. The criteria of obtaining 
assent were not extensively discussed: should assent be sought from a 
certain age or of a certain level of maturity? And does this mean that 
children that fall below the chosen criterion should be excluded from the 
study? Another topic that was not explored was the content of the 
parental consent: should parents be allowed to consent to general 
genetic research on the genetic data of their children, or only to specific 
studies? The answer to these questions is linked to the amount of risk 
that is associated with genetic research, a factor which is in itself still 
uncertain as we shall see in the next part of our discussion. Also, the 
relation between actively engaging children in decisions about genetic 
research and the trust they will have in research now and as they grow 
older needs further investigation. 
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Risk 
The requirement that non-therapeutic research should pose no more 
than minimal risk to pediatric participants is mentioned in some of the 
papers reviewed. This is a great difference with research on competent 
adults, who are deemed capable of choosing and assessing the risks for 
themselves. The requirement is often used in the context of clinical 
trials, where the risks are more tangible. In the reviewed articles, 
although some types of risks are quoted, it is not made clear to which 
extent these are minimal. Eriksson and Helgesson(5) think there is less 
risk involved in biobank research than in human subject research, as 
there is no risk of direct physical harm. They describe the following 
possible harms: Non-physical harm is for example, information being 
used to the disadvantage of the person (for example, by insurance 
companies or employers, or paternity information). They also mention 
group harms, which can be external (the attitudes towards a group may 
change based on knowledge resulting from biobank research) or 
internal (loss of self-esteem of certain groups). They also pinpoint moral 
wrongs: one may violate the autonomy, privacy or personal integrity of 
participants by storing or using their samples. This moral harm can 
occur if samples are used for research that the participants would object 
to or if researchers draw conclusion regarding paternity, or access other 
private data that individuals wish to keep for themselves. This is also 
applicable to groups, if they are for example systematically excluded 
from the benefits of research. How do these different harms apply to 
children? First, Eriksson and Helgesson think that physical risk is 
minimal. But one could argue that physical harm and the anxiety that 
results from, for example, taking blood or being put in a hospital 
environment is greater for children who cannot yet understand the 
purpose. Also, as is mentioned in some papers, the things that children 
consider private or sensible information may be different from the view 
of adults, and may change overtime and constitute a moral harm. 
Hence, also in pediatric biobank research, it is important to discern 
sensitive information per age group. Many papers also mention the risks 
of confidentiality breaches by third parties such as insurers and 
employers, which are probably equally high for minor participants as 
they are for adults. But the assessment of what is acceptable risk and 
what is not remains difficult. As Leikin (57) points out for epidemiological 
research in general, the criterion mostly used is whether the risk are 
greater than those generally encountered by children in everyday life. It 
is also highly dependent on the situation, the particular child and the 
age of the child. Hence, it remains a highly problematic criterion to allow 
inclusion of stored tissue samples from children in biobanks. On the 
other hand, group stigmatization that results from findings from biobank 
research will also affect children that are part of this group, and this 
regardless of whether they contributed to the research or not. In this 
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perspective, the risks originating from biobank research with certain 
groups are more important than those arising from the participation of 
specific children. This may act as a warning against biobank research in 
general, but also as an indication that one should not be overly 
protective of individual child participants in such research.  
 
There is agreement that non-therapeutic research on children should 
pose no more than minimal risk. However, there is much uncertainty as 
to what this would mean in the context of biobanks. First, little 
knowledge exists about the fears and privacy issues as perceived by 
children: some authors acknowledge that these issues may be different 
from those experienced by adults, but it is still unclear how access to 
their genetic information is felt by children. In the context of biobanks in 
general, confidentiality breaches by third parties such as insurers and 
companies are often quoted but it is difficult to assess how real these 
dangers are. Also, although some papers did discuss the issue of 
anonymization in general, we did not find a thorough discussion whether 
samples from children specifically would benefit from further protection 
through anonymization or coding. We think further study is needed to 
evaluate the amount of risk associated with biobanks, in general and for 
children specifically and to assess what would be the correct means to 
protect children against these risks. 
Personal and Group Benefits 
What benefit should arise from the use of pediatric tissue? Some papers 
have stated that research on children should benefit other children with 
the same age or condition. However, others, such as Holm(33) consider 
this to be too restrictive. Moreover, this seems to make longitudinal 
cohort studies which study the interaction between genes and 
environment by following children throughout the process of growing up 
impossible. Some also mention the requirement that research on 
children should benefit the participants. This is in many cases not 
applicable to biobank research, although participants might gain some 
benefits through regular health checkups. However, some of the 
empirical research we have studied shows that non-therapeutic 
research, also enrollment in a biobank, is sometimes confused with 
clinical practice and/or a personal health benefit, a phenomenon called 
‘therapeutic misconception’. De Vries and van Leeuwen(58) state that up 
to 80% of research subjects makes this mistake. It is imperative that 
during consent procedures parents, and if possible the children are 
made aware of the fact that the primary aim of the research is benefit to 
future generations.  
Literature Review 
83/233 
Return of Results 
Should any individual results be returned to participants and if so, which 
results should be returned? General biobank literature has mentioned 
that, although most biobanks have a policy of not recontacting 
participants(56), researchers often feel an obligation to disclose results 
that they believe are clinically relevant(3). Some suggest that information 
should be sent through a physician(4). Bookman et al. (59) state that 
genetic test results should be reported to study participants when the 
associated risk for the disease is significant. But at least the consent 
form should mention opting out of receiving this information.  
 
The question of return of results was not discussed in much depth with 
regard to minors. However, some specific questions arise in this context 
that would need further investigation. Should parents be allowed to 
decide not to receive vital information about their children, or should, in 
case of a severe and preventable disease, the principle of beneficence 
take precedence over parental autonomy? And, the other way around, 
do parents have the right to know details about their children’s genetic 
makeup that are not directly clinically relevant? On the one hand, as 
genetic information is mostly stable throughout a lifetime, this may put a 
limit on a parent’s right to know. On the other hand, parents are allowed 
to obtain other information about their children, such as IQ. The major 
question here is whether genetic information is in any way different from 
other information, and whether this affects the right parents have to this 
information on their children. In the literature studied there was no 
answer to this question. 
 
We have reviewed 20 articles that discuss the ethical issues 
surrounding the storage and use of pediatric tissue samples from 
children. From that we have distilled five major themes: consent, risk, 
benefit, return of results and ownership. In each of these themes, ethical 
issues, questions and answers could be discovered that are different 
from those involving tissue samples from adults. The fact that we have 
used such a variety of sources (both theoretical and empirical) could be 
a limitation of our study. However, some issues were discussed in the 
empirical literature, where others only came up in more theoretical 
papers. Another limitation is the fact that we used a broad definition of 
child, starting from newborn to the age when they reach majority and 
used all literature that dealt with minors. Ethical issues might be 
different according to different ages, but given the scarcity of the 
literature we have opted not discuss these separately, also because in 
the reviewed literature there was no systematic attention to the different 
stages of childhood. We also took ‘biobank research’ as broad as 
possible, and have also included issues related to research surrounding 
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genetic research on tissue, such as phenotypical research using 
medical data or questionnaires to gather additional information. 
 
Our review of the existing literature on genetic research on stored tissue 
samples from children has shown that still many questions exist with 
regard to the conditions under which such storage and research can 
take place. Indeed, the reviewed articles raise much more questions 
than that they provide answers. Most of these questions require a more 
fundamental reflection on the nature of consent, the nature and risks of 
genetic information and additional data on the experience of children of 
such information. Moreover, although both empirical as well as 
theoretical arguments were found, both types of literature did not seem 
to inform each other. A thorough examination of the issues at stake, 
empirical as well as theoretical seems needed. Also, a consideration of 
the themes based on different age levels is missing, and would be 
fruitful. 
Literature Review 
85/233 
Authors & Year Title Type & Content Themes 
Therrell et al. [1996] Guidelines for the retention, storage, and use of 
residual dried blood spot samples after newborn 
screening analysis: statement of the Council of 
Regional Networks for Genetic Services. 
Blood spot cards 
Guidelines for policy development by US state health 
departments considering appropriate use of newborn 
screening after screening tests are finished 
Confidentiality (risk) 
Consent Requirement  
Levels of identifiability 
(risk) 
Parental Consent 
Lysaught et al.1998 A Pilot test of DNA-based analysis using anonymized 
newborn screening cards in Iowa. Stored tissue 
samples: Ethical legal, and public policy implications 
Blood spot cards 
A description of a pilot test of DNA-based analysis using 
anonymized newborn screening cards in Iowa 
discussion about the ethical and legal  issues that arise 
when a sample obtained from patients for one purpose is 
then used for secondary purposes unrelated to the 
original intent 
Consent Requirement 
Levels of identifiability 
(risk) 
Ownership 
Parental Consent 
Elkin and Jones. 
[2000] 
Guthrie cards: legal and ethical issues Blood spot cards 
Discusses ethical and legal issues with regard to 
newborn screening and consent, consent for further 
storage and use of blood spot cards from a New Zealand 
perspective 
Levels of identifiability 
(risk) 
Consent Requirement 
Confidentiality (risk) 
Ownership 
Parental Consent 
Recontact 
Pelias and Markward. 
[2001] 
Newborn screening, informed consent, and future use 
of archived tissue samples. 
Blood spot cards 
Discusses ethical issues with regard to newborn 
screening, and further use of blood spot cards and a 
recommendation for an informed consent protocol. 
Consent Requirement  
Levels of identifiability 
(risk) 
Parental Consent 
Withdrawal 
 Baumann. [2001] Proxy consent and a national DNA databank: An 
unethical and discriminatory combination 
Ethics 
Discusses why the author thinks it is unethical to allow 
parents to give proxy consent to donate their child’s DNA 
sample to a national database.  
Confidentiality (risk) 
Parental Consent 
Avard and Knoppers. 
[2002] 
Ethical dimensions of genetics in pediatric neurology: 
a look into the future 
Ethics 
Discusses risks and benefits associated with genetic 
research, particularly the issue of consent, the use of 
genetic databases, gene therapy and genetic testing 
Assent 
Benefit 
Confidentiality (risk) 
Consent Requirement 
Levels of identifiability 
(risk) 
Parental Consent 
Knoppers et al. [2002] Children and incompetent adults in genetic research: 
consent and safeguards 
Ethics 
Discusses the fact that inclusion of children and 
incompetent adults call for additional safeguards. 
Proposes policy considerations.  
Assent 
Benefit 
Levels of identifiability 
(risk) 
Parental Consent 
Dhanda and Reilly. 
[2003] 
Legal and ethical issues of newborn screening Blood spot cards 
Discusses ethical aspects of using DNA-based methods 
Confidentiality (risk) 
Consent Requirement 
Literature Review 
86/233 
for newborn screening and further banking of the 
material 
 
Goodenough et al.. 
[2004] 
Ethical protection in research: including children in the 
debate 
Empirical 
Description of the EPEG project (Ethical Protection in 
Epidemiological Genetics). Description of 40 interviews 
with children aged 9-11: how do child participants 
perceive and understand their involvement in a major 
longitudinal epidemiological and genetic study (AVON, 
children of the 90’s) 
Assent 
Benefit 
Parental Consent 
Physical and emotional 
risk 
Withdrawal 
Williamson et al. 
[2004] 
Children’s participation in genetic epidemiology: 
consent and control 
Empirical 
Description of the EPEG project (Ethical Protection in 
Epidemiological Genetics). 
Analysis of the viewpoints of both the parents and the 
children. Discussion of the ethical and legal rights of the 
parents to consent for their children, and description of 
how child participants perceive notions of risk with 
regard to different type of information 
Assent 
Benefit 
Levels of identifiability 
(risk) 
Parental Consent 
Physical and emotional 
risk 
Reconsent 
Withdrawal 
Kharaboyan et al. 
[2004] 
Storing newborn blood spots: Modern controversies Blood spot cards 
Comparison of current guidelines and policy documents 
that apply to banking dried blood spot cards and 
assessment of the similarities and differences in storage, 
length of storage and access to stored samples 
Consent Requirement 
Levels of identifiability 
(risk) 
Parental Consent 
Reconsent 
Return of Results 
Laberge et al. [2004] Newborn Screening, Banking, and Consent Blood spot cards 
Examination and discussion of guidelines and policy 
statements about consent for treatable and untreatable 
diseases, further storage and future uses of stored 
samples 
Consent Requirement 
Levels of identifiability 
(risk) 
Parental Consent 
Return of Results 
Thomas. [2005] The use and control of heel prick blood samples Blood spot cards 
Discusses the status of blood spot cards in New Zealand 
and suggests approaches for retention and further use of 
the samples, or third party access 
Assent 
Consent Requirement 
Levels of identifiability 
(risk) 
Ownership 
Parental Consent 
Reconsent 
Withdrawal 
Holm. [2005] Informed Consent and the Bio-banking of Material 
from Children 
Ethics 
Discusses ethical issues raised by biobanking of 
material from children who are not old enough to 
consent.   
Assent 
Benefit 
Confidentiality (risk) 
Ownership 
Parental Consent 
Withdrawal 
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Helgesson. [2005] Children, Longitudinal Studies, and Informed Consent Ethics 
Discusses ethical issues relevant to longitudinal 
research involving children 
Assent 
Benefit 
Parental Consent 
Reconsent 
Withdrawal 
Burke and Diekema. 
[2006] 
 
Ethical issues arising from the participation of children 
in genetic research 
Ethics 
Discusses ethical concerns related to pediatric 
participation in genetic research, both in family studies 
and large population studies 
Confidentiality (risk) 
Parental Consent 
Reconsent 
Return of Results 
Fisher. [2006] Privacy and ethics in pediatric environmental health 
research -- part II: protecting families and communities 
Ethics 
Discusses issues arising from and potential solutions for 
the privacy and informed consent challenges of pediatric 
environmental health research.  
Assent 
Levels of identifiability 
(risk) 
Parental Consent 
Reconsent 
Withdrawal 
McHale et al. [2007] Consent for childhood cancer tissue banking in the 
UK: the effect of the Human Tissue Act 2004 
Ethics 
Discusses the human tissue act and the difference 
between pediatric consent to surgery and consent to 
retention of tissue for further use.  
Parental consent 
Neidich et al. [2008] Empirical data about women's attitudes towards a 
hypothetical pediatric biobank 
Empirical 
Survey (questionnaire) of 299 women who delivered at 
the University of Chicago about their willingness to enroll 
their children in a hypothetical biobank 
Benefits 
Confidentiality (risk) 
Parental Consent 
Kaufman et al. [2008] Ethical implications of including children in a large 
biobank for genetic-epidemiologic research: A 
qualitative study of public opinion 
Empirical 
Focus group research to check whether and under which 
conditions children could be included in a cohort study 
planned by the US National Institutes of Health 
Assent 
Benefit 
Confidentiality (risk) 
Parental Consent 
Physical and emotional 
harm 
Reconsent 
Return of Results 
Withdrawal 
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APPENDIX 
After the publication of this paper, three important articles were 
published, which we shall briefly describe here. The first publication is a 
theoretical-ethical policy forum in Science by Gurwitz et al.(60) They refer 
to the specific vulnerability of children. This vulnerability is temporary: 
most children will become competent adults one day. However, a DNA 
sample donated by his or her parents can still be used decades later. 
Given the advent of new techniques such as rapid sequencing of entire 
genomes, a donor’s privacy can never be completely guaranteed. They 
suggest that children should be recontacted when they reach the age of 
consent to allow continuing research on their samples and data. 
Moreover, they suggest that when research on pediatric data is done, 
this should be done in-house and such data should never be shared 
with researchers outside of the original institution. 
A study using telephone interviews by Goldenberg et al.(61) investigates 
the need for recontacting people for reconsent when they reach 
adulthood. They performed telephone interviews with 1186 patients 
from 5 academic medical centers by using a hypothetical scenario. 
They found that a majority (67%) would not be concerned about the use 
of their sample/data after they reached adulthood. Those respondents 
who were concerned were more likely to be more private about their 
medical records, less trusting of medical researchers, or African-
American. 46% believed consent should be obtained to continue using 
their sample and data for research. A minority 26% would not want 
researchers to use their sample/data when they could not be located to 
ask for consent. Hence, this findings support the idea that it is ‘good 
practice’ to obtain consent when donors reach adulthood, but that it is it 
is acceptable to continue to conduct research when adults cannot be 
located. 
Ries et al.(62) conducted six semi-structured telephone interviews with 
investigators of the following birth cohort studies: Born in Bradford 
(“BIB3, United Kingdom), Canadian Healthy Infant Longitudinal Study 
(“CHILD”, Canada), Copenhagen Prospective Study on Asthma in 
Childhood (“COPSAC”, Denmark), Generation R (“GenR”, Netherlands), 
Etude Longitudinale Française depuis l’Enfance (“ELFE”, France) and 
National Children’s Study (“NCS”, United States). They examined how 
these studies handled ethical, legal and social issues with regard to 
recruitment, parental consent and assent/consent from the child, 
withdrawal, confidentiality and sample/data protection, handling 
sensitive information and disclosure of results. They found that all 
studies require initial consent from the mother and paternal consent if 
the father is available. The breadth of consent varied, but no study 
asked for complete ‘blanket’ consent for all possible future studies. As 
there is frequent contact between investigators and participants in the 
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study there are opportunities to refresh the initial consent and obtain 
consent for specific activities. The cohort studies would also obtain 
ethics review for research outside the original scope of the consent. 
Children are sought to assent, sometimes from as early an age as 
seven and eight, and would also be asked for full consent in 
adolescence. The right to withdraw from the study is acknowledged in 
all six cases, and cohort members could choose not to participate in 
specific data or sample collection activities. All studies take strong data 
protection measures in the form of coding and restricted access, and 
some have special committees to deal with issues such as requests for 
access by third parties. In case of child abuse or other severe harms, 
interviewees acknowledged that they would report this to social 
services. Some mention this in the consent forms. General results of 
studies were published through newsletters. Individual results were 
returned in some cases, but conditions varied and also depended on 
clinical relevance. One study would not return individual results. 
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PART II: ETHOS 
EMPIRICAL INQUIRIES INTO THE STORAGE AND 
USE OF PEDIATRIC TISSUE SAMPLES FOR 
GENETIC RESEARCH 
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THE STORAGE AND USE OF BIOLOGICAL TISSUE 
SAMPLES FROM MINORS FOR RESEARCH: A 
FOCUS GROUP STUDY 
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ABSTRACT 
Genetic research on pediatric stored tissue samples raises specific 
ethical questions that differ from those raised when adults are the 
donors. To investigate opinions on this matter, we conducted 10 focus 
group discussions. Five focus groups were conducted with adult 
participants and 5 had teenage participants between 15 and 19 years 
old. The discussions were analyzed with NVIVO 8 (qualitative research 
software). We found the following recurrent categories: the requirement 
that research should not pose any burden on children and that it should 
benefit other children, the trust people had in the role of parents, the 
need for information and the growth towards autonomy. Both the adults 
and teenagers we interviewed thought that the inclusion of tissue 
samples from minors in research had ethical implications. A major 
concern was that nontherapeutic research would pose no extra burden 
on children, which would assume the use of nonintrusive methods of 
gathering samples and the use of samples that were gathered in a 
diagnostic context. Participants, however, also understood the necessity 
of such research. The overall impression was that parents would be the 
best persons to make decisions on behalf of a small child and that the 
same parents would engage their children in the decision-making when 
they grew older. People thought that there was a duty to recontact 
minors when they reached the age of competence but on a best-effort 
basis. 
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INTRODUCTION 
Biomedical research on biological material from minors, and the 
associated medical records can yield valuable information on the 
development and genesis of early-onset disorders and the early 
interaction of environmental and genetic factors(1,2). However, research 
on biological samples from children raises specific ethical questions that 
are different from those associated with biological samples from adults 
or from those associated with clinical trials with children(3). Literature 
has already  been published on this topic: we found theoretical 
articles(4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19), empirical studies(20,21,22,23,24) and 
reviews of existing guidelines(3,25). Themes discussed were consent, 
risks, benefit and return of result. First, with regard to consent, the 
questions discussed primarily were whether parents are allowed to 
consent to the storage and use of materials from their children. Most 
authors agreed that parents or legal guardians are the most appropriate 
persons to consent if a child cannot do so(14,15,16,17). Only Baumann 
thinks parents do not have the moral authority to decide for their 
children. She believes the risk for discrimination of children based on 
genetic results is too high(8). Some authors think that, given the fact that 
some of the information that can be acquired from stored tissue 
samples is familial in nature, families should be involved in the 
information process(9). Many authors also think that the opinions of 
children should be sought in the form of assent (the child’s willingness 
to participate) or dissent (the child’s objection)(18,9,10,15,16). The literature 
does not agree on a specific age when children would be able to make 
such decisions. For example, Wendler and Shah suggest that the scope 
of children's research decision-making should be based on the 
principles of respect for autonomy and nonmaleficence, and sets the 
threshold for assent at 14 years(26). The study by Goodenough et al. 
mentions an age of 9-11 years(20), and Meaux and Bell suggest that 
children as young as five can understand research (27). Another question 
is whether minors should be recontacted to give consent on research on 
their tissue samples. Most literature agrees that this is good practice, 
but it is unclear whether this should be done at a certain age or based 
on a level of maturity(17,16). Also it is not definite what should happen to 
samples if a researcher is unable to recontact a participant for consent, 
which can happen if samples are completely anonymized or if the 
current address of a participant is unknown. In this respect, authors also 
did not question the right of minors to withdraw from a study(15,16,21).  
A second theme in literature deals with the concept of risk. Guidelines 
refer to the idea that nontherapeutic research on tissue from minors can 
be done if there is no more than minimal risk(28,3,29,30,31,32,33,34,35). Two 
types of risk associated with the storage and use of stored tissue 
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samples are discussed in the literature. The first is the risk of physical 
and emotional harm. Children might experience fear, for example of 
venepunctures, or would be overburdened by participation. In the case 
of longitudinal cohort studies, children might feel uncomfortable about 
certain questions and knowledge(20,24,21). The second type of risk is 
confidentiality related; third parties could access the information which 
would lead to discrimination of participants or to personal stigma(5,17,15,8).  
A third theme discusses the question who should benefit from research 
on stored tissue samples of minors. General principles of research on 
children mention that research on such tissue can only be done if it is 
not possible to obtain the same results with participants that can 
consent and that participants should either benefit directly or children of 
the same age or with the same condition should benefit(29,3,30,31,33,34,35). It 
is unclear how children might benefit directly from biobank research, 
although in the case of longitudinal cohort studies, where there is more 
contact between the researchers and their subjects, regular health 
checkups may prove to be beneficial(24).  
A fourth theme is the question whether incidental findings should be 
returned to participants and/or their parents. Some authors state that 
the return of result of especially genetic analysis to parents can trigger 
anxiety and change the way in which parents treat their children(17,9,6). 
They would hence restrict this to results that could be used to improve 
health outcome. 
Next to theoretical ethical literature, we found five empirical studies 
dealing with the topic of stored tissue samples from minors. A first study 
was part of the EPEG project (Ethical Protection in Epidemiological 
Genetics), which is associated with the ALSPAC (‘children of the 
nineties’) longitudinal study. This study describes 40 interviews with 
children aged 9-11 and describes how child participants perceive and 
understand their involvement in a major longitudinal epidemiological and 
genetic study(20). A second study is also associated with the same 
project. It contains an analysis of the viewpoints of both the parents and 
the children, a discussion of the ethical and legal rights of the parents to 
consent for their children, and description of how child participants 
perceive notions of risk with regard to different type of information (21). A 
study by Neidich et al. describes a survey of 299 women, who delivered 
at the University of Chicago, about their willingness to enroll their 
children in a hypothetical biobank(23). Kaufman et al. describes focus 
group research to check whether and under which conditions children 
could be included in a cohort study planned by the US National 
Institutes of Health(24). A Canadian study describes interviews with eight 
clinical researchers in the field of pharmacogenetics on the inclusion of 
children in such research and also contains a reflection on the inclusion 
of children in biobanks(22). 
Today no data exist on the attitudes of the Belgian population towards 
research on stored tissue samples from minors. As such attitudes may 
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be dependent on cultural context, we found it useful to query these 
attitudes and opinions(36). Since we wanted to explore these questions 
into some depth, and find out whether there were any issues that did not 
come up in the existing literature, we chose focus groups as our modus 
operandi(37,38). Considering the fact that we did not find any empirical 
studies based on the opinions of young people on the verge of majority 
(within the range of 15-19 years), and as we also wanted to check 
whether their opinions were different from adults, half of the focus 
groups we conducted were with participants in this age group. 
METHODOLOGY 
We conducted ten focus groups to investigate the concerns of a Belgian 
population with regard to research on stored tissue samples. An 
overview of these focus groups is given in table 1. We provided food 
and beverages to the participants, so that, even when the focus groups 
were conducted in environments such as schools, people would feel 
relaxed. One focus group, with parents from children with a medical 
condition, was performed online, through a chat room; we thought that 
the travel distance would be an impediment for participation in this 
group(39).
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Table 1: Overview of focus groups 1 
Focus 
Group 
Age 
range 
Location of 
discussion 
Duration of 
discussion 
Recruitment 
method 
Additional 
information 
FG1 15-16 Restaurant 60 minutes One teenager 
was asked to 
gather mixed 
group of 
different 
schools 
Mixed group: 
catholic and public 
schools, secondary 
and technical 
education. 
Participants from 
Leuven and 
surroundings. 
FG2 24-48 Researcher’s 
home 
1h45 minute Internet forum 
(about 
motherhood) 
and women’s 
organization 
Group composed 
of mothers. 
Participants from 
Leuven and 
surroundings. 
FG3 16-17 School 
premises 
50 minutes Recruitment 
through teacher 
from public 
school 
Pupils from one 
class in a public 
school. in 
Aarschot. 
FG4 26-73 University 
premises 
1h30 minutes Recruitment 
through the 
Flemish 
platform of 
patient’s 
organizations 
Group composed 
of members from 
different patients’ 
organizations. 
Participants from 
Antwerp, Leuven 
and Aarschot. 
FG5 16-19 Researcher’s 
home 
60 minutes Recruitment 
through board 
of Steiner 
school 
Pupils from 
different classes of 
a Steiner school. in 
Wilsele  
FG6 31-52 Researcher’s 
home 
1h30 minutes Recruitment 
through internet 
fora and local 
Mixed group. 
Participants from 
Antwerp and 
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community 
organizations 
Leuven. 
FG7 61-77 Community 
room 
1h15 minutes Recruitment 
through 
organization of 
senior citizens  
Senior citizens. 
Participants from 
Leuven and 
surroundings. 
FG8 28-49 Online 60 minutes Recruitment 
through 
parents’ 
internet fora 
and the 
national cystic 
fibrosis 
organization 
Parents of children 
with a medical 
condition. 
Participants from 
Gent, Leuven and 
Westerlo. 
FG9 16-17 School 
premises 
45 minutes Recruitment 
through board 
of Catholic 
school 
Pupils from 
different classes 
from General 
Secondary 
Education in a 
Catholic school. in 
Leuven. 
FG10 16-19 School 
premises 
45 minutes Recruitment 
through board 
of Catholic 
school 
Pupils from 
different classes 
from Technical 
Secondary 
Education in a 
Catholic school. in 
Leuven. 
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We developed standard qualitative focus group procedures(38,37). The 
topics the moderator (Kristien Hens) introduced during the discussion 
were the willingness to donate samples for biomedical research, the 
need for consent and information, the possible dangers they saw 
associated with such research, the role of ethics committees, the need 
to return incidental research findings. The discussion guide, for this part 
of the debate, was developed based on a literature study we conducted 
before(40) and on a pilot focus group with specialists in medical law, 
medical ethics and social sciences.  The content of the discussion guide 
was revised based on the outcome of this pilot study.  
A considerable amount of time (approximately one third of the 
discussion) was spent on the use of samples of minors for research. For 
the general discussion we used three different scenarios: the use of 
surgical waste, the use of blood that was gathered in the context of a 
medical examination and a longitudinal cohort study. These scenarios 
were also continued in the discussion on the use of tissue from minors. 
The discussion was started with a general question about how 
partakers felt about the participation of children in such research. Based 
on the answers we got, we further enquired about consent, assent, risk, 
return of results, and genetic information. In the adult groups, we 
enquired about the willingness of donating tissue from their (potential) 
children or enrolling children for longitudinal research, whereas the 
teenage groups discussed how they felt about participating in such 
research themselves. Also, in the teenage groups we enquired about 
the sensitivity of certain medical and non-medical information, as we 
wanted to know how they felt about the fact that researchers and/or 
their parents would also be informed. 
The discussion groups were conducted with Kristien Hens (KH) as a 
moderator. Kris Dierickx (KD) was assistant-moderator in most of the 
groups. At the beginning of each discussion, the participants were told 
that the conversation was audio taped and that we would process our 
findings in a publishable report. They were assured that this report 
would contain only anonymous data; no one objected. Audiotapes of the 
sessions were transcribed but not corrected for grammar in order to 
capture the oral nature of the discussion. Selected quotes were 
translated in English during the write-up of this paper.  
We used NVIVO8 to do a detailed coding of the transcripts and to 
compare between focus groups and participants. We created cases for 
each focus group participant with attributes containing demographic 
values. During a first-pass analysis, we performed descriptive coding to 
assign each piece of text to a case. During a second pass analysis, we 
did a detailed coding according to the various topics in the text. We then 
reorganized these topics under the categories attitudes, consent, return 
of results and risk. These broader categories were inspired by the 
literature and discussion guide, whereas the subcategories reflected the 
issues brought up by the participants. Subsequently, we did a more 
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analytical coding to find recurrent themes across the different topics. 
This part of the coding was done by KH and KD separately and then 
compared to match themes. The themes were coded under a separate 
tree, independent from the topical categories. In a last pass, we 
reorganized these recurrent themes. Based on our literature study we 
assumed to find concerns about genetic information obtained from 
samples, and, especially amongst teenagers, a right to make their own 
decisions. Instead, the broader themes that occurred throughout the 
discussion were parental involvement, growing autonomy and need for 
information and benefits and burden. 
RESULTS 
Our focus groups discussed attitudes towards stored tissue samples 
from minors, the willingness to participate and issues of consent, risk 
and return of results. The categories that attracted attention throughout 
the whole discussion were the requirement that such research should 
not pose any burden on children and that it should benefit other 
children, the trust people had in the role of parents, the need for 
information, and the growth towards autonomy. 
Burden and Benefit 
The major theme that recurred throughout the different discussions was 
the fact that non-therapeutic research on children should not burden a 
child in any way. The combination of the fact that research might be 
distressing for children and not be of direct benefit to them was quoted 
as a major problem and was the one reason why people would not 
enroll children in research, or why teenagers would not choose to 
participate. One participant stated the conditions under which she would 
enroll her child in biobank research as follows: 
If there is no fuss, if it happens for example at school 
and it is no burden for the child (for example through a 
mouth swab), if we know the benefit of the research 
then I would probably not mind (FG8P2, female, 28). 
The burden that was quoted most was the physical discomfort of 
venepunctures. Research should be as minimally intrusive as possible 
and preferably hidden behind diagnostic procedures that should have to 
happen anyway. Some even considered the taking of an extra tube of 
blood as a burden, which would not require an extra puncture, because 
this would stretch the time a child would spend in an uncomfortable 
situation. Also, the risk that a child may be afraid of researchers and the 
research environment was quoted as a potential undesirable outcome. 
The willingness or desirability to enroll children also in primary, non-
therapeutic biobank research, with associated phenotypical 
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examinations, was strongly linked to the preferences of the children 
themselves. Both adults and most teenagers thought that such could 
only be performed if it was ‘fun’ for the children. Strikingly, the adults 
were less inclined to allow (small) children to participate in research that 
would require the taking of extra samples than the teenagers were. In 
the teenage groups, some people stated that needles were part of life 
and that a child would need to learn to deal with them anyway.  
The physical or emotional burden was also linked to the age and the 
character of the child. The older a child would be, the better it would 
understand the reason for the discomfort. Also, people stated that some 
children were more cool-headed than others and would be more willing 
to cooperate. In the group of parents with children with a medical 
condition, it was considered important that the research would not put 
additional load on children that were already burdened by medical 
treatment.  
The risks associated with genetic information were seen as problematic 
by two participants: one was a representative of a patients’ organization 
for people with a genetic disease and another one from a parent of a 
child with a medical condition. The former made a link to genetic testing: 
Yes, I know, but the question is if those parents in 
England cooperate with their children. Do they give 
permission or can they also put limitations on that? For 
example, the things that were mentioned here, from my 
point of view this is very innocent, but whichever way 
you look at it, if they take blood samples these will 
contain DNA, that is a full DNA profile. And we defend 
that children should not be tested, but if the DNA 
material is there… (FG4P2, female, 54) 
So, although she understood the nontherapeutic nature of the research 
discussed, she still thought the fact that the DNA is stored in itself is an 
item to be considered, and she thought the same guidelines as those 
regarding genetic testing of minors should be applied(41). Overall, 
however, participants did not regard the genetic nature of the 
information that can be obtained from stored tissue samples as more 
problematic than other medical information. 
People agreed that the use of stored tissue samples from children could 
be useful to understand and find treatment for typical childhood 
diseases, such as ADHD, autism, leukemia, progeria and childhood 
cancers. Especially in the group composed of parents of children with a 
medical condition, research on the disease the children had themselves 
was preferred. One participant stated this as such: ‘No, but I would like 
to find out first whether this can be used for … [the medical condition of 
her child]’ (FG8P2, female, 28). Some partakers remarked that parents 
from healthy participants would be less inclined to give consent to 
participate in research than parents of children with a condition or 
parents belonging to a family with a condition. It seems that implicitly, 
people assumed that such research, even though non-therapeutic, 
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might in the end be beneficial to the child or to the community of 
children with the same disease. This opinion, that research should 
preferably be done on children with a specific disease for a specific 
disease was far less explicit in the teenage groups. 
Parental Responsibility and Trust in Parental Decisions 
We found a great trust in the responsibility of the parents in making the 
right choices for their children, both amongst adults as well as amongst 
teenagers. This trust was seen in different contexts. First, there was 
acceptance that parents could and should make decisions about 
research participation for children who are still unable to do so for 
themselves, and there was confidence that they would make the right 
balance. We also discussed with the teenagers whether they would 
blame their parents if they would have decided to donate tissue for 
medical research when they were small and they unanimously stated 
they would not do so. It was accepted, both in the groups with adults as 
well in the groups with teenagers, that it is part of life that parents make 
decisions for children who cannot decide for themselves. In one 
teenage group (FG5), an analogy with baptism was drawn: as baptism 
in Belgium typically happens when a child is only a couple of months 
old, he or she has no say in the ritual, but this was not estimated as a 
great problem, even for children who would later lose their religion. 
Some teenagers did say that they would refuse to participate if parents 
would force them to without further discussion. No teenager, however, 
thought this was a realistic scenario, as they had faith that parents 
would discuss this with them. They showed trust that their parents 
would make the right decisions and would also involve them in these 
decisions.  
Overall, the impression amongst adults and teenagers was that the 
parents were the most suitable persons to convey information about 
research participation to their children, because they knew their children 
the best. They were hence seen as intermediaries between scientists 
and their research subjects, the children. As we shall discuss in the 
section ‘autonomy and the need to be informed’, some people also 
thought that it was the task of the parents to inform their children in due 
time about the fact that their tissue is used for research and that they 
could consent to further uses or not.  
Trust in the parent-child relationship was also apparent when the return 
of incidental research findings was discussed. Both teenagers and 
adults thought that medically important information should be told to the 
parents and the minor together. Teenagers found it logical that this 
would be shared with parents: 
You can then object to the fact that parents know it first, 
and some people will push this very far, but the real 
problem is really not with the parents if you have 
cancer. (FG5P8, male, 19) 
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In some of the teenage discussion groups we also debated the scenario 
of a 14-year old with a high amount of alcohol in his or her blood. The 
participants considered this to be private and nonmedical information 
that should not be shared with parents, although in one group it was 
stated that if this drinking habit would be so severe that it would affect 
the child’s health researchers would have the right to inform the parent. 
Hence, both teenagers and adults thought medical information is 
something that should and could be shared between children and their 
parents, and they did not consider this as information that should be 
kept private. Moreover, they considered it advisable that parents and 
children would also receive this information simultaneously. 
Autonomy and the Need to be Informed 
Although we found much trust in parental decisions, the fact that 
children might not be able to autonomously decide on research 
participation was quoted as a major ethical difference between stored 
tissue samples from minors and from adults. One participant expressed 
this very clearly: 
Yes, so, you take your baby to the doctor and you say, 
I want from my child blood to be taken so that it can be 
used for scientific research. OK no, I would think that 
wrong, that is really completely wrong; look that child 
cannot choose for himself, they would have to have a 
reason for that, at least done some proper thinking. 
(FG10P8, male, 16) 
This teenage boy stresses the relation between the lack of autonomy of 
the child and the fact that something potentially burdensome is done to 
him/her (venepunctures). In the last part of this quote he suggests that 
such actions could be done, but only with a solid (medical or research) 
reason. 
A considerable portion of the discussion time was spent on the 
children’s right to have a say in the decision as well. Both teenagers 
and adults seem to agree that children would have to be allowed to 
decide for themselves once they reach the age of understanding: 
No, of the moment that I can decide myself I want to 
decide myself, but I would not mind too much either. 
Let’s say my parents consented, and I know that now, 
yes for such a research I would not really mind. 
(FG1P2, female, 16) 
There was much discussion in most of the groups about the specific 
age on which a minor would be capable to make his or her own decision 
about donating. The age proposed ranged from 10 to 18 years old. 
Remarkably, the age that was most quoted in the groups with teenagers 
(from 15-19 years old) was higher than those in the adult groups: often 
the former thought 16 was the minimum, although they all thought they 
themselves were capable of deciding for themselves on the matters 
discussed. In the teenage groups, the fear was also expressed that 
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other teenagers would refuse because they were in puberty, but they 
themselves believed they would not refuse if asked to contribute to 
research. In the adult groups, ages quoted where more fluid and ranged 
from 10 to 18 years. In adult groups, the remark was made that children 
with a medical condition were more mature than healthy children, and 
would hence be able to understand better what was at stake, something 
that was not mentioned by the teenagers. This did not, however, 
automatically imply that this would make them more suitable as 
research subjects than ‘healthy’ participants. 
The groups also discussed participants’ attitudes towards the duty to 
recontact persons when they reached the majority age, which is 18 in 
Belgium and many other European countries(42), to ask for renewed 
consent for research on stored tissue samples. There was agreement 
amongst adults and teenagers that recontacting people to ask for 
consent to the further use of their samples was a good practice, but 
they also acknowledged the fact that this would be on a ‘best effort’ 
basis. On the one hand, focus group participants thought the initiative 
should come from the biobank participants and their parents: parents 
should make their children aware of the fact that their tissue was used 
and that they should contact researchers to (re)consent to the use. 
Again, a great role was attributed to parents and trust was placed on the 
relationship between children and parents. On the other hand, some 
thought researchers should try to contact participants when they turned 
18 on a best-effort basis. They did however think this could pose an 
administrative burden. If it was not possible to find the person in 
question, they thought tissue could still be used and would consider the 
throwing away of samples as wasteful. Hence, they saw the duty for 
recontact not as an absolute requirement but something that needs 
balancing with the potential benefits of research. When we asked the 
teenage participants whether they would expect a phone call when they 
were 18 years old, some said they would not. They thought it too much 
trouble for the researchers and did not consider investigation on their 
stored tissue samples as too big a deal. Others, however, said they 
would like to know about the research on their sample. Some teenage 
participants mentioned ‘curiosity and respect’ as the main reason why 
they would want to be informed, rather than the desire to have a final 
say. Others saw such recontact also as a token of respect: 
I think if you turn eighteen, well, I hope you are briefed 
by your parents, but that they send also a mail or a 
letter out of politeness, like, look, now you can decide 
yourself on your blood, can we continue or not. 
(FG10P7, male, 17) 
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DISCUSSION 
General Findings 
In much literature about research on children a reference is made to 
their special vulnerability(22). Children deserve, because of their limited 
autonomy, extra protection from harm. Also our study shows that many 
people’s primary concern when enrolling children in non-therapeutic 
research, be it only on their biological samples, is that this should not 
pose any burden on these children. This is consistent with the focus 
group study by Kaufman et al. (24) and with interviews with 7-year old 
children participating in a clinical cohort study by Gammelgaard and 
Bisgaard . Children in the latter study mentioned the venepunctures as 
the part of the research they disliked most(43). A solution to reduce the 
burden would be to reuse materials that are gathered in the context of 
diagnosis, or to use non-intrusive techniques, if such reuse is not 
possible. A study by Bartington et al. has shown that collecting saliva is 
a feasible and non-intrusive method(44) and could be obtained in a 
familiar atmosphere at home with the help of the children’s mother. In 
the same way, mouth swabs could be used for genetic research. In the 
ALSPAC study, which is non-therapeutic only, a local anesthetic is used 
when blood is taken and the children are shown videos to distract 
them(45).  
Next to physical risks, the literature on stored tissue samples also 
quotes privacy issues. Such samples contain genetic information, which 
is considered potentially dangerous if accessed by the wrong people, 
such as insurance companies or potential employers. Only two of our 
participants mentioned the specific nature of genetic information as a 
reason why children would be in need of extra protection. However, as 
these two participants had been in closer contact than average with the 
medical world, and were therefore more informed, the sensitivity of 
genetic and medical information is not something that should be 
disregarded. In the study by Williamson et al., where parents were 
already involved in the study through their children, some parents did 
mention fear of the long term use of genetic information (21), although 
this was not a major concern of many (46). When the issue of return of 
incidental research findings was discussed, both teenagers as well as 
adults did not see major privacy issues in the fact that parents would 
know their child’s medical data. Teenagers were, however, more 
sensitive to certain nonmedical information that could be retrieved from 
tissue. For example, they considered their drinking habits to be private. 
Only if this would become a ‘medical condition’ researchers were 
allowed to communicate this to parents. We recommend that, especially 
if longitudinal studies with minors are designed that investigate certain 
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types of information that is not strictly medical, it is good to reflect on 
these privacy issues and discuss these with the children.  
Adults and teenagers thought that research on stored tissue samples 
from children could be useful. They all quoted diseases that occur in 
childhood as important areas of study. People were willing to allow their 
(sometimes hypothetical) children to participate in such research, but 
there was a preference to enroll children in research on conditions they 
themselves had. This seems to imply that the requirement that is quoted 
in some guidelines on investigation on stored tissue samples that 
research on children should benefit other children or children with the 
same  condition(29,3,30,31,33,34,35) has some ground in moral intuition. 
However, longitudinal research, such as the ALSPAC study typically 
follows children from birth onwards to create a research resource for 
many different diseases. Policy makers should consider how to balance 
access to pediatric resources with protection of vulnerable subjects.  
Both adults and teenagers we interviewed thought parents had an 
important task in safeguarding their children’s interests and in judging 
the best course of actions. However, a trust in parental decision making 
does not contradict a need for a gradual increase in the need for 
children to be able to decide themselves. Our participants did not agree 
on the age when children would be able to understand research enough 
to decide themselves. This is in accordance with the existing literature. 
In this respect, the study by Avard states that the geneticists she 
interviewed considered 12 as a crucial age: children over 12 were 
consulted about willingness, those below 12 were involved as much as 
possible(22). Goodenough et al. state that the age between 9 and 11 was 
a crucial age, because then the balance of decision-making is shifting, 
and people are making more and more decisions for themselves(20). In 
our groups the suggestion was often made that children would gradually 
receive more information and this would imply a growing impact of the 
opinions of the children. It was thought that children have a right to be 
told in their own language about research. In one group the need for 
protection of children through ‘extra’ ethical committee oversight was 
mentioned, as there may be a limit to the knowledge and expertise of 
parents, and an extra aid in making the right decision would be helpful. 
This is also mentioned in some guidelines on stored tissue 
samples(28,3,29,47,31,32,48,35). As the ethical issues associated with stored 
tissue samples from minors are different from those with adults, and as 
children are considered vulnerable subjects(22) we think that extra ethics 
committee oversight is indeed necessary. But this is complimentary to a 
good relationship of researchers and medical staff with both parents 
and children. 
Differences between Adults and Teenagers 
One of the aims of this study was to see if, when talking about stored 
tissue samples from minors, adults and teenagers would emphasize 
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different aspects. We found that they agreed on most issues. However, 
there were two striking differences. First, teenagers often quoted a 
higher age (around sixteen) when asked at which point children were 
able to make their own decisions. They also referred to ‘puberty’ as a 
reason why teenagers would refuse to cooperate, although they 
themselves thought their own judgment would not clouded by this 
condition. Indeed, all teenagers we interviewed were well spoken and 
had clear opinions on the matter. As such they were examples of the 
fact that children can (and should be) heard. The fact that these 
teenagers put the age of consent relatively high could also suggest that 
they are not entirely comfortable making such decisions. They may 
want guidance considering the complexity of the question. A qualitative 
study by Boddington et al also shows that teenagers, when confronted 
with explanations about genetics and carrier testing, sometimes did not 
entirely understand what was said to them and, when questioned as 
adults, would have preferred more guidance(49). These findings would 
suggest that also teenagers should not and do not want to be left alone 
with questions concerning genetics. However, it could also mean that 
they consider these decisions as relatively harmless and having no 
direct bearings on their own lives, and are therefore happy to relinquish 
the responsibility.  
Another difference was that some (but not all) teenagers thought 
children could be convinced to cooperate to research even if this would 
cause them discomfort, for example because syringes were used. In the 
adult groups, participants were overall less inclined to allow such 
research on their children. As such, these teenagers took a more 
deontological approach to research and thought it was more important 
than any discomfort it might cause. We can only guess at what could be 
the reason for this difference. A possible explanation is that these 
teenagers identify themselves more with the children in research, and 
perhaps, having had similar experiences in the past, would consider the 
burden ‘not so bad after all’. The adults, on the other hand, took the 
positions of caretakers and defenders of the (vulnerable) children. In 
this position research goals are secondary compared to any possible 
negative impact these could have on children. 
Limitations 
We admit that our study has several limitations. The fact that it is a 
focus group study, on a voluntary basis, also implies that the 
participants might have been biased, either in the positive or the 
negative sense, and may not be entirely representative of the Belgian 
population. The original discussions took place in Dutch, and quotes 
were translated in English, which means that some of the nuances of 
the responses may be lost. Our teenagers questioned, had, as far as 
we could assess it, no underlying medical conditions. We do not know if 
the inclusion of such a group would have changed our general findings.  
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Our focus group study shows that both the adults and the teenagers we 
interviewed thought that the inclusion of tissue samples from minors in 
research had ethical implications.  A major concern was that non-
therapeutic research would pose no extra burden on children which 
would assume the use of non-intrusive methods of gathering samples 
and the use of these in a diagnostic context. Participants, however, also 
understood the necessity of such research. The overall impression was 
that parents would be the best persons to make decisions on behalf of 
small children, and that the same parents would engage their children in 
the decision making when they grew older. People thought that there 
was a duty to recontact minors when they reached the age of 
competence, but on a best-effort basis. 
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ABSTRACT 
Stored tissue sample collections from minors are useful for genetic 
research. The ethics of the use of stored tissue samples for genetic 
research continues to be a much debated topic of discussion. The use 
of pediatric samples poses specific ethical questions. Although a 
substantial corpus of empirical literature exists on the use of samples 
from adults, not much is known about the opinion of professionals on 
the use of samples from children. We conducted ten interviews with 
professionals in the field. Their primary concerns were the fact that 
consent procedures should not be too bureaucratic, the need for proper 
research design and privacy protections, the fact that research should 
not burden children and guidance from ethics committees. 
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INTRODUCTION 
Stored tissue sample collections from minors are useful for genetic 
research. For example, longitudinal studies such as ALSPAC(1), which 
follow children from pregnancy onwards, can shed important light on the 
relationship between genes and environment, and help to study 
diseases such as asthma, childhood obesity and allergies. Pediatric 
tumor banks are crucial in understanding childhood cancer. Other types 
of collections can take the form of disease-specific collections(2). Also, 
samples that were collected in the context of diagnosis could be useful 
for genetic epidemiology research. Such collections exist in centers for 
medical genetics throughout the world. Moreover, blood spot cards, 
containing blood that was gathered from newborns to screen for certain 
metabolic diseases, could also be used for this purpose(3).  
 
The ethics of the use of stored tissue samples for genetic research 
continues to be a much debated topic of discussion. A substantial 
corpus of both theoretical as well as empirical studies exists on the 
topics of consent, privacy, ownership, commercialization and the return 
of incidental research findings. The vast majority of these documents, 
however, deal with tissue samples from competent adults. Meanwhile, 
the use of stored tissue samples from minors poses specific ethical 
problems that are different from those posed by adults. Two recently 
published reviews of the empirical and theoretical literature and of 
existing guidelines have identified these differences(4,5). Specific ethical 
questions raised are for example, whether parents can consent for their 
children, the scope of the parental consent (generic/broad), the right to 
assent for the child, the requirement that research should not pose 
more than minimal risk to the child, the question which results should be 
returned to the parents or to the children. With regard to consent, 
different issues arise. What is the scope of parental consent? Are 
parents allowed to give consent to the indefinite storage of stored tissue 
samples from their children for genetic research or should there be a 
time limit? With regard to the content of the consent, are parents 
allowed to give broad consent for any future genetic research, or only 
for specific research(6)? Should children be allowed to assent to 
research and should they be recontacted for consent when they 
become legally competent? It is universally acknowledged that asking 
young adults to reconsent is good practice and that they should be 
allowed to withdraw their consent. It is unclear, however, to which 
extent researchers should try to contact them or what the specific 
modes of withdrawal should be(7,8). A recent article by Gurwitz et al. 
published as a policy forum in Science stresses the need for extra 
guidelines for pediatric biobanks and longitudinal studies involving 
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children(9). As children, unlike adults, cannot consent to storage and use 
of DNA themselves, restrictions should be put in place. Longitudinal 
studies should either invest in in-house processing facilities or await the 
consent of participants once they are adults. The authors refer to 
possible risks associated with stored DNA, risks which are primarily 
linked to discrimination by insurers and employers. Since DNA is stable 
throughout the lifetime of a human being, they argue that children are in 
need of extra protection and that parents should not be allowed to 
consent to all types of research using their children’s DNA. Indeed, the 
most frequently discussed issue with regard to biobanks and risks is 
privacy and confidentiality related. As research collections for biological 
samples contain genetic information, this is potentially interesting for 
third parties such as employers and insurers. Genetic information is 
thought to contain a ‘future diary’ of the individual(10). This is enhanced 
by the fact that such information may be stored for longer periods of 
time. If such third parties gain access to this information, research 
participants, who altruistically donate their samples to research, may be 
confronted by the adverse effects of their participation later in life. With 
children this is further complicated by the fact that they themselves have 
not chosen to incur this risk. Other risks that are quoted in literature are 
potential physical and emotional burden that the gathering of biological 
samples and subsequent medical examination can cause children(11) or 
the fact that children’s opinions may change or differ from their parents’ 
and their viewpoint may be disregarded(12). 
Despite the continuing debate, only limited empirical work has been 
published regarding the opinions of clinicians and researchers working 
with stored tissue samples from minors. Solely one paper directly 
addressing some of these issues was found; it reported findings of a 
survey that investigated the views of health care professionals working in 
childhood cancer about seeking consent for tissue banking from potential 
donors(13). We also found a study reporting on eight interviews with 
pharmacogeneticists on the implications of pharmacogenomic research with 
children(14), and one study querying the opinions of researchers in Spain 
and USA on the issue of stored tissue samples in general(15). Ries et 
al.(16) conducted six semi-structured telephone interviews with 
investigators of six birth cohort studies. They examined how these 
studies handled ethical, legal and social issues with regard to 
recruitment, parental consent and assent/consent from the child, 
withdrawal, confidentiality and sample/data protection, handling 
sensitive information and disclosure of results(17). 
It is still largely unknown what professionals consider ethically sound 
and realistic guidelines(17). Therefore, we considered it a necessity to 
interview such professionals in order to find out their thoughts and 
opinions regarding the main ethical issues involved in the storage and 
use of tissue samples from minors. Herein, this article presents the 
principal findings of these interviews. We shall use the term ‘minor’ and 
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‘child’ in the rest of this paper, denoting persons unable to fully consent 
to research because of their age. 
METHODOLOGY 
As not much is known about the opinions of professionals on genetic 
research on tissue samples from children, we chose to perform in-depth 
interviews with professionals involved in such research. The qualitative 
method of analysis allowed us to detect themes of importance. This is a 
preliminary study of the issues at stake, and we think our findings could 
serve as a basis for further quantitative research in the form of surveys. 
Interviewees were selected through the snowballing technique, which 
resulted in ten interviews. These interviews took place during the period 
of January 2009 to August 2009. The interviews were conducted with 
health care professionals or researchers from Belgium (3 persons), the 
UK (6 persons) and from Saudi-Arabia (1 person). Six interviews were 
conducted face-to-face, while for practical reasons, the four remaining 
interviews were accomplished by telephone. The interviewees’ profiles 
and main area of specialty varied (Table 1) but they are/were all 
involved in the procurement and/or management of tissues for research 
or in the research itself. 
 
Table 1 Information about the interviewees 
  # 
Profession of interviewees Clinical geneticist 
Gynecologist 
Epidemiologist 
Oncologist 
Research Team Leader 
Internist 
4 
1 
2 
1 
1 
1 
Gender of interviewees Female 
Male 
4 
6 
Location of interviewees Belgium 
United Kingdom 
Saudi Arabia 
3 
6 
1 
Type of collection Diagnostics collection in a centre for 
medical genetics 
Longitudinal Study 
Tumor bank 
Research-only collection 
4 
 
3 
1 
2 
Type of interview Live 
Telephone 
6 
4 
Interviewees were initially contacted via email and face-to-face or 
telephone meetings were then arranged. Each interview took between 
40 to 90 minutes. The language of the interviews was English or Dutch.  
 
We developed an interview guide based on a literature review(18). The 
interview guide contained the themes consent, assent, usefulness of 
research, genetic information, return of result and minimal risk. Our 
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approach was a loosely-structured interview rather than a structured 
one as we wanted to elaborate interesting remarks and finding during 
the interview. Kristien Hens (KH) was the interviewer in all ten cases; 
Kris Dierickx (KD) was assistant interviewer at the first interview. 
 
Audiotapes of the sessions were transcribed but not corrected for 
grammar, in order to capture the oral nature of the discussion. We used 
NVivo 8 to code the transcripts(19). First, the texts were coded according 
to the ten cases, reflecting the ten interviews, allowing us to check 
distribution of certain themes. Then we did a detailed topical coding. We 
subsequently combined the codes into broader thematic categories. As 
a last pass, we did a fresh, analytic coding to grasp common themes 
across the different topics. We selected quotes that were especially 
illustrative of these themes and subthemes. We have specified the 
profession of the interviewee and the type of interview with each quote. 
These common themes and the associated extracts are reported in the 
‘results’ section. An overview of the themes is given in table 2. Given 
the limited number of interviewees and to protect their anonymity, we 
shall use the pronoun ‘she’ when referring to the interviewee. 
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RESULTS 
Table 2: overview of themes and findings 
Themes Findings 
Bureaucracy 
Governance 
Ethics Committees 
Long written consent forms for children and their parents is often 
considered unnecessary burdensome for participants 
Need for proper privacy and data protection 
Ethics committees should review whether reconsent is needed 
for when research protocols change 
Ethics committees should review burden of research for children 
Process of decision 
making 
People are willing to contribute and consent to research on 
stored tissue samples from their children 
Good communication between researcher, parents and children 
is important 
Children should be given information at their level 
Whether a child should be asked to assent should be decided on 
a case-by-case basis rather than on a fixed age threshold 
Burden 
Benefit 
If possible, samples and information should be reused for 
research purposes to decrease burden for children 
If possible, anesthetic cream should be used for venepunctures 
Research on children should be for pediatric conditions or for 
conditions that develop during childhood 
Genetic information Genetic information considered to be similar to other information 
The difference lies in the familial nature of the information 
Bureaucracy, Good Governance and Ethics Committees 
The word bureaucracy or a derivative was mentioned 11 times by seven 
different sources. Official requirements regarding consent and assent 
for stored tissue samples and minors were often seen as bureaucratic. 
Interviewees from the UK and one from Belgium stated that they 
thought requirements of having children sign consent forms were 
superfluous. As a seven year old, or even an older child, is never asked 
to sign forms in every day life, these interviewees considered asking 
children to do so for research was useless. They also complained of the 
long consent forms the ethics committee asked them to use. 
Interviewees stated that the longer the information sheet and the more 
boxes parents and children had to tick, the less confidence participants 
had in the research and the less likely they were to consent. Written 
consent was seen by these professionals as a legal requirement to 
avoid prosecution, rather than as added value to the relationship 
researcher-participant. The UK interviewees referred to the stringent 
requirements they had to fulfill after the Alder Hey scandal, which 
involved the use of post-mortem tissue samples without consent. They 
thought that this was not applicable to tissue from children that were still 
alive, as people were overall willing to contribute to research. 
Researchers did think that good governance of samples with adequate 
data protection and scientifically sound research design was essential. 
If these requirements were fulfilled, they thought research was ethical, 
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and not too many restrictions should be put in place. This as is well 
illustrated by this quote from a professional involved in a cohort study 
with children: 
I think transparency is the key, and having good 
systems, if people do retract their consent, which 
people do, we are able to destroy samples, giving 
people assurance that we are treating it well and ehm, 
being very robust about anonymization of samples. We 
had consent about the transfer within between 
countries, there may be concern about that, I think the 
key for us is we have a wonderful resource in terms of 
performing future ehm health policies, and that is what 
people have signed up for, and we should not over 
bureaucratize it I think. (Epidemiologist, telephone 
interview) 
This person clearly summarizes what was also quoted by others as 
good research with good governance. Projects should be transparent, 
people should be able to withdraw and samples should not be 
identifiable to the researchers working with them. Note the use of the 
word ‘anonymization’ here, which used by some interviewees, but upon 
further questioning this in all cases meant ‘coded’. Although ethics 
committees were sometimes seen as being too stringent and requiring 
too long and bureaucratic consent, interviewees also saw a great 
advantage in having research ethics committees review protocols. Such 
committees could help deciding about the acceptable level of 
involvement that researchers could ask from children. They could also 
help in deciding whether reconsent for certain research proposals was 
necessary. Indeed, some of our interviewees though that parents could 
be asked to give broad consent for research on stored tissue samples 
from their children. However, after further elaborating this point, all of 
them agreed that broad consent did not necessary mean ‘any and 
every’ research for them. For example, they all thought GWAS studies 
might be too far from the original research protocol: in such cases they 
would seek advice from an ethics committee to check whether 
reconsent was necessary. Two interviewees also used the term ‘fishing 
expedition’, a colloquial expression to denote an attempt to extract more 
or other – in this case genetic - information than was specified in the 
research protocols. Hence, although they supported a more general 
consent for research, they suggested that a research protocol should 
specify the type of information that is sought. 
Process of Decision Making 
Overall, interviewees stated that people were happy to contribute and to 
give consent for research on stored tissue samples of children, 
especially when these children had a medical condition themselves. 
Also interviewees thought that many parents were willing to enroll 
during pregnancy for population studies, because they saw the spread 
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of certain childhood diseases in their environment, and participating 
made them feel part of something important. They thought it would be 
unacceptable to not use tissue samples from children for research and 
were convinced parents would not be pleased if existing information and 
samples could not be used to the benefit of medical science.  
They did not think, however, that this positive attitude towards scientific 
research amongst parents should be taken for granted, as parents and 
children also have the right to proper information. Therefore they 
thought good communication and a good relation between researchers 
and families was indispensable. When research samples are gathered 
in a diagnostics circuit, this is obvious. However, also the interviewees 
associated with research-only projects stated the need for proper 
communication, for time spent with parents and children to explain the 
procedures. They also thought that parents were the primary decision 
makers when the child was small, but that it was important that children 
are given explanations on their level and would be gradually more 
involved in the decision making:  
Even with the little babies, before you give them an 
injection the majority would still say it is going to be a 
sharp scratch. The baby has no clue what you are 
saying, but you still tell them what you are doing. And it 
just gets more detailed what you are doing when they 
get older. So the guidelines say at seven you should 
start giving information, you are doing that from eight 
weeks old, you are just doing that in a completely 
different way. (Team leader, oral interview) 
The above quote shows the difficulty of setting a definite age threshold 
from which point onwards a child can understand information or should 
be given the opportunity to consent. In this context, interviewees quoted 
the fact that some children have mental retardation due to genetic 
illnesses, and that some children are more knowledgeable than others 
at a given age. Hence, they thought the amount of information given to 
children and whether or not these children could be asked to assent 
should be evaluated on a case-by-case basis. Related to this, the fact 
whether small children should be allowed to dissent to certain 
procedures was discussed with some professionals. Many interviewees 
claimed that they would not force a screaming child to undergo a 
venepuncture, and would hence give priority to the dissent of the child 
over their own research goals. However, one interviewee stated that 
she thought parents should be the ones to decide whether to continue 
the procedure or not, but that she thought there was also a difference 
between healthy and sick children: 
..and you had a four year old with cancer and a healthy 
four year old, and they would both say no, I don’t want 
the needle. I think I would accept the view of the four 
year old with cancer because she or he would have 
had hundreds of needles before and if she is saying no 
I don’t want it, she knows what it is about. A normal 
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four year old is saying no, they would just say no…So I 
think they just have a different experience and 
therefore should be dealt with differently. I am not 
saying you should just pin every four year old 
down…(Team leader, oral interview) 
This interviewee links the ability to dissent to the experiences children 
have with the procedures. In this respect, children with a medical 
condition such as cancer, who had to undergo the procedure frequently 
would be more able to make a judgment about whether they wanted to 
participate or not. But healthy children could be stimulated to participate 
if there parents agree to it, as they might say no without actually 
knowing what they say no to. In this respect, she considers the 
procedure (venepuncture) as relatively harmless: participating in 
research involving such procedure may be considered as part of normal 
activities children just have to do, despite of their wishes. 
Burden and Benefit 
None of our interviewees stated that research on stored tissue samples 
from minors would not be useful. On the contrary, two of them stated 
explicitly that they thought too many restrictions would be unethical, as 
children would be disadvantaged. 
In several guidelines on stored tissue samples and biobanks, the 
section on minors states that research on children should be for children 
(4)
. We asked some interviewees whether they thought this restriction 
made sense. They agreed, although they thought this should be 
interpreted rather broadly. For example, some diseases may be not 
typically ‘child specific’ but may develop during childhood. Other 
diseases may also occur in adulthood, but the adult variant may not be 
entirely analogous with the childhood one. One interviewee stated that 
in her line of research, it is easier to work with tissue from children than 
from adults, because the genetic condition she studied caused severe 
mental retardation. It is easier to get parental consent for research when 
the child has not yet reached the age of majority than it is to get consent 
for an incompetent adult.  
Although interviewees though that there was not much risk associated 
with genetic research on stored tissue samples from minors, they 
agreed that children should not be burdened with research. On the one 
hand, the use of anesthetic cream was mentioned nine different times 
by four different interviewees. They thought the use of this cream, 
possibly in combination with a video and proper professional assistance 
was enough to satisfy the non-burden requirement, as is illustrated by 
the following quote: 
I suppose it is not actively beneficial, but I think the risk 
is pretty minimal. And I think taking blood from a child 
who is not struggling hard is also minimal, I do not see 
that as a major problem. Particularly at least now, in the 
past, before anesthetic creams are used, there were 
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some children that really became quite distressed, but 
that shouldn’t be a problem now. (Clinical geneticist, 
oral interview) 
On the other hand, the reuse of information and samples gathered in a 
diagnostics context was seen as good practice. One interviewee 
mentioned the risk of thrombosis through venepuncture, and though 
that, although this risk is low, drawing of blood should be restricted to 
the minimum and samples should be reused as much as possible. 
Along the same lines, cooperation with schools and the possibility to 
collect medical data through the health care system was applauded as 
a good way of reducing the burden on children. The following quote 
states clearly that researchers have an ethical responsibility towards 
research participants to be as least intrusive as possible: 
Researchers duplicate and we are collecting, we do 
have to collect additional information sometimes, but 
we have got clinicians doing all these measures and 
assessments on one side, and in parallel we have got 
researchers doing the same think I think there is a 
responsibility vis a vis the parents to say we’ll be slick, 
we won’t disturb you where possible. (Epidemiologist, 
phone interview) 
This interviewee thought that redoing measurements and collecting 
duplicate information because of stringent consent requirements was 
unethical. The need for informed consent to reuse data and samples 
from a diagnostics collection is sometimes hard to obtain. It may be 
easier to gather again samples and data and consent from research 
participants. However, this causes extra burden as procedures would 
have to be done twice. Especially when children are concerned, the 
issue of burden becomes important and the need to reduce this burden 
may be more important than the need to gain consent for each new use 
of samples and information.  
Specialty of Genetic Information 
Most of our interviewees did not consider genetic research as different 
from other medical research, provided that proper data protection 
measures are put in place. Some referred to the difference between the 
European and the US context, and the fact that many assumptions are 
based on the latter. They thought that in the context of a public health 
care system, where health insurance is strictly regulated, the risk of 
participating in genetic research is minimal. As such, they did not see a 
big difference between the risks for children as for adults. They also 
thought that their research participants did not consider genetic 
research as particularly different or potentially risky, as is illustrated by 
the following quote: 
People are not so concerned about the genetics. 
Especially not in Belgium, in a safe situation. It is illegal 
to abuse such information, and as a doctor you are not 
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obliged to give that information. The genetic aspect is 
not an issue for patients. (Internist, oral interview) 
This interviewee thought that in Belgium, as it has an extensive public 
health system and legal restrictions on the use of genetic information, 
people were not concerned about privacy issues related to this type of 
information. Hence, her viewpoint on the risks of this information is 
related to potential misuses of this information through ‘malevolent’ third 
parties such as insurers and employers.  
Three interviewees mentioned that familial nature of genetic information 
sets it apart from other information. Two of them considered this to be 
positive: genetic family trees can explain and provide a reason for 
certain conditions, and hence provide a way to handle these conditions. 
One interviewee saw a potential danger in genetic information that can 
be acquired from longitudinal studies: 
Take the example of Huntington, if you do a study were 
you are looking in a population for the Huntington’s 
gene, and you find a child of 11 or 12 or so with the 
gene, which we do not have a the moment, and if you 
are looking in the parents and you find it in the parents 
and they’ve got a young child, even when the child is 
not in the study, ehm, what are the implications for the 
children about that, knowing about the Huntington 
condition where there is no remedy…(Gynecologist, 
oral interview) 
On the one hand, this interviewee considers the fact that people do not 
understand genetic information, and might be influenced by the media 
as potentially hazardous. On the other hand, the fact that through 
genetic research on biological samples researchers could detect certain 
genes leading to untreatable diseases poses additional difficulties. The 
question whether and how to return such incidental findings requires 
much reflection beforehand. 
DISCUSSION 
We interviewed 10 professionals working in the field of stored tissue 
samples on the topic of research on pediatric biological samples. We 
found that researchers were concerned about the bureaucratic 
restrictions of consent procedures on research. But we also found the 
need for guidance from ethics committees with regard to the scope and 
content of consent. Interviewees thought that children should not be 
burdened with research and should be told, in their own language, 
about the research. There was some disagreement on the issue of 
dissent of small children. Interviewees did not think genetic research 
was too different from other research; the difference was situated in the 
familial nature of genetic information.  
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Our interviewees thought that genetic research on stored tissue 
samples was useful and should not be complicated by bureaucratic 
consent procedures. Especially the fact that young children should also 
sign consent forms was often seen as a useless requirement, with no 
relation to the actual reality of children’s life. The interviewees thought 
the researcher, in conjunction with the parents, would be in the right 
position to assess what and when to tell a child about research. As 
some of our interviewees have also argued, long information sheets 
would frighten participants. Proper communication and building a 
relationship of trust with both parents and children was seen as 
essential. This is consistent with two other studies in the field. Avard et 
al. did eight interviews with professionals in the field of 
pharmacogenomics, where the researchers highlighted the need to 
communicate with children in a clear and concise manner, and to 
appropriately involve children(14). A survey of Jackson et al amongst 
health professionals in childhood cancer also stresses the need for 
conversations with families, next to the written information(20). 
Although our interviewees denounced complex formal rules on 
children’s assent and consent, they also thought that research should 
be ethically sound. For many of our interviewees, this meant that 
research protocols were reviewed by ethics committees and that 
research was transparent. However, there is a limit to what 
transparency can accomplish. As Onora O’ Neill has argued, 
transparency and a culture of accountability is though to replace the 
need for (naive) trust in biomedical research(21). But it is now also 
acknowledged that transparency cannot completely replace trust. De 
Vries has made a similar remark: there is more to trust than simple 
transparency. Disclosure can alert of potential problems but does not fix 
them as such(22). Our interviewees seem to implicitly acknowledge that: 
a good policy that protects the confidentiality of the genetic information 
in samples should be laid down in research protocols and implemented 
before any sample gathering takes place. And participants or their 
parents should be properly informed about these measures.  
One of the difficulties of formal consent and assent requirements when 
children and youngsters are concerned is the near impossibility of 
setting a fixed age threshold. The study of Avard et al. suggested that 
as of an age of 12 and older minors should be consulted about their 
willingness to participate in research(14). Also in the survey by Jackson 
et al the age of 12 was the mean age quoted for consent, although 
some respondents in that study gave an age as low as four. Our 
interviewees acknowledged that beside age, there are other factors to 
be considered: for example, a child with a chronic illness may be more 
knowledgeable about medical procedures. Related to this topic is the 
question if and under which circumstances the dissent of a child should 
be taken into account. The Convention on the Rights of the Child 
asserts that children have a right to say what they think should happen 
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when adults make decisions that affect them (Article 12)(23). Does this 
mean that researchers would have to respect the wishes of a four year 
old regarding the taking of blood for research purposes, regardless of 
the wishes of his or her parents? Can such a child be forced to donate 
blood for research? We think that anyone involved in pediatric research 
should be trained to assess these situations. Ethics committees should 
also double-check whether this issue is sufficiently thought through 
when they review research protocol. 
In a survey study by Ruiz-Canella et al. amongst geneticists in Spain 
and the US about the use of stored tissue samples for research(24), and 
in the survey study by Jackson et al. it is shown that many researchers 
would prefer broad consent for future research. This is also the 
preference of some of our interviewees expressed. However, when we 
investigated what they understood by ‘broad consent’, and whether this 
would include GWAS studies, we found that for them, broad consent 
was not analogous to ‘any possible future research’. Broad consent was 
seen as a convenience to allow research to proceed without too many 
impediments. However, interviewees still thought that for research that 
would cross certain milestones, such as a study that would require a full 
genome sequences, or research protocols that would be completely 
different from the original context, ethics committees should review the 
consent and decide whether recontacting the donors was necessary. 
We think that it would be extremely useful in the debate between about 
specific versus broad context to investigate further the content of these 
concepts, as ‘broad’ might mean something different to both parties. 
The question about the desirability of broad consent is complicated by 
the tension between the traditional right to personal autonomy of 
research participants and the need for solidarity(25). Some authors have 
argued that, as research on stored tissue samples does not require 
much effort from the participants and carries potentially huge benefits 
for future generations, the duty to participate to such research is higher 
than the need to emphasize personal autonomy(26). In this context, it is 
acceptable to ask for broad consent. However, children do not easily fit 
into the solidarity paradigm(27). In some contexts, they are exempt from 
certain duties that adults have, such as paying taxes and being 
employed, although in other contexts, civilized behavior is expected 
from them. Although we agree that to ask broad consent from adults 
may be a good balance between the right to personal autonomy and the 
duty to solidarity in medical research, we also think that for children this 
may be different, as the decision to give broad consent for research is 
done by the parents and for small children their wishes are largely 
unknown. We acknowledge that asking parents or older children to 
reconsent to any change in the research protocols for research on their 
samples may be burdensome as well. A compromise would be to allow 
parents and older children to reconsent or assent to major changes in 
Interviews with Professionals 
130/233 
types of research carried out on their samples and to ask for final broad 
consent when the young adult reaches the age of competence. 
Our interviewees thought the risks associated with research on stored 
tissue samples from children were fairly minimal. They first and 
foremost referred to physical discomfort that children might feel and 
thought this could be minimized by using properly trained personnel and 
anesthetic cream. This is also found in the study by Avard et al. where 
researchers mentioned buccal swaps, spitting and the reuse of blood 
taken in a diagnostics context. With regard to the genetic nature of the 
information this was seen as similar to other medical information in most 
aspects. The interviewees thought the familial nature of the information 
was the most important aspect that sets aside genetic information. This 
has repercussions not so much for the research per se but for the 
discussion about whether and how individual genetic results should be 
communicated to the participants, and whether family members also 
have the right to this information. Interviewees did not spontaneously 
mention the use of genetic information by third parties as problematic, 
an issue that is discussed in great depth the literature. This is 
analogous with the findings by Avard et al. who found that some 
researchers thought that genetic privacy concerns about third party 
access should not hold back research(14).  
Our study has shown that the issues related to the use of pediatric 
tissue for genetic research described in theoretical literature do not 
always correspond to the opinions and experiences of professionals in 
the field. Specifically, formal and elaborate consent and assent 
requirements are sometimes considered superfluous and even an 
impediment to a proper relation between researchers and participants. 
They put much emphasis on a good individual relation between 
researchers, parents and their children, which is more important than 
fixed guidelines on the age of assent or the need to reconsent for 
certain changes in research protocols. They thought ethics committees 
could fulfill an important task in aiding researchers in developing this 
relation and making decisions about desirability and burden of research. 
Many also thought the risks of genetic privacy breaches and third party 
access to genetic information were exaggerated and not applicable to 
countries with a public health system. Considerations of this kind should 
in any case not prevent research on children’s tissue to proceed. They 
did acknowledge that measures to protect confidentiality should be put 
in place and were part of proper research design, and that research 
should not unnecessarily burden children.  
We acknowledge that our study has several limitations. First, we used 
the snowballing technique for selecting participants. This is not a 
systematic way of selecting interviewees, and we have probably missed 
out interesting interviewees. The geographical and cultural diversity of 
our sample was limited (three countries), which would explain the 
conformity of answers to certain questions, especially those about third 
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party access and risk. We also used both telephone with live interviews, 
two different types that do not allow for one-to-one comparison. 
However, we believed that our data were interesting enough to allow for 
further analysis and reporting, especially because this is an area largely 
unexplored, and because the opinions of the professionals in our 
samples did not necessarily correspond with the issues that are 
considered important in the theoretical literature on this topic. Further 
research could include in-depth interviews in countries with a less 
elaborate public health system. Also, a quantitative survey of 
professionals on the themes discovered in this study could assess the 
prevalence of similar opinions in a larger data set.  
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ABSTRACT 
The ethical aspects of the use of stored tissue samples collected from 
minors are of topical interest. However, the views of professionals 
working in the field of genetics have not been investigated in depth 
anywhere. We conducted a survey among 194 such professionals in 
Belgium. This list was composed of the members of the High Council for 
Anthropogenetics, supplemented with all professionals working in the 
field of genetics that we found on the websites of the eight Belgian 
centers of human genetics and of the associated university registries. 
We achieved a response rate of 35.5%. The vast majority (92%) think 
that research on stored tissue samples is useful. Most respondents 
stated that parental consent is valid (82.5%), and 76.5% thought that 
children should also be given the right to assent when they are able to 
comprehend the implications of the storage of biological samples and of 
genetic research. Slightly more than half put the age at which young 
people can understand storage or research rather high: 16-18 years (51 
and 53.1%, respectively). Although there is some consensus in the 
literature that donors should be allowed to give broad consent for future 
research on their biological samples, only 47.6% in our survey thought 
that parents should be allowed to consent to any future research on 
their children’s samples. The aim of our study was to give some basis 
for future ethical reflections and policies on the subject of stored tissue 
samples from minors for genetic research. We concluded that a large 
majority of Belgian researchers and clinicians in the field of genetic 
research think research on stored tissue samples from minors is useful. 
They also think that parental consent for such research is valid, but that 
children should be allowed to assent as they grow older. 
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INTRODUCTION 
The use of stored tissue samples from minors has gained some 
attention lately after the publication of a policy forum in Science(1). In 
this policy forum, it is stated that population biobanks involving children 
and their tissue raise specific ethical issues that are not covered by the 
general discussion, which assumes that participants are adults that can 
autonomously decide on participation. A recently published literature 
review has confirmed this(2). The main theme in the existing literature is 
consent: is parental consent sufficient or valid for storing biological 
samples from children in biobanks? Should children be allowed to give 
assent (‘permission’) when they have reached an age at which they can 
understand the implications of storage and research? What is this age? 
Are parents allowed to give broad consent for research on the stored 
tissue samples of their children?  
There is already a substantial body of empirical literature on stored 
tissue samples in general. This literature is based on surveys querying 
the general population(3,4), patients(5,6,7,8) or biobank participants(9). The 
views of professionals on the ethical questions regarding stored tissue 
samples are far less investigated. Ruiz-Canela et al.(10) did a survey of 
researchers in the USA and Spain on the issue of informed consent and 
the subjects’ right to know the results of a study. With regard to stored 
tissue samples from minors, we found three surveys(11,12,13), two 
qualitative studies investigating children’s views(14,15) and a focus group 
study(16). Only one study queried the viewpoints of professionals on the 
issue of tumor banking: Jackson et al.(17) did a survey among pediatric 
oncology health professionals on the usefulness of tissue banking and 
the issue of consent in pediatric research on tumors.  
Given the lack of publications in this specific area, we found it 
necessary to query the opinions of Belgian professionals who work with 
DNA samples, with regard to this subject. We asked about their opinion 
on the usefulness of research on stored tissue samples of children, the 
validity and scope of parental consent, the need for a child’s assent and 
the age at which they thought children could understand storage of 
biological samples and research on these samples. This paper is a 
report of our findings.  
METHODS 
To compile the list of addressees of our survey, we took the names of 
the members of the High Council for Anthropogenetics, an official 
Belgian body composed of geneticists from all different centers in 
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Belgium with the task of coordinating the activities of the eight Belgian 
centers for human genetics. We supplemented this list with 
professionals whom we found on the websites of all the eight Belgian 
centers of human genetics and of the associated university registries. 
We took a broad approach to the selection of participants: if the website 
did not specify otherwise, we assumed the people enlisted were 
involved in or had a professional opinion on stored tissue samples for 
genetic research. 
We created a structured questionnaire based on a review of the ethics 
literature on stored tissue samples(18). The survey was reviewed by one 
medical doctor, one researcher in genetics and one researcher in 
biochemistry. These reviewers did not participate in the final survey. 
A total of 194 questionnaires were sent out via email starting on 
September 11, 2008. We sent out 8 reminders during the period of 
September 2008 to September 2009, including one postal 
questionnaire. No monetary or other incentive was offered. We received 
six notifications that the person had left the institution. We received 
eight notifications of people stating they did not work in the field of 
genetic research and that they thought the questionnaire was not 
applicable to them. A total of 64 surveys were returned completed 
(response rate = 35.5 %). We believe the rather low return rate can be 
attributed to different reasons. First, as we sent out the questionnaire to 
a rather broad audience, several recipients must have thought this was 
not applicable to them. Second, the questionnaire took 20 to 30 min to 
complete. We talked to some of the recipients, and they told us that 
their busy schedule did not allow them to complete questionnaires. 
Third, the low return rate for questionnaires among professionals in 
general is well known(19). As 95.3 % of our respondents claimed that 
their institute stores biological samples for genetic research, and as 
46.9 % stated that their educational background was in science and 
48.4 % medicine, we still think that the data we gathered is 
representative of the viewpoints of professionals in the field of genetic 
research in Belgium.  
Response implied informed consent. The questionnaires were coded 
upon receipt and processed using SPSS 16.0. We generated frequency 
tables and used Fisher’s exact chi –square test to calculate significant 
relations between the findings. When we found significance in findings, 
we indicated this below. 
RESULTS 
We collected the following biographical data of respondents: gender, 
year of birth, whether they have children, in which province (including 
Brussels) do they live, educational background, number of years 
involved in genetic research and whether the institute in which they 
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work stores human biological samples for non-therapeutic research. We 
had a fairly even distribution of males and females (42.9 % vs. 57.1 %), 
most of our respondents had children (80.6 %) and the majority had 
been involved in genetic research for over 4 years (70.2 % in all cases). 
The mean age of our respondents was 44 years (SD 11; range 24-69). 
An overview of these demographics can be found in Table 1. 
 
Table 1 Biographical data 
  % 
Gender* Female 
Male 
57.1 
42.9 
Age* 21-30 
31-40 
41-50 
51-60 
61-70 
11.3 
32.3 
35.5 
9.7 
11.3 
Have children* Yes 
No 
80.6 
19.4 
Province* ** Antwerpen 
Brabant Wallon 
Brussels 
Hainaut 
Liège 
Limburg 
Luxemburg 
Namur 
Oost-Vlaanderen 
Vlaams-Brabant 
West-Vlaanderen 
12.7 
4.8 
14.3 
4.8 
12.7 
3.2 
1.6 
0 
14.3 
30.2 
1.6 
Educational background Science (biology, (bio)chemistry, 
(bio)engineering) 
Medicine 
Humanities 
Pharmacy 
46.9 
48.4 
1.6 
3.1 
Years involved in genetic research <1 
1-3 
4-6 
11-20 
Longer than 20 
3.1 
6.2 
39.1 
31.2 
20.3 
Does institute you work for store human biological 
samples for further non-therapeutic research* 
Yes 
No 
95.1 
4.9 
* As some respondents (maximum 3) skipped certain boxes, the valid percentages are given  
** Including Brussels 
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Our first set of questions was related to the usefulness of stored tissue 
samples from minors for research and to the need for parental consent 
and the assent of the child. The vast majority of respondents thought 
that genetic data from minors is useful for research (92%). They also 
thought that parental consent is valid (82.5%). However, the majority 
also believed that children should be given the opportunity to assent 
once they could understand the implications of storage and genetic 
research (76.5 %). An overwhelming majority thought that young people 
should be given the right to withdraw their data from a collection when 
they reach the age of 18 (95.2 %). Table 2 gives an overview of the 
findings for the first set of questions.  
 
Table 2 Likert-scale questions about usefulness, consent and assent 
   % 
Genetic data from minors is useful for research* Strongly agree 
Agree 
Neither agree nor 
disagree 
Disagree 
Strongly disagree 
45.2 
46.8 
6.5 
1.6 
0 
Parental consent is sufficient for storage of biological 
samples for genetic research of any child who cannot 
assent (‘give permission’) because he or she cannot 
understand the nature of the research* 
Strongly agree 
Agree 
Neither agree nor 
disagree 
Disagree 
Strongly disagree 
20.6 
61.9 
7.9 
3.2 
6.3 
Once a child can understand the implications of 
biological sample storage and genetic research, he or 
she should be allowed to assent (‘give permission’) 
Strongly agree 
Agree 
Neither agree nor 
disagree 
Disagree 
Strongly disagree 
20.3 
56.2 
6.2 
14.1 
3.1 
A child should have the right to withdraw their data 
from a biological sample collection when he or she is 
18 years old* 
Strongly agree 
Agree 
Neither agree nor 
disagree 
Disagree 
Strongly disagree 
33.3 
61.9 
0 
3.2 
1.6 
* As some respondents (maximum 3) skipped certain boxes, the valid percentages are given 
 
We also investigated the scope of parental consent. We asked for which 
types of research could parents give consent. The majority of 
respondents agreed that parents should be allowed to consent to either 
well-specified research (79.4 %) or research for a specific condition 
(77.8 %). A little less than half of them thought parents could consent to 
any possible research (47.6 %). The results are in Table 3. 
 
Table 3. To which type of research should parents be allowed to consent for 
their children? 
  % 
Research that is well specified at the time of consent* 79.4 
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Genetic research related to a specific gene* 58.7 
Genetic research related to a specific condition* 77.8 
Any possible future genetic research* 47.6 
* As one respondent skipped this question, the valid percentages are given 
 
We also investigated at which age respondents thought children were 
able to understand the implications of storage of biological samples and 
of genetic research. A small majority thought this age was 16-18 years 
for both the storage of samples (51.5 %) as for the genetic research 
(53.1 %). We found a correlation between the age of the respondents 
and the answers to the question about which age people can 
understand the implications of storage (Fisher’s exact test, P=0.039). 
The results are in Table 4. 
 
Table 4 Age of understanding  
  % 
From which age do you think children can 
understand the implications of storage of 
biological samples for future genetic 
research? 
0-3 years 
4-6 years 
7-9 years 
10-12 years 
13-15 years 
16-18 years 
0 
0 
1.6 
17.2 
29.7 
51.6 
From which age do you think children can 
understand the implications of genetic 
research? 
0-3 years 
4-6 years 
7-9 years 
10-12 years 
13-15 years 
16-18 years 
0 
0 
0 
14.1 
32.8 
53.1 
DISCUSSION 
This study demonstrates that a large majority of researchers and 
clinicians in the field of genetic research think that research on stored 
tissue samples from minors is useful. They also thought parental 
consent is valid, but that minors should be given the opportunity to 
assent once they are able to understand the implications of the storage 
of biological samples and of genetic research. The age when minors 
would be able to do so was set quite high by a small majority: around 
16-18 years. Respondents also thought people should be able to 
withdraw their data from a biological sample collection when they turn 
18. 
The need for assent from minors is consistent with the ethics 
literature(2,20,21). It is seen as a general duty to include children in the 
decision making, at the moment that they can understand what is at 
stake. This is a right that is laid down in the United Nations Convention 
on the Rights of the Child(22) and can also be linked to the fact that in 
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order to develop autonomy, a child should be able to exercise it(21). A 
small majority of our respondents suggested a fairly high age at which 
children can understand the implications of genetic research and the 
storage of their samples (16-18 years old). In a survey of clinical 
geneticists to decide at which age a minor can decide on having a 
carrier test, also this age (around 16) is given(23). There is, however, 
much discussion about the age at which a minor can understand 
genetic research. General literature regarding the capability of children 
to make decisions suggests that even at a very young age children can 
be involved in decision making(24). However, with regard to genetic 
testing, others have found that even teenagers have difficulties grasping 
the full scope and impact of genetic information(25). Also, the legal 
situation in the EU on the position of minors in a health care setting is 
not straightforward. An overview of legal regulations shows that this 
position varies: the age and circumstances under which minors are 
allowed to make health care decisions vary in different countries, and is 
sometimes set as low as 14 (Portugal)(26). One could even question 
whether it is possible to establish a fixed threshold for assent or whether 
this is dependent on maturity and social context, and must be decided 
on a case-by-case basis(27,28). And, even if children have no thorough 
understanding of the implications at the moment that they are enrolled 
in research, do they not have the right to be informed in terminology that 
they can understand, even when they are below the official threshold for 
assent?  
Our respondents almost unanimously agreed that donors should be 
given the opportunity to withdraw their data from a biological sample 
collection when they are 18 years old. This is in accordance to the 
ethics literature on the subject(29). Holm, for example, argues that as 
children have not been able to autonomously consent and give up the 
right to withdraw at the moment of donation, the right to withdraw for 
children is more important than for adults(20). It is less clear whether this 
entails a positive duty on the side of the researchers to recontact donors 
when they are 18 to inform them about their samples, or whether it can 
be left to the parents to inform their children of their participation.  
A topic much discussed in the general ethics literature on stored tissue 
samples is the scope of consent. Should donors of biological samples 
be allowed to consent to any future research or should they be 
recontacted to give consent for each specific research? The study by 
Ruiz-Canela shows that professionals prefer a less restrictive 
consent(30). Also, a systematic review by Wendler has indicated that 
most donors would not mind giving one-time general consent(31). 
However, our respondents were somewhat more restrictive, as they in 
general preferred consent for well-specified research or research on 
specific diseases. The difference is the fact that we asked about the 
right of parents to consent for their children. Whether they have this 
right is not often questioned in ethics literature(2), but the fact that this is 
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proxy consent possibly limits the actual scope of the consent. How to 
best balance on the one hand feasibility and on the other hand respect 
for the rights of children to make their own decisions should be 
determined by policy makers of pediatric biobanks before enrolling 
donors.  
Our study has several limitations. First, there is the fairly low response 
rate (35.5 %), which may make our study not entirely representative of 
the Belgian professionals working with biological samples. Second, the 
section on biological samples from minors was only a part of the survey; 
this may or may not have influenced some of the answers., however, as 
we still obtained a fairly large sample of Belgian professionals in the 
field of genetics, and as this is a largely untrodden area, we think that 
our study can be the onset of a more thorough discussion. 
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ABSTRACT 
Objective: Research on biological samples from children and pediatric 
biobanks can be useful for the progress of medical science. However, 
such research also raises specific ethical questions.  
Study design: We investigate the principles of risks, benefit and 
solidarity in relation to pediatric biobanks, based on a study of the 
existing theoretical and empirical literature. We formulate our own 
conclusions on how children can be included in genetic research on 
stored tissue samples in an ethical way. 
Results: We argue that, because of the principle of limited solidarity that 
is applicable to children, stored tissue samples from children can be 
used for genetic research. However, we propose some limitations that 
are related to specific risks and to the type of research that is 
performed. Specifically, research should not burden children and 
respect their values. Also, although the requirement of personal benefit 
that is often used in clinical trials may not be transferrable to pediatric 
biobanks, and the requirement of group benefit may be too vague, the 
requirement that such research should only be done if it cannot be done 
on adults is a valid one.  
Conclusion: Genetic research on stored tissue samples from children 
can be done under specific circumstances.  
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INTRODUCTION: CHILDREN AND SOLIDARITY 
Research on biological samples from children and pediatric biobanks 
can be useful for the progress of medical science. For example, genetic 
cohort studies can shed an important light on the interaction between 
genes and environment and help understand diseases such as asthma, 
food intolerances, autism and ADHD. Also, disease-specific collections 
can help understanding the importance of gene variations in the 
development of the disease in question. Collections of samples and 
extracted DNA can typically be stored over a longer period of time, and 
research on them can change overtime. Collections can be gathered 
primarily for research purposes, or collections originally gathered for 
diagnostics purposes could be reused for genetic research. And, 
although useful, such collections also pose specific ethical problems 
that are not covered by the discussion on stored tissue samples from 
adults. Existing discussions often link the question whether children 
should and can participate to the question of minimal risk and benefit. In 
this paper we want to explore these topics further in the context of 
pediatric biobanks, and provide some suggestions as to the ethical 
inclusion of children in biobank research. We shall use the term 
‘children’ rather broadly, from birth until the legal age of competence, 
although we admit that each phase in growing up has specific issues 
and therefore requires a slightly different approach. We also admit that 
there is a difference between the use of collections of samples that were 
gathered in a diagnostics context, and the gathering of new samples 
from children with the sole purpose therapeutic research. This 
difference has ethical implications which we shall come back to in due 
course. 
In the context of biobanks, some have argued that the traditional 
autonomy paradigm in bioethics has failed(1,2). In this respect, the 
principle of solidarity is used, which is put forward as an alternative to 
the more traditional principles that were first laid down by Beauchamp 
and Childress (autonomy, nonmaleficence, beneficence and justice)(3). 
Indeed, as contributing to genetic research on stored tissue samples 
typically does not require too much effort from participants, and as this 
generates potentially huge benefits for future generations, biobanks 
have the right to appeal to citizens to participate in such research. More 
specifically, this is true if the research aims to develop interventions for 
diseases which impair individual autonomous and social 
functioning(4,5,6).  
Solidarity as a principle is relatively new in bioethics. Its application to 
politics and society in general has been laid down by authors such as 
Léon Bourgeois(7). Bourgeois describes solidarity as a natural and 
practical middle ground between individualism and collectivism. It is 
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natural, because it arises organically from the fact that all individuals are 
associated in society, and that this association helps individuals. In 
return, individuals also have an obligation towards society. Indeed, he 
believes that all people are born with an obligation to society. However, 
this is not the same as collectivism, as this obligation grows naturally 
from the fact that individuals can only thrive within society.  
This way of thinking can be applied to biomedical ethics to provide an 
alternative to autonomy-centered principlism, without losing the 
necessary respect for individual values. The principle of solidarity 
implies that researchers in medical sciences can appeal to the solidarity 
of individuals, as these individuals have benefitted from previous 
research and will possibly benefit from future research. However, 
individuals still have the right to refuse participation. Their duty consists 
of the fact that they should at least consider such appeal, and 
substantiate a refusal with valid arguments(8).  
But even the advocates of the solidarity principle make an exception for 
children(9). On the one hand, until they reach the age of competence, 
children have a limited autonomy and hence their wishes are unknown. 
So even if there is a strong appeal to participate, they are not in the 
position of considering a substantiated refusal. Also, in everyday life 
they are exempt from many duties adults have. In this respect, the 
moral appeal one could make on children to participate in research may 
be restricted. On the other hand, some have argued that we must not 
assume, for incompetent children, that they would not want to 
participate in research if they had the capacity to consent(10). Moreover, 
we do expect certain civilized and solidary behavior from our children in 
everyday life. And exercising some level of solidarity during childhood 
may help them develop into more solidary adults. Therefore, we 
propose a model of limited solidarity for children. As some research, 
which is potentially beneficial to future generations of children, just 
cannot be performed on stored tissue samples from adults, for example 
if the disease develops or occurs in childhood, children can be asked to 
enroll for such research. But children are different from adults in that it is 
generally assumed that, as they are vulnerable persons: they should be 
shielded from too risky or burdensome procedures. Indeed, traditionally, 
discussions about children’s participation in research and biobanks 
have focused on the fact that there should be no more than minimal 
risks and at least some benefit to the participating individual or the 
group to which he or she belongs(11,12). In the next sections we shall 
discuss these principles, elaborate on which risks form a reasonable 
restriction to the right of biobankers to appeal to children to participate in 
genetic biobank research and discuss the issue of benefits. In table 1 
we give an overview of the arguments that are used in the rest of this 
text. 
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Table 1 
Background Researchers have the right to appeal to children and their parents to 
ask them to participate in biobank research. However; this right is 
limited by the special vulnerability of children. Issues of risks and 
benefits of participation should be considered 
Privacy risks There is a risk that genetic information is abused by third parties 
such as insurance companies and employers. In our opinion, this 
does not warrant the exclusion of children from biobank.  
Risks of physical and 
emotional burdens 
Children may experience pain or be frightened of certain methods 
used to gather samples. 
Risks of breaches of 
values 
Genetic research on stored tissue samples may spread over longer 
periods of time. Children may have different values than their 
parents and may not agree with certain research parents consented 
to.  
Benefits Requirement of direct benefit is not applicable to pediatric biobanks 
Requirement of group benefit is difficult to substantiate in case of 
genetic research 
Requirement that it can only be done on children if it cannot be 
done on adults is a straightforward one. 
Recommendations Issues of privacy risks should be solved a priori on societal level 
(just society with legally controlled public health system) and with 
adequate data protection measurements on the level of biobank 
governance. 
Research on children should not burden children physically or 
emotionally. Preferably, samples gathered in a diagnostics context 
should be used. If this is not possible, the research protocol should 
be first assessed by an ethics committee and then by the parents, 
the researcher and the specific child. 
A child’s current and future values should be respected, and a child 
should be given the opportunity to reconsent when research on his 
or her samples takes a different form from what was originally 
intended.  
Research on children’s tissue should only be done if the same 
research cannot be done on tissue from adults. 
 
MINIMAL RISKS  
In pediatric research, the principle is often held that children can only 
participate in research that offers no direct benefit to them if the risks 
are minimal or, under certain conditions, a minor increase over minimal 
risk(13). Also the discussion whether children can participate in biobank 
research is sometimes framed in terms of minimal risk. Indeed, some 
guidelines and position papers mention ‘minimal risk in the context of 
children(11,14,15). The CIOMS International Ethical Guidelines for 
Biomedical Research Involving Human Subjects gives a definition of 
what minimal risk might entail: “the risk from research interventions that 
do not hold out the prospect of direct benefit for the individual subject 
should be no more likely and not greater than the risk attached to 
routine medical or psychological examination of such persons.”(16) Other 
interpretations of the minimal risk standard refer to situations children 
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encounter in everyday life(17). Wendler et al. have pointed out that both 
the reference to everyday life or to routine medical examinations pose 
some problems. For example, the risks posed to children by riding in a 
car of going to the swimming pool are much higher than the physical 
risks linked to for example venepunctures(13). Would this mean that 
children could possibly be exposed to higher risks in research than they 
are now? The risks may be more intangible, for example, trauma or 
psychological damage resulting from fear may be non existent for one 
child but greater for another child. And children with a medical history 
have more experience with examinations than healthy children. It seems 
unfair, however that this would make them preferred research subjects. 
The issue is further complicated when the research in question is on 
stored tissue samples, such as is the case in biobank research. In this 
case, risks will depend on the way information is gathered and the type 
of biobank. The reuse of samples that were gathered in a diagnostics 
context will pose different (and possibly less) issues than research that 
gathers blood samples from children specifically for research purposes 
Also, the genetic aspect could entail possible risks that do not occur in 
other types of pediatric research. The fact that these samples could be 
used for longer periods of time, until and after the child reaches 
adulthood may also introduce additional risks that are not analogous to 
risks encountered in one-time clinical trials.  
Eriksson and Helgesson believe that there is less risk involved in 
biobank research than in human subject research because of the limited 
physical risk. But they acknowledge there may be other risks, such as 
moral harms, as the storage and use of samples may violate the 
autonomy, privacy or personal integrity of participants. Also, they see 
the possibility of non-physical harm, for example, information derived 
from samples can be used to the disadvantage of the person by 
employers or insurance companies(18). In the following section we shall 
discuss three types of possible risks in relation to pediatric biobanks: 
Privacy risks related to genetic information, physical and emotional 
harms and disrespect of values. We shall assess each of them and see 
if they warrant the exclusion of children from biobank research or, if they 
do not do so, how they can be best tackled.   
Risks Related to Genetic Information (Privacy Risks) 
Much has been written about the risks to which the individual can be 
exposed when his or her genetic information is determined. As Boenink 
and Van der Burg have argued, in the context of genetic testing risk 
discourse is predominant: the main focus lies on the reduction of the 
occurrence of certain genetic conditions, conditions that may occur in 
the future of the tested individual(19). The risks associated with genetic 
information available through genetic research and in biobanks are at 
first sight different, but are the other side of the same coin. These risks 
are predominantly privacy related. Genetic information, it is stated, can 
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be misused by third parties such as insurance companies and 
employers if they gain access to the biobank(20,21). These risks are also 
similar in the case of the reuse of diagnostics collections or the 
gathering of samples specifically for research. They are enhanced by 
the fact that such research may spread over time and samples and 
information may be stored for longer periods of time, and future risks or 
possible privacy breaches are hard to foresee upon installation of the 
collection. In this respect, both types of risks associated with genetic 
information (genetic testing to prevent risks and genetic research 
generating risks) are related, because they are concerned with the 
specific nature of genetic information. As it is stable across a lifetime 
and contains information about potential health problems in the future, it 
is often considered a ‘future diary’ (22). As such, the genetic risks are 
good examples of what Ulrich Beck describes in his seminal work Risk 
Society(23). Such society is confronted with risks that stretch out across 
borders and time and are the result of technological changes, and that 
can no longer be contained or prevented by individual choices. But, it is 
also true that risks are often socially constructed, and hard to objectify. 
As an extreme example, the risks of boarding a plane is experienced by 
many as more risky than riding in a car, as the former is a less familiar 
experience than the latter(13). Genetic information may fit into this 
pattern, because of the relatively newness and uncanniness of the 
matter. The issue at stake here is whether the risk associated with 
genetic information is real enough to warrant the exclusion of children 
from biobank research, and, if not, whether and which restrictions 
should apply. To answer this, we must first consider the objective reality 
of this type of risk, the relation it has to other risks children face, and the 
possible limitations these risks would pose on pediatric research.  
First, what is the objective reality of the risks associated with genetic 
information? These risks bear similarities to a concept called ‘genetic 
exceptionalism’. Genetic exceptionalists consider genetic information as 
fundamentally different from other medical information, as it contains 
information about a person’s medical future and might divulge 
information about relatives and be used for purposes of 
discrimination(24). However, others have specified that other types of 
medical information can also contain such information and it would be 
equally harmful if such information is misused by employers and 
insurers. People do not typically question health examinations offered 
by employers or medical data stored in files at the GP’s office and most 
people are not afraid that such information is misused by insurance 
companies. In a research context, how realistic is it that insurance 
companies would hack into databases or bribe researchers to provide 
information about certain individuals, especially in countries where there 
is an elaborate and legally controlled public health care system. We do 
agree that there is something special about genetic information. Firstly, 
it is familial in nature and shared with other people. Secondly, potentially 
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a huge amount of information can be gathered from one single source. 
Especially with the advent of GWAS techniques this could eventually 
lead to the publication of people’s entire genome. It has recently been 
shown that it is possible to reidentify completely anonymized 
samples(25). 
Our second question is, whether these possible risks warrant the 
exclusion of children from biobank research, as some have argued(26). 
In this respect, we do not think that the privacy risks associated with 
pediatric biobank research are higher than other risks they encounter in 
everyday life. If adults release health information about themselves 
without reasonable fear of this information being misused by third 
parties, this is especially the case of children. Indeed, one could argue 
that much potentially harmful medical (but non genetic) information is 
stored in databases of public health services monitoring children from 
birth until they reach adulthood. Files may contain the length and weight 
of children at a certain age, whether they are breast fed or bottle fed 
and their dental care, all of which may potentially affect future health of 
the individual in question, based on statistical assumptions. Such 
information is typically also used for epidemiological research without 
explicit consent of parents or children, and may be more easily 
accessible to and interesting for insurance companies or employers 
than genetic research databases. Hence, potential third party access to 
data is no sufficient risk to warrant non-inclusion of children of biobanks.  
Third, we must ask whether the existence of certain privacy risks may 
warrant certain limitations. Indeed, a recent policy paper in Science has 
argued that because of the potential risks (and the lack of consent), 
longitudinal studies should either invest in in-house processing facilities 
or await the consent of participants once they are adults. Hence they 
believe pediatric samples should not be shared or sent to researchers 
outside the facility(27). We think that the link between consent and risk is 
a flawed one. Indeed, in many of the literature on biobanks this link is 
made, as informed consent is often seen as a way to transfer the 
responsibility of ill luck in outcomes from doctor (or researcher) to 
patient (or research participant)(28,2). However, we think that the 
reasonable prevention of risks should precede consent; both in case of 
adult and minor participants, as they or their parents should only be 
allowed to consent to relatively risk-low research. Like Hoedemaekers 
et al. we assume that privacy risks can be adequately controlled by 
policy measures(6). Risks related to genetic privacy should be solved on 
two levels, first in society in general (through just institutions and genetic 
privacy laws) and second, on governance level, in appropriate data 
protection policies of biobanks, especially when samples are shared. In 
an empirical study about practices of six cohort studies involving 
children, representatives of these cohort studies emphasized strong 
data protection measures using coding and restricted access. Some 
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studies also have established committees to advise on data handling 
issues such as requests by third parties(29).  
Risk of Physical and Emotional Burden  
Literature on clinical trials often quotes the fact that research should 
only minimally burden children(30). Also, in the empirical research on 
opinions of lay people on the inclusion of children in biobank research, 
the fact that this should not cause any burden on children is mentioned 
as a major concern. Specifically, the concern that the gathering of 
samples could cause children pain is a major impediment for the 
inclusion of children in research on tissue samples. A focus group study 
by Hens et al. shows similar findings, and stresses a preference that 
samples gathered in a diagnostics context could be reused(31). But next 
to physical discomfort, other types of burden are mentioned. For 
example, a focus group study by Kaufman et al shows that children 
might experience fear, or that children might by overburdened by 
participation, especially as they had already a long list of activities(32). 
Goodenough et al. interviewed minor participants of a large cohort study 
between the age of 7 and 11 and found that some would not enroll in 
the research again if they could choose again, because it interfered too 
much with other activities(33). This is a risk that only occurs when 
samples are primarily gathered for research, and not in the case of the 
reuse of diagnostics collections, making this a major ethical difference 
between the two types of databases. 
It is interesting to investigate why intuitively so much emphasis is put on 
the reduction of burden in case of children, whereas the same type of 
burden seems to occur when adults are enrolled. This is related to the 
fact that children are more vulnerable than adults. This vulnerability has 
different aspects. First, it has to do with the limited autonomy of 
children. They are only enrolled in the research by means of the proxy 
consent of their parents. It may be perfectly alright to consent for 
oneself to research that is even more than minimally burdensome, but 
to do this for another, incompetent person, is awkward. This is in sharp 
contrast to consenting for medical procedures for a child’s benefit. 
Although the decision is awkward here as well it is more readily taken. A 
second, related, aspect of the vulnerability is the lack of understanding 
of especially small children. If it is not for their own benefit, the fact that 
a child is being hurt or frightened and that she cannot understand the 
reason why makes the procedure more problematic. And although we 
believe that children can be asked to contribute to research because of 
the principle of solidarity, it seems that, if such research involves an 
infringement of their specific vulnerability, this right to appeal is 
lessened or even non-existing.  
Of course, the assessment of which kind of burden is acceptable is a 
hard one and may depend on specific circumstances and characteristics 
of a specific child. As mentioned before, the standard of ‘everyday risk’ 
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does not really apply here, as children who are often in contact with 
medical procedures may be more familiar with the procedures, but may 
be more vulnerable and hence exempt from yet another venepuncture. 
Also a four year old may be very upset at first by a venepuncture, but 
easily soothed and pleased if she receives a small sticker or child-
friendly reward afterwards. We believe that, because of the vulnerability 
described before and the impossibility to create a burden threshold for 
all children alike, that the precautionary principle should prevail here. 
This principle assumes that if there are good reasons based on 
empirical evidence or causal hypothesis that damage could happen, 
that adequate measures should be taken to prevent potential harmful 
outcomes(34). One important aspect would be that research protocols 
requiring blood or other samples for genetic research should try to reuse 
existing samples and data as much as possible. It is now sometimes the 
case that, because of strict consent procedures and the difficulty to gain 
consent for existing samples, new procedures are performed although 
material from diagnostics collections was available. For example, large 
collections of blood spot cards exist, which are gathered from newborns. 
As of yet, these are in many countries not used, unless anonymized, 
because of the lack of consent for research and the administrative 
burden of trying to track parents or children for consent. Possibilities 
should be explored to use these in an ethical way. Also, procedures 
such as the use of oral fluid or local anesthetics should be explored if 
reuse of material is not possible(35). 
A first assessment of the amount of burden research would pose on 
children, and the alternatives, should be done by the ethics committee 
investigating a research proposal. This committee should have a 
pediatrician as a member. Second, if a research proposal is considered 
acceptable, for each case, the researcher, the parent and the child 
should decide on the desirability of a procedure. It is important that 
researchers are trained to assess reactions of the child in question, so 
that neither researcher nor parent would allow a procedure with would 
emotionally harm the child, solely for the purpose of the progress of 
science.  
Risk of Breaches of Values of Child 
The combination of children and stored samples collections, be it the 
reuse of diagnostic collection for research or the inception of new 
collections specifically for research, pose a difficulty that may not arise 
in, for example, clinical trials. On the one hand, samples can be stored 
in tissue sample collections for a longer period of time. Hence, genetic 
research on them may spread over a longer period of time and new 
types of research can be carried out on them. On the other hand, what 
is specific about minors is their lack of autonomy when they are small 
and their gradual growth towards autonomy and acquiring of certain 
values when they grow older(36). Typically, parents make many 
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decisions for their small children but would allow their children to 
gradually make more decisions for themselves as they grow older. 
Parents, as proxy decision makers, do not know the opinions of their 
children and would hence make decisions based on their own values, 
and in what they think is the best interest of their children15. Hence, it is 
possible that they would make decisions that their children would not 
make if they had to redo the decision. This is however, considered, part 
of childhood and accepted, as long as children are allowed to develop 
their own values and opinions in the course of growing up, as is shown 
also in empirical literature(37). In the context of biobanks, this poses a 
specific risk. As research continues over time, and would take new 
forms, it is possible that research done on samples for which parental 
consent was obtained when the child was two, is contrary to the wishes 
of the participant who is now 16 years old. Especially if this research is 
non-reversible this seems unacceptable, as children have the right to an 
open future and the right to make their own autonomous decisions when 
they are ready for it(38). For example, parents could have consented to a 
full genome scan of their child, the data of which are still circulating 
years later. Or, they could have given broad consent to any research on 
samples, and the samples are at a given moment used for controversial 
research. Although we do not question the rights of parents to enroll 
their children in longitudinal biobank research, we also think it is 
important that the child, as a person who is gradually acquiring and 
exercising autonomy, is consulted and made aware of new research on 
her samples, especially if this research takes a great leap away from the 
original protocols. Hence, we believe that parents should not be allowed 
to make any too definite decisions. Although to ask broad consent may 
be acceptable for adults, final decisions of this kind should be 
postponed until the child reaches the age of majority. This does not 
mean, however, that parents or older children should be asked to 
reconsent to each small change in research protocol. Ethics committees 
can decide whether a new type of research is sufficiently covered by the 
original consent or if reconsent is needed16. We agree that the feasibility 
                                               
 
 
 
 
 
 
15
 A related question is wether both parents should consent to the use of tissue from their 
child for genetic research. Given the familiar nature of genetic information this may be 
desirable. However, as many children are not living with both parents and consent from both 
parents may be not easy to obtain, this should probably be seen as a best practice rather 
than a strict rule. 
16
 An objection may be that asking older minors to reconsent is too burdensome and may 
hamper research. However, technologies such as a website that would, given proper 
identification, allow an individual to review his or her consent could make the reconsent 
process more flexible.  
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of such reconsent also depends on the type of biobank and will be 
easier in case of longitudinal cohort studies than in case of the reuse of 
possibly anonymized samples from a diagnostics collection. In the latter 
case, the decision whether research can proceed without reconsent 
may depend on the evaluation of the ethics committee. 
BENEFITS 
We have described the restrictions that can and must be put on biobank 
research on children because of the potential risks. Restrictions can 
also be related to the types of research that is done. The most often 
quoted restrictions in this respect are related to either direct or group 
benefits or to the fact that such research can only be done on children if 
it cannot be done on adults.  
With regard to direct benefits, it is difficult to see how this criterion can 
applied to non-therapeutic genetic research on samples from children. 
True, regular checkups of children in case of longitudinal cohort studies 
may increase children’s health if information is fed back to them(32). But 
direct benefit is never the primary aim of pediatric biobank research, 
and most of the children participating may never experience any health 
benefit from their participation. In this respect, we think that the 
restriction ‘direct benefit’ is too stringent in the case of pediatric 
biobanks. Also, there is a strong link between the amount of risk 
participants are exposed to, and the benefit requirement. In clinical 
trials, this is especially relevant. Children may be exposed to higher 
than minimal risk, if the procedures are of potentially great benefit to 
them. As we are talking here on research on stored tissue samples, and 
the risks are relatively lower than in clinical trials, the requirement of 
direct benefit is less important.  
There are two other restrictions often quoted in the literature on medical 
research on children and in biobank guidelines and have their origin in 
the Declaration of Helsinki, that wanted to create an opening to allow 
research on subjects unable to consent. In its 2008 revision it states that 
“These (i.e. incompetent) individuals must not be included in a research 
study that has no likelihood of benefit for them unless it is intended to 
promote the health of the population represented by the potential 
subject, the research cannot instead be performed with competent 
persons, and the research entails only minimal risk and minimal 
burden”(39). 
The second restriction is a causal one and states that medical research 
can only be done on children if it cannot be done on adults. Several 
guidelines quote this restriction(16,15,14). We believe that this restriction is 
a straightforward one and a valid one to complement the restricted duty 
to solidarity that we advocate for children in genetic research.  
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The third restriction, of group benefits, is related to the post factum 
results of the research and states that research on minors should be for 
the benefit of children of the same age or with the same condition. Such 
provisions are quoted for example by the CIOMS guideline, the World 
Health Organization and the German Nationaler Etikrat(16,40,41). 
However, the requirement of group benefit is questioned by Holm. The 
argument behind the group benefit, he says, is that even if there is no 
direct benefit to the participant, he or she benefits indirectly through the 
group benefit. But in case of children, the membership is not stable, if a 
disease only afflicts a particular age group, or when a condition is 
rapidly progressive or when research is spread over a long period of 
time (such as is the case with cohort studies). Or when the knowledge 
sought is the prevention of a certain disease(42). As we shall further 
argue, this is complicated if the research in question is genetic research. 
But we agree with Holm that there are certain problems if we try to limit 
research on children ‘intrinsically’ by referring to either group benefits in 
the case of genetic biobank research. Indeed, in the case of genetic 
research on stored tissue samples it is hard to pin down exactly what 
the immediate benefits will be for children that suffer from the condition. 
Imagine research that tries to find a relationship between autism and a 
gene mutation. Many parents of children with ASD will be happy to 
enroll their children for such research. Such research may indeed have 
beneficial consequences. An understanding of the relation between 
gene and condition may help parents of these children to cope with the 
condition and this knowledge may relieve them from guilt. In this 
respect, it may benefit the children as it may ease the familial situation. 
Also, if newborns were screened for this specific gene mutation this 
could prevent further harm by ensuring adequate follow-up and provide 
further assistance to families. However, some have argued that it is not 
always true that the earlier a disease is detected the better it is for the 
patient(43,44). And the discovery may also lead to the development of 
prenatal tests, which often lead to prevention through termination. 
Although the existence of such a test may be desired by certain parents, 
it is unclear how this fits the requirement of ‘benefitting children with the 
same condition’. Hence, the requirement of group benefit becomes 
more problematic with genetic research, as here more steps are needed 
to reach the ultimate goal, medical benefit, and this goal may be unclear 
during the first, fundamental, steps of research. In first instance, the 
goal of such research may be the good of science in general rather than 
the health of a specific group of children. Hence, we doubt that the 
requirement of group benefits can easily be transferred from a clinical 
trial perspective to genetic biobank research. Therefore we would argue 
that as a restriction, the fact that ‘research cannot be done on adults’ is 
a more straightforward one. We do not mean, however, that the 
consideration of benefit for other children is not important. It is the task 
of ethics committees reviewing protocols to always ask the question 
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who benefits from this research, and what are the ultimate goals of 
research, in combination with a risk assessment. Enrolling vulnerable 
subjects for the purpose of the progress of science only, without at least 
a possible positive end goal, is questionable. It could also erode trust in 
science with children who will once be competent adults. And although 
we acknowledge that clashes in values are ultimately unavoidable, they 
deserve consideration before research is undertaken. 
CONCLUSIONS AND RECOMMENDATIONS  
Biobanks can appeal to the general public to participate in genetic 
research based on the principle of solidarity, provided the aim of such 
research is to aid diagnosis and treatment of severe diseases or 
conditions. This counts for adults as well as for children. But in the latter 
case, the solidarity principle is limited by certain considerations. 
Children are a vulnerable population given their limited capabilities of 
making autonomous choices, their lack of understanding of the 
background and reason of certain procedures and their right to an open 
future. Therefore, some limitations should be considered. These 
limitations are related to the requirement that such research should not 
pose more than minimal risk and to the type of research.  
With regard to the minimal risk standard, we first believe that the risks 
associated with genetic information should be solved on a policy and a 
societal level. Only if there is sufficient guarantee that data are 
protected and cannot be accessed or misused by third parties should 
anyone (not only children), be asked to consent to biobank research. 
Second, we think that research should be as minimally burdensome as 
possible for children. Any physical or emotional harm should be 
avoided. This means, in the first place, that ethics committees should 
advise that all possibilities to reuse material gathered in a diagnostics 
environment are explored. If this is impossible, techniques such as 
buccal swabs or anaesthetic creams, together with adequate rewards 
suitable for children, and home visits should be used to make research 
as least intrusive as possible. Last, it is the task of the 
researcher/research nurse, the parents and the child together to check 
whether a specific procedure in a specific case is not too burdensome. 
Third, as biobank research may stretch over time and children grow 
over time towards more and more autonomy, their values should be 
respected. This means that parents should not be asked to give broad 
consent to each and any genetic research on their children’s samples, 
but that reconsent of parent and/or child should be evaluated when 
research takes a major leap forward from the original protocols.  
The fact that children and their parents have a responsibility to consider 
participation in genetic biobank research is also linked to the fact that 
some research just cannot be done on adults. Therefore, we think this 
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limitation, based on the type of research, is a valid one. Another often 
quoted limitation, of benefit to other children, is more problematic for 
genetic research, as its final medical application is often uncertain at the 
time the research is done. However, we believe that any ethics 
committee should investigate the potential benefits of research on 
pediatric data and that at least the possibility of such benefit should 
exist.  
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ABSTRACT 
The use of stored tissue samples from children for genetic research 
raises specific ethical questions that are not all analogous to those 
raised when adult participants are concerned. These include issues with 
regard to consent, as it is typically a parent who consents to the use of 
samples from children. In this paper, we discuss the scope of parental 
consent. This scope has a temporal dimension and one related to the 
content of consent. It is not questioned that the temporal scope of 
parental consent is limited and that young adults have the right to 
decide on the faith of their samples when they reach the age of maturity. 
With regard to the content of consent, the question remains whether 
parents are allowed to give full broad consent to any possible future 
research on the samples of their children. We argue that they should not 
be allowed to do so, based on two premises. First, it is generally 
acknowledged that children have a right to express their own values and 
that they should be given the opportunity to develop their own autonomy 
as they grow older. Second; research and science are not completely 
value free and some types of research may be more sensitive than 
other types. Children should be given the opportunity to express their 
values also in this respect. 
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INTRODUCTION 
The use of stored tissue samples from children for genetic research 
raises specific ethical questions that are not all analogous to those 
raised when adult participants are concerned. The most obvious 
difference is that, for small children at least, their DNA is used for 
research without their own consent. As it is typically a parent who 
consents to the use of the samples, it is unsure what the wishes of the 
child would be. The issue of consent can furthermore be split up into 
some issues which, in themselves, have been more or less discussed in 
guidelines and ethical literature. These issues involve questions about 
who should consent, the right of a child to assent or dissent, the right of 
a child to withdraw their data and the scope of parental consent. The 
scope of parental consent has in its turn two dimensions. First, there is 
a temporal dimension: do parents have the right to consent to the 
storage and use of pediatric material ad aeternam or do children have to 
be asked to reconsent when they reach the age of competence. 
Second, there is a dimension of content. Do parents have the right to 
consent to any possible research on the stored tissue samples of their 
children, the so-called broad consent, or are they only allowed to give 
specific consent? Although a substantial theoretical and empirical 
corpus already exists on the topic of broad versus specific consent 
when adult participants are concerned, the question is as of yet 
relatively untouched when participants are children. In this paper we 
shall first give an overview of the existing literature with regard to 
biobanks, children and consent. We shall then briefly describe the issue 
of broad versus specific consent as it is discussed in the context of 
adults, and provide a reflection on how this issue should be tackled 
when children are concerned.  
CHILDREN AND CONSENT: EXISTING LITERATURE 
A recent review has shown that guidelines on the use of stored tissue 
samples from minors discuss the following issues: the fact that a parent 
or legal guardian must consent, that a child’s assent and dissent should 
be taken in to account, and that children should be recontacted as 
young adults either when they are old enough to understand the 
research or when they reach the age of competence(1). A review of the 
literature has identified similar themes(2). There is consensus that 
biological samples from children should not be used without consent or 
at least notification and that the people best suited to give this consent 
are the parents or the legal guardian. In this respect, the Organizations 
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of Medical Science (CIOMS) guideline mentions, for example, that ‘the 
parent or guardian who gives permission for a child to participate in 
research should be given the opportunity, to a reasonable extent, to 
observe the research as it proceeds, so as to be able to withdraw the 
child if the parent or guardian decides it is in the child’s best interest to 
do so’(3). Holm justifies this right of the parents to consent by referring to 
the fact that biobank research in most cases does not have negative 
effects on children(4). Also other authors seem to suggest that consent 
by one parent is enough, although one may ask whether the fact that 
genetic research is involved might complicate this matter, as a child’s 
genes are shared with both parents. However, many children do not live 
with both biological parents, and a too stringent requirement in this 
respect may hamper research. Hence we think the fact that both 
parents should consent to such research could be seen as a best 
practice rather than an absolute rule(5).  
Several guidelines and the ethical literature mention the fact that 
minors, as soon as they are mentally capable to do so, should be asked 
to assent to research, and that their dissent should be taken into 
account(1). For example, in papers from Holm and Helgesson, it is 
stressed that older children should be asked to assent and dissent(4,6). 
Helgesson links this to the fact that children develop autonomy also by 
being given the chance to exercise it to the degree they are capable of. 
There is less certainty about whether there should be a fixed age 
threshold for assent, or whether this should be evaluated on a case by 
case basis. A qualitative study based on interviews with professionals in 
the field of stored tissue samples from minors has suggested that 
professionals do not believe in fixed age thresholds and that they see 
legal requirements to ask small children to sign papers as unrealistic 
and bureaucratic(7). Ashcroft et al. have also suggested that maturity is 
a better criterion than age because the capacity to assent is dependent 
on social context and personal experience(8). We agree with this stance. 
We also believe that in many cohort studies with children or studies in 
the context of specific diseases there is plenty of opportunity for informal 
assessments of maturity, as in such cases there is frequent contact 
between researchers and children. In any case, all children, also very 
small ones, have a right to information at a level they can understand. It 
is also the task of the professional, be it researcher, clinician or 
research nurse, together with the parents, to assess the value of a 
child’s dissent. On the one hand many children may have an 
unreasonable fear of certain procedures, a fear which might be easily 
overcome by rewards, such as a sticker or small present, from the 
researcher or the parent. On the other hand, no child should be 
subjected to procedures she obviously dislikes, whatever the parents’ or 
researcher’s noble aims to aid the progress of science. And of course 
this assumes that an ethics committee, with a pediatrician as member, 
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has already assessed the burden of the procedures and decided that it 
is reasonable.  
An important question with regard to consent to research on samples 
that are stored over a longer period of time is related to the scope of 
consent. This scope has two dimensions: a temporal one and one 
related to content. The temporal dimension is discussed to some extent 
in existing literature. Guidelines and the literature agree that the 
temporal scope of parental consent is valid until the child reaches the 
age of competence(2,1). In this respect, CIOMS mentions that “If such 
research subjects, including children, become capable of giving 
independent informed consent during the research, their consent to 
continued participation should be obtained”(3). Burke and Diekema, for 
example, are in favor of such reconsent because this would allow 
minors to participate more as they grow older(9), a thought which is 
supported by empirical research(10). However, this may be impossible in 
some cases: Samples may be stored for many years, and there may be 
no possibility to recontact the children. One qualitative focus group 
study has suggested that in this case, a best effort to recontact young 
adults is sufficient, but that it is still seen as a sign of respect from 
researchers(11). Another study, however, found that children should be 
recontacted(12). In any case, there was consensus that minors should be 
allowed to withdraw their samples and data from a study for which their 
parents consented. Holm states in this respect that as children have not 
been able to autonomously consent and give up the right to withdraw at 
the moment of donation, the right to withdraw for children is more 
important than the right to withdraw for adult donors(4).  
We agree that in principle, biobankers should make an effort to 
recontact young adults for reconsent once they are capable of giving 
consent. We also agree that young adults have the right to withdraw 
their samples and data. In this respect, the temporal scope of parental 
consent is limited.  
A topic much less discussed in the context of pediatric biobanks is that 
of the content of parental consent. Are parents allowed to give ‘broad 
consent’ to any possible future genetic research on their children’s 
samples or should this consent be better specified. In the next 
paragraphs we shall describe the existing discussion of broad versus 
specific consent in general, and then specify why we think the issues 
are different when participants are minors.  
BROAD VERSUS SPECIFIC CONSENT 
Traditional informed consent, which assumes the fully informed, mostly 
written consent of a participant to a specific research proposal, has 
become the theoretical standard in research bioethics, as it is deemed 
the most appropriate sign of respect for the autonomy of an individual. 
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However, it is not specifically well suited for the inclusion of samples in 
biobanks. Such biobanks form a resource for future research, the 
specific content and extent of which, at the time of storage, are often 
unknown. Therefore, it is argued that consent for such research is never 
truly informed(13). But recontacting donors for consent to each and every 
different research protocol is costly and may hamper the advancement 
of research(14). Some have argued that these technical difficulties do not 
provide a sufficient ethical ground for broad consent(15). However, it has 
also been argued in the theoretical literature that principles of justice 
and solidarity can justify consent procedures which diverge from the 
ideal standard of prior, free, informed and explicit consent(16). Such 
principles are based on the concept of medical science as a ‘collective 
good’, a notion which may be true in the case of some research aims, 
but may that be naïve in other cases(17). Also, there is a range of 
possibilities between giving true informed and specific consent, and 
completely blanket consent, which implies that no restrictions are put on 
the scope and direction of the possible research(18). Broad consent, as it 
is now often deployed, is still subject to certain restrictions, and not 
completely analogous with ‘blanket consent’. A study by Elger et al.(19) 
concerning European guidelines has shown that many of them take the 
view that general or broad consent is acceptable for unspecified future 
research use, if two conditions are met: a research ethics committee 
approves future projects, and participants have the right to withdraw 
their samples at any time. This viewpoint is shared by Hansson(20), and 
is backed up by many empirical studies. Indeed, a meta-review of 
Wendler et al. of empirical studies regarding this topic has shown that a 
majority of donors do not object to broad consent(21), although other 
studies have pointed out that individuals want ongoing choices and 
control over access to their samples and information(22). 
Furthermore, in practice, broad consent seems to be the route taken by 
most biobanks to-date as well. An analysis of 52 ENGAGE consent 
forms and information documents (European Network for Genetic and 
Genomic Epidemiology) has shown that 27 of the studies involved used 
broad consent and 25 specific consent, and that information sheets of 
35 studies mentioned that the samples would be used for DNA 
extraction or genetic analysis. The information sheets of the remaining 
17 did not mention genetic research per se but only biological 
research(23). The seminal UK biobank states in its consent form: 
I give permission for long-term storage and use of my 
blood and urine samples for health-related research 
purposes (even after my incapacity or death), and 
Scope of Parental Consent 
172/233 
relinquish all rights to these samples which I am 
donating to UK Biobank.17 
Hence, the only limitation as to the content of the research being done 
is that it has to be ‘health-related’ research. The Estonian Gene Bank18 
has similar provisions, but it is even broader in specifying the type of 
research, in that it refers to “The use thereof for genetic research, public 
health research and statistical and other purposes in accordance with 
the law.” Hence, they ask consent to virtually any type of research that 
is legally allowed.  
BROAD VERSUS SPECIFIC CONSENT IN PEDIATRIC 
BIOBANKS 
We believe that the issue of broad versus specific consent is even more 
complicated when participants are minors, as their parents provide 
consent for them. In the next paragraphs, we shall first describe the 
scarce literature that exists on this topic. Next, we shall discuss in more 
depth why we think this issue is further complicated and needs thorough 
reflection. We admit that the definition of ‘broad consent’ is in itself 
problematic, as it can refer to a whole range of items, from complete 
‘blanket’ consent, to more restricted, but still fairly general consent. We 
shall use the term ‘broad consent’ as it is used in the literature, to refer 
to consent to unspecified future research, but under the supervision of a 
research ethics committee and while participants have the right to 
withdraw at any time.  
Broad versus Specific Consent in Pediatric Biobanks: 
Empirical Studies 
Not much study has been done with regard to the question of broad 
consent in pediatric biobanks. An overview of consent procedures in six 
cohort studies has shown that ‘broad’ consent is typically requested. 
One could argue, however, that that this is not really blanket consent, as 
the specific context of these studies allow for frequent contact between 
researchers, children and parents thereby providing many opportunities 
to reconsent.(24) An interview-based study with professionals associated 
                                               
 
 
 
 
 
 
17
 http://www.ukbiobank.ac.uk/docs/2006ConsentformA.pdf 
18
 http://www.geenivaramu.ee/index.php?id=100 
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with pediatric biobanks has shown that they would prefer ‘broad 
consent’ but also think that if the research takes a too big step away 
from the original protocols, ethics committees should decide whether 
reconsent is necessary(7). These studies suggest a discrepancy 
between what is formally consented (which is fairly broad and includes 
any potential future research) and the actual practices researchers feel 
comfortable with. There seems to be a moral awareness amongst 
researchers which leads them to believe that reconsent is necessary for 
research that is very different from what is possible at the time of 
inception of the biobank. Hence, their interpretation of what is broad 
consent is more restricted than what the formal definition would 
suggest. Moreover, a survey amongst Belgian professionals has shown 
that for research on stored tissue samples from children, although there 
is still support for broad consent (47,6%), more professionals would 
support specific consent (79,4%) (25). And a survey of Helgesson et al 
(26)
 of parents with and without earlier research experience showed that 
parents thought research studying the possible prevention of disease 
and research exploring the impact and importance of environmental 
factors were the most important followed by research into the role of 
genetic factors behind disease development. The least important 
research was deemed to be on medical substances and special groups 
of children. These findings suggest that parents (and possibly the 
general public) hold a certain value scheme about science, and that not 
all research is equally important to them. That being said, a survey by 
Neidich et al. shows that women who were willing to enroll their children 
in a pediatric biobank put very little restrictions on the type of research 
that could be performed on these samples, with the exception of cloning 
(27)
. 
Two Presuppositions 
We accept that, for biobanks containing only adult material, it may be 
perfectly acceptable that at time of donation some form of general 
consent is requested. We agree that this should not be completely 
blanket consent in that certain conditions should be met. Sensible 
conditions are the requirement that there is ethics committee oversight 
of the research proposals and that donors have the right to withdraw 
their samples at any time. We also accept that parents are entitled to 
make certain decisions for their children, and that this is a fact of life. 
This fact seems not to be questioned by children either(28,11). Indeed, 
empirical studies on the enrolment of children in genetic biobank 
research have shown that overall parents are happy to enroll their 
children in biobank research, provided it is not burdensome or risky and 
that it can aid other children(11,27). We agree that the decision to donate 
biological samples from children to genetic research is not too radical, 
provided that proper governance structures and data protection are put 
in place(29). In this respect, we disagree with authors who either argue 
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that parents do not have the right to consent to the inclusion of their 
children’s samples in biobanks(30), or that sharing of samples between 
research institutes should await the children’s full consent(31).  
Broad Parental Consent and its Limitations 
We question the fact that the right to make decisions on behalf of 
children should include the right to give broad consent to any future 
unspecified genetic research on these samples. This belief is based on 
the idea that children are allowed to develop and express their own 
values as they grow older, and that we should respect these values, and 
on the fact that medical research is not value free. We shall elaborate 
on these ideas in the next paragraphs. In this respect, our concept of 
informed consent is not so much based on a contractual approach, 
where the conditions and risks of participation are explained to 
participants who can then decide for themselves whether they would 
take these risks or not(32). Rather, it is based on a concept of consent as 
acknowledgement that individuals may hold certain values concerning 
research and on an acknowledgement of respect for these values. In 
this regard, our concept is linked with traditional concepts of consent as 
sign of respect of someone’s autonomous right to hold certain values 
and his or her dignity as human person. This need not contradict with 
the assumption that biobanks and medical research can appeal to the 
solidarity of participants and therefore deploy consent strategies that are 
not completely analogous to informed consent. An autonomous person 
is always also a member of a community(33). In that regard, respect for 
values of individuals does not necessarily mean that each and every 
decision must be left to the individual but that circumstances can 
influence the decision of the individual. However, we do believe that 
children are a special case for that matter.  
 
The fact that parents should not be allowed to give full broad consent to 
any possible research on their children’s samples is linked to the special 
status of children. They are gradually becoming more autonomous in 
their thinking and are acquiring their own values as they grow older. 
Moreover, next to being a transitory phase towards adult autonomy, 
childhood is now more and more seen as a phase valuable and 
deserving respect in itself. Children may have different opinions and 
beliefs from those they shall have as adults, but this in itself is seen as 
something that should be respected(34). These opinions have now also 
been laid down in the Convention on the Rights of the Child(35): 
(article 12) 1. States Parties shall assure to the child 
who is capable of forming his or her own views the right 
to express those views freely in all matters affecting the 
child, the views of the child being given due weight in 
accordance with the age and maturity of the child.  
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With genetic research on biobank samples this poses specific issues. 
Typically, biobanks form a resource for potential future research which 
is unknown at the time of the storage of samples. Although this may be 
perfectly acceptable for adults, who make the decision for themselves, 
for children some types of research may be too definite. As has been 
argued by Feinstein, children have a right to an open future(36). Choices 
made for children should not be too definite in that they should not 
prevent the children from making different choices themselves as soon 
as they are capable of doing so. An exception is made if such choices 
are deemed in the best interest of the child, where parents are 
considered to be allowed to make definite choices, even contrary to the 
wishes of the child. Examples of such choices are life saving operations 
or vaccinations. However, giving broad consent to any future genetic, 
parents cannot claim this ‘best interest’ argument and it prevents 
children from making their own choices and revising them as they learn 
to become more competent. In case of biobanks, risks quoted are often 
related to privacy breaches and third party access, such as the use of 
information by insurers or employers. As we have argued elsewhere, we 
think that such risks should be tackled by good governance and policy 
structures(29). But genetic privacy in itself is a value, regardless of the 
risks associated with third party access. Hence, the publication of full 
genomes, which might reveal increasingly more information about the 
individual concerned as science progresses, should be up to that 
individual alone, and should not be considered part of any broad 
consent by parents. In this respect, Lunshof has described the idea of 
‘open’ consent. We think that such ‘open’ consent can never be asked 
from parents for their children(18).  
 
A second factor, which is related to the growing autonomy of children, is 
the fact that science and research are not completely value-free. 
Although parents may, in good conscience, consent to future research 
on the samples of their children out of a feeling of altruism, and in line 
with the solidarity argument, ‘for the benefit of science’, their children 
may have a different opinion on what constitutes a valid research aim. 
As we have pointed out above, existing consent forms are vague as to 
the meaning of what is included in broad consent, and contain a general 
reference to either genetic research or medical research. But does 
research investigating the relationship between genes and IQ or certain 
behavior fit this description? If the primary aim of a research proposal is 
the development of a prenatal test possibly leading to pregnancy 
termination, does it fall under the denominator ‘health related research’? 
As opinions vary on that, and are personal, it is indeed impossible to 
draw sharp dividing lines between what kind of research is comprised in 
a ‘broad consent’ and what is not, if the latter is not further specified or 
only described in general terms. We believe that genomic research 
which has the potential to develop treatment or diagnosis for serious 
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diseases is legitimate, and not something many people would question. 
Hence researchers and biobankers can appeal to solidarity of 
participants, including parents and children if such research is 
undertaken(16). But does research focusing on IQ, behavior or 
performance enhancement fit that description? We think that, although 
parents might be asked consent to such research specifically, this 
should not be considered as part of the general consent for pediatric 
biobanks, and that some form of reconsent or notification is necessary 
in this case.  
Challenges 
There are some practical difficulties associated with our approach. We 
acknowledge that it is impossible to provide strict rules as to which type 
of research is included in the original parental consent and which 
research is possibly sensitive. We believe that the initial consent can be 
sufficiently broad to include research which intends to prevent and treat 
relatively burdensome diseases. Ethics committees that supervise 
research proposals should evaluate whether the research falls under 
this category. Furthermore, biobank participants or their parents should 
have access to descriptions of goals and modalities of research, and 
have the opportunity to opt-out of contributing. This can be done 
through a newsletter or central website. As is already argued by 
Caulfield and Kaye for reconsent, the informatization of samples and 
medical data could also allow easy notification of participants through 
techniques such as emails or phone messages(15). Although this still 
may constitute an administrative overhead for researchers, who are 
then obliged to formulate proposals also in lay terms, it is a sign of 
respect for participants and their parents and ultimately it will enhance 
trust in and education about the biobank and science in general. 
 
A further difficulty is related to the difference between assent and 
consent. We do not suggest that parents cannot consent to research on 
tissue samples from their children if this research may be sensitive for 
some, only that they or their children should be given the opportunity to 
object to inclusion of their samples in such potentially sensitive 
research. We argue that there is a need for respect for the values of 
parents and specifically for children. Given the importance that should 
be given to the values and opinions of the children, they should be 
asked for their opinion and, if they are old enough, asked to assent as 
well. Practically, this respect may be translated in different forms 
depending on the type of collection. Most research on stored tissue 
samples from children requires extensive follow-up and hence frequent 
contact with parents and children. This will make it easier for 
researchers or associated clinicians to discuss the various types of 
research and assess the maturity of children. In case of research on 
stored tissue samples and data that does not require additional contacts 
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after recruitment, parents and children should still be notified of new 
research using new techniques described above. Moreover, if there is 
limited contact between researcher and families, for example because 
there was a one time donation of a sample and no further information is 
gathered from the donors, a fixed age threshold can be used at which 
young persons are contacted for full consent.  
At which point, then, does the opinion of the young person become the 
only one that should be taken into account? There is no fixed answer to 
that, but we do believe that for the question of recontacting and 
reconsenting to specific research protocols, the opinion of the child 
matters most. As there is not much risk involved, and as this is not a 
question of acting in the (medical) best interest of a child, such consent 
may be an excellent opportunity for children to reflect on their own 
values and exercise their growing autonomy. Hence, children who are 
below the legal age of consent may be asked for full consent in this 
case as well.  
We have assumed that samples and information in biobanks are not 
completely deidentified and that recontacting donors is possible. We 
admit that when samples are completely anonymized it is impossible for 
biobank participants to be recontacted or to withdraw samples. The 
issues related to complete anonymization have been discussed in some 
depth in the literature on biobanks. We believe in most cases a coded 
system rather than complete anonymization is now used, as this 
provides sufficient privacy protection and takes away some of the 
drawbacks of complete anonymization. This may be especially true for 
pediatric research, as in most cases this requires some follow up of 
participants.  
CONCLUSION 
One of the ethical issues associated with pediatric biobanks and genetic 
research on stored tissue samples from children is the question about 
the scope of parental consent. This scope has two dimensions. First 
there is a temporal one. It is generally acknowledged that children, as 
they grow older and approach a certain level of maturity, should be 
allowed to have a say on what happens with their samples and possibly 
withdraw them from a collection. Hence the temporal scope of parental 
consent is limited. Next, there is also the aspect of content. Should 
parents be allowed to give broad consent to any genetic research on 
their children’s samples or only give specific consent? We have argued 
that, given the specificity of childhood, where children are gradually 
acquiring their own values and developing their own autonomy, and the 
fact that medical research and science is value laden, parents can give 
permission for research which intends to understand and treat diseases. 
However, research that is more sensitive, such as behavioral research 
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or IQ related research, or research that would infringe the right to 
privacy, such as the publication of a child’s full genome, would not be 
part of the original parental consent.  
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ABSTRACT 
The combination of the issue of return of individual genetic 
results/incidental findings and pediatric biobanks is not much discussed 
in the ethical literature. The traditional arguments pro and con return of 
such findings focus on principles such as respect for persons, autonomy 
and solidarity. Two dimensions have been distilled from the discussion 
on return of individual results in a genetic research context: the respect 
for a participant’s autonomy and the duty of the researcher. Concepts 
such as autonomy and solidarity do not fit easily in the discussion when 
pediatric biobanks are concerned. Although parents may be allowed to 
enroll children in minimal risk genetic research on stored tissue 
samples, they should not be given the option to opt out of receiving 
important health information. Also, children have a right to an open 
future: parents do not have the right to access any genetic data that a 
biobank holds on their children. In this respect, the guidelines on genetic 
testing of minors are applicable. With regard to the duty of the 
researcher the question remains whether researchers have a more 
stringent duty to return important health information when their research 
subjects are children is more difficult to answer. A researcher’s primary 
duty is to perform useful research, a policy to return individual results 
must not hamper this task. However, the fact that vulnerable children 
are concerned is an additional factor that should be considered when a 
policy of returning results is laid down for a specific collection or 
research project.  
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INTRODUCTION 
Pediatric biobanks and longitudinal studies involving children form an 
excellent resource to study the genetic components of conditions that 
affect children. However, such collections also raise ethical questions 
that are not completely analogous to those raised by collections 
containing only adult material and data(1). As a recent literature review 
has shown, the issue of the validity of parental consent to research on 
children’s DNA, as well as the privacy risks associated with the storage 
of pediatric stored tissue samples and data has been discussed in some 
ethical papers already(2). The protection of children has also been the 
subject of a Policy Forum in Science(3,4,5,6). 
 
Next to the issue of pediatric biobanks, another topic much discussed in 
the recent biobank literature is the return of individual research 
findings(7). The major questions asked are whether biobanks should 
return such individual results to participants and if so, which results 
should be returned. Such research findings may have two forms: there 
may be individual findings that are to be expected based on the study 
design, and there may be incidental findings, certain anomalies that 
were not originally looked for(8). To date the chance that researchers 
may find genetic conditions that they may not be looking for may seem 
low. However, with the advent of new techniques, such findings may 
become more frequent. For example, array comparative genomic 
hybridization may be used to study the relation between a certain 
phenotype and a Copy Number Variation in a pediatric population (9). As 
the resolution that can be acquired with this technique can be quite 
high, it is not unthinkable that other significant variations are discovered 
next to the variations under investigation(10). Also, with the rise of 
genome-wide association studies, it is possible that variants are found 
whose significance is not so clear: for example, they could point to the 
possibility of late-onset conditions(11). With the vast increase of 
knowledge in the field of genetics it can be expected that these 
situations will occur more frequently and require a thorough 
investigation. 
 
We admit that the question about the return of individual results in 
genetic research is quite complex. It is nearly impossible to give an 
answer fitting all situations. The answer is highly dependent on different 
variables: the type of genetic information found, the context (research-
only or research that is still somewhat linked to a diagnostics context) 
and the capabilities of the researchers. The type of biobank and modes 
of recruitment can also be deciding factors, as the duty to return results 
is higher when the recruiter is a general practitioner (GP) or clinician in 
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frequent contact with a patient than when the recruiter is a researcher or 
research nurse and the contact is one-off. Also, the question is multi-
layered: what information should be returned by the researcher to a 
clinical geneticist and/or GP and what information should be returned by 
the latter or the former to the research participants themselves? There 
is an aspect of contingency when incidental findings are concerned: a 
researcher working on certain genes may be unaware of the 
significance of a variation that is outside her field. Therefore, not all 
researchers may be able to feed all potentially relevant information 
back. As we shall demonstrate, we have discovered two dimensions to 
the question, which are often confounded in the literature: the duty of 
the researcher to inform versus the right of the participants to know 
such information. These two dimensions, however, cannot be reduced 
to one another.  
 
In the next sections we shall first describe the arguments that are 
usually given pro and con the return of individual research results. We 
shall give an overview of the general discussion, which focuses on adult 
participants. Then we shall describe our own viewpoint on the matter. 
We shall end with recommendations for policy makers. In this paper we 
shall use individual research results both for the findings that are to be 
expected in the context of a study and for incidental findings. We 
acknowledge that there may be subtle differences in the ethical dealings 
with the two kinds of findings, but for the limited scope of this paper they 
can be treated simultaneously; as the net result is very much alike.  
OVERVIEW OF THE ARGUMENTS 
In the past few years, many articles have discussed the pros and cons 
of return of individual genetic results in a research context, specifically 
with adult participants in mind. In the theoretical literature, we basically 
find three viewpoints here, and some variants. A first line of thought is 
that individual research results should never be returned to research 
participants. Arguments for this stance are that genetic results are 
usually inconclusive, and as such can cause anxiety(12). Authors also 
refer to the therapeutic misconception: returning results could give the 
impression to research participants that the research is for their own 
personal benefit. Particularly in large biobank contexts there is no need 
for researchers to take on the task of clinicians, because these are 
primarily focused on the advance of public health(13). Also returning 
individual results is considered too resource-intensive(14). An example of 
a biobank with a policy of not returning individual results is the UK 
Biobank(15). 
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A second line of thought states that all individual results should be given 
to the research participants if they do so want, as research participants 
should not be treated as mere means to (research) ends. Respect for 
participants means respecting their autonomy(16). Returning individual 
results may also ensure better enrolment(17). The Estonian Gene Bank 
is an example of a biobank that recruits through general practitioners 
and allows individuals to access their records and genetic data, but not 
genealogical information. It also provides genetic counseling(19). The 
CIOMS guideline on epidemiology specifies that individuals must be 
informed about their health status(18). 
 
A third line of thought is reflected in the WHO report on Genetic 
Databases(19) and in a paper by Bookman(20) and states that individuals 
have a right to individual research results if these are of clinical 
significance, scientific valid and if they provide a potential benefit to the 
participants. A NIH-proposed large cohort study is of this type(21). 
Related to this is the idea of the ancillary duty of care(22). This concept is 
based on the idea that when participants signed up for a study they 
partially entrust certain aspects of their health into the researcher’s 
hands. So if something is found that can significantly increase the health 
of a participant, this information should be returned. However, this does 
not imply that researchers have an active duty to hunt for findings.  
There are several variants of the above positions(23). The much 
discussed paper of Ravitsky and Wilfond(24) proposes a result-
evaluation approach based on analytic validity, clinical utility, context of 
study, personal meaning to study-participants and nature of participant-
researcher relationship. An approach called ‘tiered disclosure’ by 
Rothstein(25) suggests that participants could select from options for 
research disclosure when they enroll for the study.  
 
From the above arguments, we can distill two dimensions of the 
question. These dimensions influence each other but cannot be reduced 
to one another. First, there is the question of the right of the participants 
to decide for themselves if and what information they should receive. 
Second, there is the duty of the researcher to return information that has 
clinical significance and can be validated. An emphasis on the right-to-
know of the participant may influence the duty of the researcher, but 
there may be valid grounds to relieve the latter of this duty. This does 
not automatically imply a disrespect of the former. Moreover, there may 
be situations where the researcher may have the duty to return certain 
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findings if the wishes of the participants are unknown, or even contrary 
to their wishes.  
 
RETURN OF INDIVIDUAL RESULTS IN PEDIATRIC 
BIOBANKS 
We believe that the question of returning individual results for pediatric 
participants does not easily fit in the above models. We shall formulate 
our own thoughts under the two dimensions sketched above: 
‘participant autonomy’ and ‘duty of researcher’. To conclude, we shall 
formulate some recommendations that can be used by policy makers.  
Participant Autonomy  
A first dimension in the ethical reflection on the return of individual 
results in genetic research on stored tissue samples is related to the 
autonomy principle and the right of participants to decide whether they 
want to receive certain information about their health or not. Authors 
that stress this autonomy would opt for the second line of thought in our 
above summary: individual results should be returned if participants do 
so wish. We believe that the situation in case of pediatric biobanks 
enrolling incompetent minors is slightly different, as the persons making 
this choice are not the participants themselves.  
First, we believe the right not to know does not apply to parents with 
regard to information for early-onset treatable or preventable diseases. 
In the case of pediatric biobanks, if the biobank has a policy to return 
such information, with the option of opting out, this option should not be 
made available if the consent form is filled out by the parents of under-
age participants. We agree that competent adults have the right not to 
know their genetic status, even if this can save their own lives. In this 
respect we follow the paper by Andorno that this right not to know is 
based on autonomy and on people’s interest in not being 
psychologically harmed by the results of genetic tests or genetic 
research(26). Our situation of parents deciding for their children is 
somewhat different, in the sense that the decision is made for a third 
person. Hence, the autonomy in question is that of the parent and not of 
the child, and is always limited by considerations about the best interest 
of the child. It is not unthinkable that some parents might opt out of 
receiving such information as a result of magical thinking (‘ignorance is 
bliss’). Although there are many areas in which parental decisions 
should not be questioned, this is one area where others can take the 
decision to return information, even against the parents’ wishes. Take 
the example of Familial Adenomatous Polyposis (FAP). Early detection 
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of mutations in the APC gene can lead to screening for colonic and 
extracolonic tumors and be potentially lifesaving (27). A parent does not 
have the right of opting out of receiving such information about his or 
her child.  
Secondly, based on the principle of respect for participant’s autonomy 
and the right to know, some biobanks may have the option to provide 
access to participants to all their individual genetic information if they do 
so want. However, this should not apply when parents have enrolled 
their children in the biobank. In the clinical context, literature on genetic 
screening and testing of minors has amply discussed the negative side 
effects of allowing parents access to non-crucial genetic information. On 
a practical level, knowing that a child carries a certain gene associated 
with a condition later in life may cause anxiety in a family. Parents may 
start treating their children as if they already have the condition(28,29). 
Carrier status may be interpreted as having an affect on their child’s 
health. On a more theoretical level, children should have a right to an 
open future(30), to decide on the information they want to know about 
themselves when they are ready to do so, and be shielded from too 
much curiosity from their parents’ side. We believe, based on these 
data, that allowing parents full access to all genetic data of their 
children, possibly out of respect for parental autonomy, is not in the best 
interest of the children in question and should be prohibited. 
In a research context, the same considerations apply. One guideline on 
research on human tissue of the UK Medical Research Council (31) even 
explicitly specifies that “Tests of known predictive value for adult onset 
diseases should not be done for research purposes on individually 
identifiable sample from children”. But even if anonymous 
epidemiological research on such diseases may, for practical purposes, 
in some cases be allowed on pediatric samples such as DNA from 
blood spot cards, we agree that the same restrictions should apply with 
regard to return of individual research findings. If postponing the access 
to such information does not deprive children of possible preventable 
treatment, it should be delayed until later and left to the choice of the 
participant when he or she becomes an adult(32). Some may argue that 
there can be some benefit in knowing early-onset unpreventable or 
untreatable disorders(33). However, these benefits are not completely 
transparent, and as we are speaking here of non-sought for information 
in a research context, we believe such information should not be 
communicated. 
In the case of research on stored tissue samples and data, a 
complicating issue is the fact that such tissue samples are often stored 
for longer periods of time, and that the research can continue after the 
child has reached the age of competence. At this point, the participant 
should be allowed to make the same decisions as other ‘adult’ 
participants. If the biobank gives web access to participants to their 
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genetic data, this should be given to participants when they turn 18 
years of age.  
Duty of Researchers 
Up till now, our suggestions focused on the right (not) to know and on 
participant’s autonomy. However, a difficult question is still untouched: 
is a ‘no individual results shall be returned’ policy for adults, like that of 
the UK Biobank still defensible when children are concerned? As we 
have seen before, the advocates of such position (our first ‘line of 
arguments’) refer to the fact that genetic results are inconclusive and 
can cause anxiety, the therapeutic misconception, the duty to solidarity 
to participate (and not expect anything back) and the fact that the 
administrative burden of a policy of returning results would stall 
important research.  
 
The first argument refers to the fact that genetic results are inconclusive 
and cause anxiety. However, for well-known early onset treatable or 
preventable conditions this argument does not hold. Of course 
communication of such information may never be only communication 
of the plain facts, and may thus be outside of the researcher’s 
competence. We observe that the genetic research children participate 
in is often of the type of longitudinal cohort study, which allows for 
frequent contact with researchers and research nurses. Or children who 
already have a medical condition are enrolled through their physician or 
clinical geneticist. Therefore, the infrastructure for good follow-up is 
already there. Moreover, there is a fundamental difference between 
adult and pediatric research participants. The latter have limited 
autonomy and are as such vulnerable. They have not enrolled 
themselves in the research, and as such it is acknowledged that they 
are in need of extra protection. In the literature on clinical trials, there is 
often the requirement that research on children should be for the benefit 
of children(34). Although we admit that research on pediatric tissue 
samples is different from clinical trials due to the minimal physical risk 
involved, we think that the communication of findings of early-onset 
treatable and preventable diseases can be interpreted as a benefit in 
this context. In this respect, the ‘therapeutic misconception’ argument is 
flawed as well. We agree that parents and children should be aware that 
research is not done for their own benefit; we do not believe that this 
potential misconception is enough reason not to return important health 
information about vulnerable participants.  
 
This relation between vulnerability and benefit requires some further 
elaboration. A concept that can be of help here is the “duty of care” of 
researchers. In this respect, the term “ancillary care” has been framed. 
Such care is care that is not required to make a study scientifically valid. 
For example, the following up on a diagnosis found by protocol tests or 
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treating ailments that are unrelated to the study’s aim would be ancillary 
care(35,36). The return of findings about early-onset treatable or 
preventable diseases in genetic studies fits this description. This model 
is based on the fact that the relationship between participant and 
researcher involves a partial entrustment of the former’s health to the 
latter. Indeed, participants entrust medical information and samples to 
researchers, and the informed consent process transfers rights to use 
these to researchers. In this respect participants are vulnerable to 
researchers. Richardson et al. acknowledge a general duty to act 
compassionately towards the needy, vulnerable and dependent. 
However, given the research context, this duty is limited to specific 
aspects of the participant’s health. A researcher is not responsible for all 
aspects of the health of participants, only those that arise within the 
study. The strength of the ancillary care duty is moreover influenced by 
different factors, such as the participants’ vulnerability, the risks and 
burdens of the study, the depth of the relationship between the 
researchers and participants and the modes of alternative access. Do 
participants have other means to obtain the same information?  
We think that this ancillary care model is specifically applicable to 
children in genetic research. First, genetic information is not typically 
acquired in ordinary health care. Second, many of such research, when 
done on children, involves a close contact between researchers and 
under age participants. Third, children are recognized as a vulnerable 
population, which would make them especially entitled to ancillary care 
from researchers. Richardson et al. link the vulnerability of research 
participants to the fact that they transfer certain aspects of their health 
to researchers. With children, this is further complicated by the fact that 
they often do not make the decision to participate themselves. Indeed, 
vulnerability in children is linked to their lack of autonomy. As we do not 
know (with small children) what their choice would be, or as their current 
choice (as an older child) may not be their ‘definite’ one, children may 
seem vulnerable in their choices. Indeed we should prevent them from 
making choices that are too definite and that would close down other 
options later on(30). Hence, the fact that the participants are children 
would make the ancillary care duty higher in the case of pediatric 
biobanks.  
We think returning results about early-onset treatable and preventable 
diseases could also satisfy the requirement that research should be 
somehow beneficial to children. True, such research is potentially 
beneficial to children in general. However, the fact that these 
participants are even more vulnerable, because they have a limited 
autonomy, may suggest that there should also be some limited personal 
benefit. Such benefit may be interpreted in many ways, but we think the 
opportunity to be informed of potentially severe conditions suits this 
purpose better than for example a monetary compensation. Indeed, as 
is argued by Brock, children may even have a higher claim to health 
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care than do adults. This is again linked to their vulnerability, which also 
consists in the fact that they do not understand their own need, and 
cannot provide for their own health care, unlike consenting adult 
participants. Therefore, he argues, access to health care is not enough, 
we must make sure children actually receive it(37). And although it is true 
that pediatric biobanks are not diagnostic tools, we believe these 
reflections do enhance the ancillary care duty of researchers to provide 
information about early onset treatable and preventable diseases, if they 
accidentally stumble upon it. 
 
The third argument, that of solidarity is also problematic. The principle of 
solidarity has been used by some authors to suggest that participants 
should participate in biobank research without expecting anything 
back(38,39). However, the principle of solidarity cannot be applied without 
restrictions to children(40). Children are exempt from certain duties such 
as paying taxes and having a job, although other civilized behavior is 
expected from them. At least researchers have the right to appeal to 
children to participate in biobank research. This does not automatically 
entail that children need to participate without expecting any benefit 
back, especially if this in the form of found information about 
preventable or treatable disorders. Moreover, solidarity has an 
additional meaning, referring to the idea that the weakest and most 
vulnerable in society should be protected and some of their burdens 
carried by others. Although it is true that biobank research is not so 
invasive or burdensome that children should be exempted from being 
solidary in this respect altogether, they may be compensated by at least 
providing them with information.  
 
The fourth argument may make the most sense. In some context, such 
as (anonymous) epidemiology on blood spot cards it may be unfeasible 
to provide individual results because the infrastructure is not there. We 
agree with Affleck, that in the context of pure economics, a policy of not 
returning results may be allowed (41). We might extend this argument 
even for pediatric biobanks, especially if the burden for the children is 
very low and the contact between researchers and children is minimal, 
as is sometimes the case for research on older, archived collections. 
Related to this, the duty to return individual results is higher if a GP or a 
clinician who is in frequent contact with the patient is involved in the 
recruitment of the samples than if the recruitment is done by a 
researcher or a research nurse and there is no further contact with 
donors afterwards. However, deciding not to return individual results 
may never be just an easy way out: if the subjects are incompetent 
minors, the issue of returning individual results may require even more 
consideration for incompetent minors than when adults are concerned, 
because the former are vulnerable research subjects with limited 
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autonomy. This is especially the case in contexts where there is a 
frequent contact between minors and the research institute. 
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CONCLUSIONS AND RECOMMENDATIONS 
We have distilled two dimensions from the discussion on return of 
individual results in a genetic research context: the respect for a 
participant’s autonomy and the duty of the researcher. Starting from 
these two dimensions, we have investigated what is different if the 
research participants are minors, and have concluded that the 
arguments pro or con return of individual results are somewhat different 
here. With respect to the first dimension, we believe that parents should 
not be allowed to opt out of receiving information about preventable or 
treatable early-onset conditions. But they should also not be given 
access to any and all genetic data research may produce. As for the 
second dimension, because children have a special status in research, 
traditional arguments such as those about therapeutic misconception or 
solidarity seem flawed, and the duty to return results that yield important 
health benefits is greater than with adult participants. Still, in projects 
that require no extra contact with participants such as epidemiology on 
blood spot cards, and that do not have the appropriate infrastructure, 
logistical considerations may push the pendulum towards the decision 
not to return individual results.  
We understand that by using the example of the small incompetent child 
we are oversimplifying matters. Considering an older child or a teenager 
would have to include a decision whether he or she can or cannot 
understand what is at stake. The issue is even more complex when 
inheritable diseases are at stake: the age that people can reproduce is 
lower than the generally accepted age of majority. To which extent 
should the communication of inheritable, but late onset diseases 
correspond to the age of sexual maturity? Also, as new genes are to be 
discovered and new treatments possible, the situation may become 
more complex, and more and more genetic variants may show up that 
would warrant communication. For example, there is increasing 
evidence that aneurysm has a genetic component(42). If such evidence 
becomes conclusive, this would be a good example that should be 
communicated, even at an early date. We also think that guidelines for 
biobank research on pediatric stored tissue should tackle the issue of 
the return of individual results separately when children are concerned. 
In particular we propose the following:  
-Researchers should return information to parents and children about 
early-onset treatable or preventable diseases, unless there are 
compelling reasons not to do so 
-If the biobank has a general ‘tick box’ option to allow the participant to 
choose whether to receive information or not, this tick box should not be 
available to parents on behalf of their children.  
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-All other results should be postponed until the child is 18. At that point, 
the return of results policy should be renegotiated with the participant. 
This is preferably systematically done but at least before any 
communication about health information is done.  
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ABSTRACT 
The last decade has seen an exponential growth in genetic research. In 
order for such research to be possible, there is a need for collections of 
human tissue and extracted DNA. The storage and use of such 
biological materials raise certain ethical questions, specifically related to 
consent, risk, privacy and return of results. The last century has also 
seen a shift in the way children are treated and respected. Once they 
were thought of as second-rate citizens, but now they are seen as a 
population deserving extra respect and consideration. Also in medical 
research, there has been a shift. It is mostly not questioned that 
research on children and on their DNA should be done, but such 
research has certain ethical implications. In this doctoral thesis, we have 
investigated the ethical implications of the storage and use of stored 
tissue samples from minors for genetic research. In this concluding 
chapter, we shall first provide a summary of our findings. Next we shall 
formulate a set of recommendations, which can be used or further 
elaborated by professional organizations. To conclude we point out the 
limitations of our research and some directions for further research. 
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SUMMARY OF FINDINGS 
In the introduction we have discussed the fact that biobanks raise 
specific ethical questions. The ones most discussed are related to 
informed consent, risk, privacy, the return of individual research results, 
solidarity, ownership and commercialization. Also, the study of genetic 
material from minors can yield valuable information for medical science, 
especially since many studies nowadays do not only study the 
prevalence of genes but the relationship between genes and the 
environment. However, such research poses specific questions which 
are different from those posed by adults, given the fact that minors have 
no or limited autonomy and capacity to consent to research. Also, these 
questions are different from those raised by pediatric clinical trials, 
although many of the concepts, such as minimal risk and benefit, that 
are predominant in the literature and guidelines on pediatric biobanks, 
are deduced from the clinical trials context. However, the fact that we 
are talking here about genetic research, done on stored tissue samples 
rather than the child’s body, and the fact that such research is non-
therapeutic and does not generate direct benefit for the participant, 
raises different issues and makes the ethical discussion on clinical trials 
not directly transferrable to the context of pediatric biobanks. In the first 
part of our doctoral project we have performed a review to find out what 
are the ethical issues surrounding this subject as they are discussed in 
the literature and guidelines? In the second part we have investigated 
the current ethos. We have queried the opinions of lay people through 
qualitative, focus group research, and of professionals through in-depth 
interviews (qualitative research) and a survey. In the third part we have 
performed an in-depth theoretical reflection on the issues of risk, benefit 
and solidarity, broad versus specific consent and the issue of returning 
individual research results or incidental findings in the case of pediatric 
biobanks.  
 
In chapter 1 we performed a review of the existing guidelines. We 
investigated 29 international, European and policy documents. We 
found out that 18 out of 29 had a specific section on stored tissue 
samples and children. The majority of documents discussed the fact 
that a parent or legal guardian should consent, that children should 
have a right to assent, and that they should be recontacted when they 
reach the legal age of competence or a certain maturity level. Some 
documents also referred to the general principles of non-therapeutic 
research on vulnerable populations, which are the condition that such 
research should not pose more than minimal risk, that there should be 
either a direct or group benefit, and that the research can only be done 
if it cannot be done on adults. Only 7 out of 29 documents mention the 
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need for extra ethics committee oversight when children are enrolled. 
The different ethical themes were not consistently covered by each 
document. We found no reflection on the content of parental consent 
(broad versus specific consent) or the issue of returning individual 
results to participants. 
 
In chapter 2 we performed a systematic review of the ethical literature 
surrounding biobanks and children. We found 20 articles, including 
theoretical reflections, empirical findings and documents discussing the 
use of blood spot cards for research. Similar themes were discussed in 
the ethical literature as in the guidelines discussed in chapter 1. There 
was consensus that such research should only be done if there is at 
least consent by the parents. The majority of authors agreed that 
parents could consent to the use of stored tissue samples for genetic 
research, but all authors also agreed that children should be asked to 
assent. There was no agreement on the specific age children could be 
asked to consent, or whether a maturity standard would be more 
suitable. In principle, people agreed that the right to withdraw was 
important for children and young adults and that they should also be 
given the opportunity to reconsent when they reached a certain age or 
maturity level. This is the temporal component of the scope of consent. 
Much less discussed was the content of parental consent (broad versus 
specific). Authors also discussed the question of risks and biobank 
research. These risks were primarily seen as privacy related, but also 
physical and moral risks and harms were mentioned. However, the 
question how to assess the minimal risk standard in cases of biobank 
research remained open. We found one author questioning the principle 
of group benefit, which was considered too restrictive. The issue of 
return of individual results or incidental findings was not discussed in 
much depth, so the question remains which rights parents have to this 
type of information on their children and whether researchers have a 
greater duty to return important information when participants are 
children. 
 
In chapter 3 we described the findings based on ten focus group 
discussions we conducted with adults and teenagers on the topic of 
genetic research on stored tissue samples from minors. Themes 
introduced during the discussion were consent, assent, risk, privacy and 
return of results. We found that participants understood the importance 
of such research, but that they thought it should be minimally 
burdensome for children. Burdens quoted were primarily related to 
venepunctures and the fact that children might experience fear during 
the procedures. The risks associated with genetic information in the 
context of pediatric research were mentioned by two participants. We 
found a great trust in parental decision making both among adults as 
well as among teenagers. It was assumed that parents would make 
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decisions on research participation in good faith. Also, participants had 
no problem with the fact that relevant medical information would be 
communicated with children and parents at the same time. People 
thought, however, that children should be given information on their 
level, and be gradually more involved in the decision making as they 
would grow older. 
 
In chapter 4 we describe findings based on ten in-depth interviews with 
professionals in the United Kingdom, Belgium and Saudi Arabia 
involved in or with ties with genetic research on pediatric tissue 
samples. Themes introduced during the discussion were consent, 
assent, the usefulness of research, the specialty of genetic information, 
return of results and minimal risk. We found that people were adverse of 
bureaucratic consent procedures, and thought that good governance of 
samples, good research design and proper communication with parents 
and children was more important. Ethics committees were seen as 
having an important task in reviewing research protocols. They thought 
it was difficult to set a fixed age threshold for assent or consent, and 
maturity of minor participants should be assessed by the people 
involved, not by fixed guidelines. There was some disagreement on the 
weight that should be put on the right of the child to dissent. People 
though that the principle of research on children for the benefit of 
children made sense, but that this should be broadly interpreted. They 
also agreed that research should not burden children: preferable 
samples and data should be reused, and if that was not possible, 
procedures such as mouth swabs or anesthetic creams should be used. 
Many did not see genetic information as more risky than other medical 
information, especially not in a society with a system of public health 
insurance, and not private insurance. The main difference between 
genetic and other information was the familial nature of the former.  
 
In chapter 5 we described the findings of a survey among Belgian 
professionals working in the field of genetics. We asked about the 
usefulness of stored tissue samples of minors, the modes of consent 
and assent, the right to withdraw, the age of understanding storage and 
research and the scope of parental consent. We found that the vast 
majority of respondents thought that genetic data from children was 
useful for research (92%), and that parents could be asked to consent 
to such research (82.5%). But 76.5% also thought that children should 
be given the opportunity to assent once they could understand the 
implications of storage and genetic research. The right of young adults 
to withdraw samples when they reach the age of legal competence was 
not questioned by the vast majority (95.2 %). A small majority thought 
the age at which young people could understand the storage of samples 
(51.5 %) and genetic research (53.1 %) was 16-18. With regard to the 
content of parental consent, the majority of respondents thought that 
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parents should be allowed to consent to either well-specified research 
(79.4 %) or research for a specific condition (77.8 %). A little less than 
half of them thought parents could consent to any possible future 
research (47.6 %). 
 
Chapter 6 contained a theoretical reflection on the principles of 
solidarity, minimal risk and benefit in the case of pediatric biobanks. 
This reflection was also inspired by our empirical research. We started 
from the assumption that, for medical research with potential to aid and 
treat certain diseases, researchers can appeal to the principle of 
solidarity to enroll participants. However, this principle only applies in a 
restricted sense to children: they are vulnerable in that they have a 
limited autonomy and understanding, and as such should not be 
exposed to more than minimal risks. Risks associated with biobank 
research discussed most in the literature are related to genetic privacy 
and the fear the information of participants may be abused by third 
parties such as private insurance companies. We think however, that 
these risks should be solved by the public authorities, and are not as 
such a reason why children should not participate in such research. 
Empirical research has shown that people worry most about the fact 
that non-therapeutic medical research should not burden children. In 
order to be as minimally invasive as possible, data and samples should 
be reused or procedures such as mouth swaps and anesthetic creams 
should be used. Also, as small children’s wishes are unknown and as 
they develop while they grow older, there is the risk that certain 
research would go counter their wishes, especially since research on 
stored tissue samples can extend over time. We think children have a 
right to a say on the destination of their samples, and that this right 
gradually increases when they develop more and more autonomy. 
Biobanks should make sure that they gradually put more emphasis on a 
child’s assent and eventually consent. Another principle is that of 
benefit. Although the possibility of direct benefit to a child is small in 
case of non-therapeutic research, guidelines and literature mention also 
‘group benefit’. This is a concept of clinical trials’ ethics that cannot be 
easily transferred to genetic research, as there are more steps needed 
towards an actual cure or treatment of conditions. But ethics committees 
should still evaluate the potential benefit of research when they evaluate 
protocols.  
 
In chapter 7 we investigated the issue of consent with regard to 
pediatric biobanks. Especially the scope of consent was discussed. The 
scope of consent has two dimensions. First there is the temporal scope. 
In this respect, the fact that children grow towards maturity and have a 
right to their own opinions implies that the temporal scope of parental 
consent is limited. Hence, young adults should be given the opportunity 
to withdraw their samples and data from biological sample collections if 
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they do so wish. Preferably they should also be recontacted for renewed 
consent when they reach a certain age or maturity level. This may not in 
all cases be feasible, for example if people change address. Therefore, 
the duty to recontact should be seen on a best effort basis. However, 
given the emergence of new technologies recontacting might become 
easier in the future. Moreover, pediatric research on stored tissue 
samples often assumes frequent contact between researcher and 
participants, which makes reconsenting easier. The content of consent 
is the other dimension of scope. Also in the general discussion on 
consent and biobanks the question whether (adult) participants can be 
asked to consent to future unspecified consent (which is often referred 
to as broad consent) is still open. There seems to be at least some 
agreement that broad consent is a feasible option, provided participants 
have the right to withdraw their samples and that there is ethics 
committee oversight of research protocols. In case of pediatric stored 
tissue samples this issue is further complicated by the fact that parents 
give consent for their children. Can parents be allowed to give broad 
consent for any future research on their children’s samples? On the one 
hand, children, as persons growing towards autonomy and acquiring 
their own values, should be given the opportunity to express these 
values. On the other hand, it may also be an administrative overhead to 
recontact children and/or their parents for each change in research 
protocol. Science is, however, not value-free: there is much general 
support for research that would lead to treatment or better 
understanding of medical conditions. It may be alright to assume that 
such research is part of the original parental consent and that children 
would not object to this. Other types of research, such as related to 
behavior or IQ are much more value-laden. Parents or their older 
children should be made aware of such research, and given the 
opportunity not to participate. Ethics committees may decide when 
research takes a big leap forward from the original spirit of the consent 
and whether recontact is necessary.  
 
In chapter 8 we investigated the issue of returning individual results and 
incidental findings in the case of pediatric biobanks. In this chapter we 
took a more deontological approach. Our empirical research has 
suggested that children and parents do not mind sharing medical 
information. However, much research has been done in the field of 
predictive genetic testing and carrier testing, findings we also included 
in our discussion. The issue of returning individual results is much 
discussed in case of adult biobanks. Basically three stances can be 
distinguished. A first stance is that no individual results are returned, 
based on the idea that such results would generate anxiety, that it would 
enhance the therapeutic misconception and that it would burden the 
researchers. A second stance is that, based on respect of autonomy of 
the participants, results should be returned if they do so wish. A third 
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approach is based on the potential benefits and states that results 
should be returned if they are clinically relevant and scientifically valid. 
We have discovered two dimensions in the discussion. First, there is the 
question of the right of participants to such information. Second there is 
the question about the duty of the researcher to provide such 
information. Especially when participants are children, these two 
dimensions become apparent. First, as children do not themselves 
enroll in the research, the question becomes related to the parent’s right 
to know and not to know certain genetic information about their children. 
We think that parents do not have the right to opt out of receiving 
information that may be relevant to the health of their children. In this 
case, this would refer to early-onset treatable and preventable 
disorders. We also believe that, in the line of genetic testing, parents do 
not have the right to know all possible information that such research 
should generate. Revelation of information about conditions that are not 
early-onset treatable and preventable should hence be postponed until 
the young person reaches the age of competence. In the dimension of 
the duty of the researcher, we think that in case of pediatric biobanks, 
the duty to return information about early onset preventable or treatable 
conditions is more stringent than in case of adults, as children are a 
vulnerable population and are not participants out of their own volition. 
From a practical side, studies involving children mostly assume a more 
direct contact between researchers and children. We do admit that there 
may be an exception for epidemiological research that puts no burden 
on children and that implies no contact between researcher and the 
child. 
 
RECOMMENDATIONS 
Genetic research on stored tissue samples from children is growing 
steadily. We have identified and investigated the ethical issues 
associated with such research. In the following paragraphs we provide 
some suggestions for recommendations as to how tissue samples from 
children can be stored and used for research in an ethical way. These 
recommendations are based on the research presented in this doctoral 
thesis. We plan to further elaborate them together with professional 
organizations.  
Preamble 
1) The changing status of the child in society and family requires an 
adequate reflection on the participation of children in genetic research 
on stored tissue sample collections (also called biobanks). Children are 
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nowadays considered as individuals with a right to respect for their own 
values and opinions.  
 
2) There is support for and need for research on stored tissue samples 
from minors in empirical and theoretical literature. However, it is 
acknowledged that such research poses specific ethical issues. 
Professional organizations need to reflect on the issues associated with 
the participation of children in such research and provide a thorough 
reflection and recommendation on these issues in their guidelines. 
 
3) Genetic information is special in that it can potentially reveal much 
information about the health status of the individual. Research on 
genetic information should therefore be done in a context of good 
governance and data protection. 
Risks  
There is an important distinction between research on children 
themselves, as for example in clinical trials and research on stored 
tissue samples from children. The requirement that pediatric research 
should not pose more than minimal risk for participants needs to be 
specifically interpreted in the latter context. Basically, three groups of 
risks can be identified in theoretical and empirical literature. First, there 
is the risk associated with confidentiality and third party access to 
genetic information. Second, there is the risk of emotional and physical 
harm. Third, there is the risk that values of participants are not 
respected. As stated in the preamble, the first type of risk should be 
minimized by good governance and adequate data protection schemes. 
We shall discuss the third risk under the heading of ‘consent’.  
 
Recommendation #1: Research on stored tissue samples should 
not burden children physically or emotionally.  
 
Preferably samples should be used that are gathered in a diagnostics 
context. If this is not possible, less invasive techniques such as mouth 
swabs should be used. If additional data are gathered next to samples, 
this should be done in a child-friendly way. If possible, gathering of 
samples, measurements and observations should be done in an 
environment that is familiar to the child or child-friendly.  
Benefits 
Genetic research on stored tissue samples typically provides no 
personal benefit to the participant. Hence, any reference to the 
requirement that pediatric research should provide such benefit is 
misleading and should be avoided. Also, the requirement that, if there is 
no personal benefit, pediatric research should provide benefit to children 
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with the same age or condition is problematic in the context of genetic 
research on stored tissue samples, as such research is often still many 
steps away from actual clinical application. The reference to such group 
benefit should be avoided if it can not be made more explicit. However, 
given the vulnerability of children in general and in research context, 
some restriction on the type of research is needed.  
 
Recommendation #2: Genetic research on stored tissue samples 
from children can only be done if the same research cannot be 
done on samples from adults. 
 
This means that such research can be done regarding pediatric 
diseases, but also regarding other diseases that may be caused by 
factors that occur during childhood. 
Consent 
The parental right to make decisions on behalf of children is not 
questioned in theoretical and empirical studies. However, this right is 
accompanied by the need for respect for the growing autonomy of 
children and the right to have their own values. As it is impossible to set 
a fixed age threshold as of when children may be expected to be able to 
assess for themselves whether they would want to participate or not, 
maturity should preferably be assessed by researchers, parents and 
children on a case-by-case basis. This is appropriate especially if there 
is frequent contact between researchers and children. If there is a one-
time donation of samples without further contact, this may be more 
difficult.  
 
Recommendation #3: Consent for research on stored tissue 
samples is needed. This should be done by both parents or the 
legal guardian. 
 
Given the familial nature of genetic information, it is good practice to 
involve both parents in the decision making, although this may not 
always be practically feasible, as many children do not live with both 
their biological parents.  
 
Recommendation #4: The focus of the right to have a say on the 
storage and use of samples shifts from the parents to the child or 
young adult as he or she grows older. 
 
Recommendation #5: Children should receive information on their 
maturity level and a child’s assent or dissent should be respected. 
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Whether a child is sufficiently capable of receiving certain types of 
information or whether he or she is able to provide assent should be 
based on an assessment of his or her maturity level rather than on a 
fixed age threshold. This assessment should be done by the researcher, 
research nurse or clinician involved in research, in dialogue with the 
parents. As for the issue of dissent, given the fact that the research in 
question has no direct benefit for the child, a child’s dissent should be 
taken into account, unless there are compelling reasons not to do so.  
 
Recommendation #6: Mature minors should be recontacted and 
given the opportunity formally to withdraw their samples when 
they reach the age of understanding or the age of majority. 
 
This should be done when the young person is considered sufficiently 
mature to do so, and may happen at a lower age than the legal age of 
competence. In a setting where there is frequent contact between 
researchers and participating families this can be assessed on a case-
by-case basis. If there is no further contact with families after the 
donation, a fixed age threshold can be used. Again this threshold may 
be lower than the legal age to consent. We acknowledge that in some 
cases recontact is impossible, as participants may have changed 
addresses. In such cases, an ethics committee may decide whether 
research on samples can continue. 
 
Recommendation #7: Parents and young people should be notified 
of new research done on samples and given the possibility to 
refuse to participate to research if they object to it. 
 
Parents should not be allowed to give full broad consent to any genetic 
research on the stored tissue samples of their children. It is unfeasible 
to recontact parents and/or young people for each small change of 
research protocol. However, some research may be more sensitive than 
other research. The duty to respect values of children and their growing 
autonomy, together with the fact that their samples are in a collection 
because their parents consented, imply that full broad consent should 
be avoided. 
RETURN OF INDIVIDUAL RESULTS 
Non-therapeutic research on stored tissue samples in principle does not 
aim to provide health benefits to participants. Nevertheless, the 
communication of certain incidental findings and certain individual 
results may result in health benefits. Many biobanks have a policy not to 
return such results because of the administrative overhead this may 
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induce. Although this may be a valid policy in case of adult participants, 
for pediatric biobanks the situation is different. 
 
Recommendation #8: Parents should not be allowed to opt out of 
receiving information about preventable or treatable early-onset 
diseases. 
 
Although biobanks with adult participants may offer the opportunity to 
decide whether one wants to receive individual results or not, they 
should offer no such option when participants are children. In this 
respect, the potential benefits for the child, in case of preventable or 
treatable early-onset diseases, override the parental autonomy.  
 
Recommendation #9: Parents should not be given access to any 
and all genetic data that research may produce. 
 
In the literature it has been demonstrated that providing genetic 
information about conditions that are not preventable or treatable or 
early-onset or about carrier-status may cause anxiety with parents. 
Moreover, it is part of the right of the child to an open future that he or 
she can decide for him or herself whether certain genetic information is 
revealed or not.  
 
Recommendation #10: Biobanks should consider returning 
information about preventable or treatable early onset conditions 
when participants are minors. 
 
Given the fact that children are a vulnerable population and their 
enrolment in research is not based on their own fully informed consent, 
the duty to care and to provide information that may be of health benefit 
to them is higher than when participants are fully competent adults. This 
is especially so if there is frequent contact between researchers and 
families.  
Ethics Committee Oversight 
Children are a vulnerable population. Therefore, there is need for 
careful ethics committee oversight.  
 
Recommendation #11: The ethics committee supervising research 
on stored tissue samples from minors should contain specialists 
in pediatric research, pediatric genetics and child psychology. 
 
Tasks of this ethics committee include deciding whether research is not 
burdensome for children, whether certain research is very different from 
original protocols and hence whether parents and children should be 
Summary and Recommendations 
212/233 
recontacted, what mechanisms are put in place to assess a child’s 
understanding of the research and to evaluate information brochures. 
They should also evaluate whether researchers are capable of 
assessing a child’s dissent. Although the principle that pediatric 
research should provide ‘group benefits’ to children with the same age 
or condition is hard to assess in case of genetic research on stored 
tissue samples, an ethics committee should assess whether the 
research at least has the potential to fulfill this requirement.  
LIMITATIONS AND SUGGESTIONS FOR FURTHER 
RESEARCH 
We admit that our research has several limitations and that more 
research is needed in this area. To begin with, we have performed 
empirical research followed by a theoretical reflection. Ideally, this 
reflection would again, after some time, be followed and tested by new 
empirical research in the future. This is needed because public opinions 
may change overtime. We must only look at the Alder Hey scandal in 
the United Kingdom to see how certain events can influence public trust 
in medical science. We also acknowledge that our research is culturally 
biased in that it assumes a public health system and trustworthy society. 
Also, we assume a model of child/parent relationship that is prevalent in 
Western countries, but not in others. Therefore, our findings may not be 
transferrable to other contexts, and more research needs to be done 
there.  
In our discussion, we have covered an age range between birth and the 
legal age of competence. We acknowledge that, for practical 
implementation of our findings, more study and understanding of the 
needs of each individual age group is necessary. Such study can take 
the form of new qualitative research with children of different ages and 
their parents. Also we assumed both healthy participants as well as 
participants with a medical condition. However, these two groups may 
need different accents and a slightly different approach. Also, parents of 
children with a medical condition may be more vulnerable than parents 
of healthy children, which may either lead to more protectiveness or to 
more willingness to enroll children. We have also not discussed the 
issue of children with a mental retardation who, perhaps, may never 
reach the age of competence. We acknowledge that especially in 
genetic research many children may fall in this category and believe that 
this topic indeed needs special attention.  
We have assumed that science is not value free and that there may be 
different categories from acceptable research to less acceptable 
research or not acceptable at all. To-date we found no adequate 
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subdivisions of these categories on which decisions of recontact may be 
based. We think that extensive empirical research and theoretical 
reflection is needed here. Until that is done, common sense may be the 
best basis to go on. 
On the practical side, we have concluded that the reuse of existing 
samples and information may be the most appropriate when children 
are concerned, as this would imply the least burden on them. However, 
the reuse of samples, for example blood spot cards, raises new ethical 
questions about consent and notification of use. Hence, the 
implementation of such an approach requires additional reflection, both 
on the ethical as well as on the logistical side. Related to this, we have 
suggested the use of new technologies to keep participants and the 
general public informed about research and to offer them the possibility 
to form an opinion. But again, such new technologies may require 
additional ethical reflection and a thorough review of the ethical and 
logistical issues. 
The possibility of (cheap) full genome sequencing for research in the 
near future, the fact that such information is more and more available in 
electronic format and the fact that full anonymization of samples has 
become virtually impossible raise additional ethical issues, also with 
respect to minors. These issues also need further reflection.  
We have assumed that ethics committees take up a big part of the 
responsibility of evaluation of this type of research. This assumes that 
their members are properly educated about the ethical sensitivities in 
this area, and that they not, for example, just take over principles from 
clinical trials. More research is needed to examine how ready they are 
to do so and what extra training they may need.
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SCIENTIFIC SUMMARY 
Introduction 
In history, children were often regarded as second-rate citizens, both in 
society in general and in medical research specifically. They were 
considered expendable and used as preferred research subjects, for 
example to test new vaccines. Much has changed during the last 
century, as clinical research on children became the subject of ethical 
reflections resulting in guidelines that try to define a balance between 
participation in research and protection against abuse. 
Recently there has been a rise in genetic research in general. Such 
research is supported by the availability of tissue collections, often 
referred to as biobanks. The establishment of such biobanks has been 
associated with certain ethical issues, which are discussed in some 
depth in the literature. Also research on stored tissue samples from 
children can yield valuable information. This raises specific ethical 
issues which are not completely analogous to the issues raised by the 
use of adult biological materials. Although much has been written about 
both the ethical issues related to pediatric clinical trials and those 
related to adult biobanks, much less has been written about the ethical 
issues related to pediatric biobanks. These include the scope of 
parental consent, the balance between risks and benefits and the return 
of individual research results. In this doctoral thesis we have 
investigated and assessed these themes in order to provide guidance 
and recommendations. 
Study Design and Results 
Our ethical inquiry and subsequent recommendations are based on four 
steps. First, we performed a state-of-the-art of the concepts and themes 
in current literature and guidelines. Second, we investigated the current 
ethos and checked it against the theoretical state-of-the-art. Our 
investigation of the ethos is done through empirical research of opinions 
of lay people and professionals. Third, concepts and themes that arose 
from the first and second part are elaborated, investigated and checked 
for consistency in in-depth theoretical reflections. Finally, based on the 
cumulative experiences from the previous parts, we have formulated 
recommendations.  
Part 1: State-of-the-art of the ethical aspects of genetic research on 
pediatric stored tissue samples 
We performed two reviews. With the first review we investigated 
guidelines and position papers on the topic of biobanks and biological 
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sample collections to check what they recommend for pediatric 
participants. This review had the form of a systematic review. We found 
18 documents that dealt with the issue of stored tissue samples of 
minors separately. The content of these documents was categorized 
according to four themes: consent, principles of non-therapeutic 
research on vulnerable populations, ethics committee approval and 
difference between anonymous and identifiable samples. With the 
second review we investigated the existing ethical literature on the topic 
of research on stored tissue samples from minors. We found 20 
theoretical and empirical documents dealing with the issue. After review, 
we distilled five clusters of themes: consent, risks, benefits, return of 
results and ownership. We did not find a consistent covering of the 
ethical themes in either the guidelines or the ethical literature. 
Part 2: Ethos: Empirical inquiries into the storage and use of 
pediatric tissue samples for genetic research 
In this part, we studied the opinions of lay people and professionals on 
the topic of using stored tissue samples from minors for genetic 
research. 
To query the opinion of lay people we performed ten focus group 
discussions (qualitative method), five with adults and five with young 
people (aged 15-19). After analysis of the discussions, we found the 
following recurrent categories: the requirement that research should not 
pose any burden on children and that it should benefit other children, 
the trust people had in the role of parents, the need for information and 
the growth towards autonomy. Both the adults and the teenagers we 
interviewed thought that the inclusion of tissue samples from minors in 
research had ethical implications. A major concern was that non-
therapeutic research would pose no extra burden on children, which 
would assume the use of non-intrusive methods of gathering samples 
and the use of samples that were gathered in a diagnostic context. The 
overall impression was that parents would be the best persons to make 
decisions on behalf of a small child, and that the same parents would 
engage their children in the decision making when they grew older. 
To query the opinion of professionals, we took a two step approach. We 
performed ten semi-structured interviews (qualitative method) with 
professionals from Belgium, UK and Saudi Arabia involved in genetic 
research on stored tissue samples from minors. After analysis, we found 
that researchers were concerned about too bureaucratic consent 
procedures. But we also found the need for guidance from ethics 
committees with regard to the scope of consent. Interviewees thought 
that children should not be burdened with research and should be told, 
in their own language, about the research. Secondly, we also did a 
survey among Belgian geneticists. We found that the vast majority of 
the respondents (92 %) thought that research on stored tissue samples 
is useful. A majority of respondents stated that parental consent is valid 
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(82,5 %) and 76,5 % thought that children should also be given the right 
to assent when they understood the implications of storage of biological 
samples and of genetic research. A small majority put the age at which 
young people can understand storage or research rather high: 16-18 
years (51 % and 53,1 % respectively). Although there is some 
consensus in the literature that donors should be allowed to give broad 
consent for future research on their biological samples, only 47,6 % 
thought that parents should be allowed to consent to any future 
research on their children’s samples. 
Our empirical inquiry has demonstrated that there is a support for and a 
belief in the usefulness of genetic research on stored tissue samples 
from children and that the right of parents to consent to such research is 
not questioned. However, there is a strong emphasis on the fact that 
research should not burden children. Also, children should be involved 
in the decision making process as they grow older, but it is 
acknowledged that the capacity of a child to understand what is at stake 
does not correspond to fixed age thresholds and should preferably be 
assessed on a case-by-case basis.  
Part 3: Normative and theoretical reflections  
In this part, we provided in-depth normative and theoretical reflections 
on three important topics with regard to the ethical use of stored tissue 
samples for genetic research (risk and benefit/consent/return of 
individual results), based on the findings from part one and two and 
supplemented by theoretical foundations. In a first reflection we 
question whether and how the idea of ‘minimal risk’ is applicable to 
pediatric research on stored tissue samples. The duty to solidarity, 
which is often quoted in the context of biobank participation, is limited 
when participants are minors. We argue that the main issues at stake 
are the fact that research should not burden children and that their 
values are respected. Also, the prerequisite of ‘group benefit’ as it is 
often used in the context of clinical trials is hard to maintain when 
genetic research is at stake, as future benefits of such research are 
hard to define at the onset. The requirement that research on children’s 
tissue can be done if the same research cannot be done on adults is 
more straightforward. 
A second reflection deals with the scope of parental consent for non-
therapeutic genetic research. This scope has two dimensions, a 
temporal one and one related to the content of what is consented to. 
The temporal scope of parental consent is limited. Young adults have 
the right to decide autonomously on the faith of their samples once they 
reach the age of understanding or competence. With regard to the 
content of what is consented to, there is a growing tendency to ask for 
broad consent to any future genetic research when participants are 
adults. We argue that this tendency cannot be directly transferred to 
parental consent. As children have the right to develop and exercise 
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their own autonomy and have their own values, and as research and 
science are not completely value-free, they should be given the 
opportunity to revise the consent given by their parents for research on 
their samples. 
A third reflection deals with the question of the return of individual 
results in pediatric biobanks. Biobanks with adult participants may have 
different policies with regard to the return of such research. They can 
decide not to return any results, return results that are clinically relevant 
and can be acted upon or leave the choice to the participants whether 
or not to receive specific results. The situation is different when 
participants are children. As they have not autonomously decided to 
participate in the research and are a vulnerable population the duty to 
return information that may be relevant to their health is higher. Also, 
parents do not have the right to opt out of receiving such information. 
However, parents should not be given access to genetic information 
about their children that has no direct relevance to their health or 
important clinical significance. 
Conclusion and Recommendations 
Based on the inquiries in parts one and two and the in-depth reflections 
of the third part, we have formulated recommendations with regard to 
the use of stored tissue samples from minors. These recommendations 
can be used and further elaborated by professional organizations. With 
regard to risks and benefits we state that research on stored tissue 
samples should not burden children physically or emotionally and that 
genetic research on stored tissue samples from children can only be 
done if the same research cannot be done on samples from adults. With 
regard to consent, we state that consent by a legal guardian or parent is 
needed, and that the focus of the right to have a say shifts from the 
parent(s) to the children as the latter grow older. All children should 
receive information on their level and a child’s assent or dissent should 
be taken into account. Mature minors should be recontacted and given 
the opportunity formally to withdraw their samples when they reach the 
age of understanding or the age of majority. Parents and young people 
should be notified of new research done on samples and given the 
possibility to refuse to participate to research if they object to it. With 
regard to the return of individual results, we state that parents should 
not be allowed to opt out of receiving information about preventable or 
treatable early-onset diseases. Also, they should not be given access to 
any and all genetic data that research may produce. Biobanks should 
consider returning information about preventable or treatable early 
onset conditions when participants are minors. Finally, the ethics 
committee supervising research on stored tissue samples from minors 
should contain specialists in pediatric research, pediatric genetics and 
child psychology.
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SAMENVATTING 
Inleiding 
In de recente geschiedenis werden kinderen vaak als tweedehands 
burgers beschouwd, zowel algemeen maatschappelijk als specifiek in 
medisch onderzoek. Men beschouwde hen als vervangbaar en ze 
werden ingezet als onderzoeksobjecten, bijvoorbeeld bij het testen van 
nieuwe vaccins. Gedurende de twintigste eeuw is er echter veel 
veranderd. Klinisch onderzoek op kinderen werd onderworpen aan 
ethische beschouwingen die op hun beurt leidden tot richtlijnen die een 
evenwicht zochten tussen pediatrische deelname aan onderzoek en 
bescherming tegen misbruik.  
Recentelijk kende ook het genetisch onderzoek een enorme vlucht. Zulk 
onderzoek maakt vaak gebruik van collecties van lichaamsmateriaal, 
vaak biobanken genoemd. Ook onderzoek op lichaamsmateriaal van 
kinderen kan interessant zijn. Echter, de ethische vragen die zulk 
onderzoek oproept zijn vaak verschillend van de vragen die het gebruik 
van lichaamsmateriaal van volwassenen oproept. Zowel als over de 
ethische kwesties die te maken hebben met klinische proeven als over 
de ethische kwesties die te maken hebben met lichaamsmateriaal van 
volwassenen is er al veel geschreven. Echter, de ethische vragen die 
het gebruik van lichaamsmateriaal van kinderen oproept zijn veel 
minder besproken. Zulke vragen hebben te maken met de reikwijdte 
van de ouderlijke toestemming, het evenwicht tussen risico’s en 
voordelen en de plicht om individuele onderzoeksresultaten mee te 
delen aan de deelnemers. In deze doctoraatsverhandeling hebben we 
deze vragen onderzocht en beoordeeld, met als doel aanbevelingen te 
formuleren.  
Studieopzet en resultaten 
Ons ethisch onderzoek bestaat uit vier fases. Eerst hebben we de 
huidige stand van zaken onderzocht in de bestaande richtlijnen en 
literatuur. Vervolgens hebben we het heersende ethos onderzocht door 
middel van empirisch onderzoek. We onderzochten de meningen van 
leken en professionelen. Dan hebben we de concepten en thema’s die 
uit deze eerste twee fases bleken verder uitgewerkt en onderzocht en 
theoretisch onderbouwd. Als laatste hebben we aanbevelingen 
geformuleerd die gebaseerd zijn op onze ervaringen uit de vorige drie 
fases.  
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Fase 1: Stand van zaken  
In deze fase deden we twee systematische reviews. Eerst onderzochten 
we richtlijnen en standpunten over biobanken en verzamelingen van 
lichaamsmateriaal. We bekeken wat deze aanraden in verband met het 
gebruik van lichaamsmateriaal van kinderen. We vonden 18 
documenten die specifiek iets vermelden over minderjarigen. De inhoud 
van deze documenten werd gecatalogiseerd in vier thema’s: 
geïnformeerde toestemming, principes van fundamenteel onderzoek op 
kwetsbare groepen, goedkeuring van ethische comités en het verschil 
tussen anonieme en identificeerbare stalen. In de tweede review 
onderzochten we de bestaande ethische literatuur over onderzoek op 
stalen van minderjarigen. We vonden 20 theoretische en empirische 
documenten waaruit we vijf thema’s extraheerden: toestemming, 
risico’s, voordelen, terugkoppeling van resultaten en eigendom. We 
vonden geen consistente behandeling van de thema’s noch in de 
richtlijnen, noch in de literatuur. 
Fase 2: Ethos 
In dit gedeelte hebben we de meningen van leken en professionelen 
over het gebruik voor genetisch onderzoek van opgeslagen 
lichaamsmateriaal van minderjarigen bestudeerd.  
Om de meningen van leken te bestuderen organiseerden we tien 
discussiegroepen, vijf met volwassenen en vijf met jonge mensen 
tussen 15 en 19 jaar. Na analyse van de discussies vonden we de 
volgende terugkerende thema’s: de vereiste dat onderzoek kinderen 
niet extra zou belasten, dat het andere kinderen ten goede zou komen, 
het vertrouwen dat mensen hebben in de rol van ouders, de noodzaak 
van informatie op het niveau van de deelnemers en de groei naar 
autonomie van kinderen. Zowel de volwassenen als de 
jongvolwassenen dachten dat er specifieke ethische vragen verbonden 
zijn aan het gebruik van lichaamsmateriaal van minderjarigen. Men 
benadrukte het feit dat onderzoek kinderen niet zou belasten en dat 
stalen verzameld zouden worden door middel van niet-intrusieve 
methodes of dat diagnostisch materiaal hergebruikt zou worden. De 
algemene indruk was dat ouders het best geplaatst waren om 
beslissingen te nemen voor kleine kinderen en dat deze ouders hun 
kinderen geleidelijk meer zouden betrekken in het beslissingsproces als 
deze kinderen ouder werden. 
Om de mening van professionelen te onderzoeken, gebruikten we twee 
methodes. We deden tien semigestructureerde interviews met 
professionelen uit België, het Verenigd Koninkrijk en Saoedi-Arabië, die 
betrokken waren bij onderzoek op lichaamsmateriaal van minderjarigen. 
Na analyse vonden we dat de onderzoekers bezorgd waren dat 
bepaalde vereisten voor geïnformeerde toestemming te bureaucratisch 
waren. Maar ze begrepen ook de noodzaak van richtlijnen van ethische 
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comités met betrekking tot de reikwijdte van geïnformeerde 
toestemming. De ondervraagden dachten dat kinderen niet extra belast 
mochten worden met onderzoek en dat zij recht hebben om in 
aangepaste termen uitleg te krijgen over het onderzoek. We stuurden 
ook een vragenlijst naar Belgisch genetici. Na analyse vonden we dat 
een grote meerderheid van de ondervraagden dachten dat onderzoek 
op stalen van minderjarigen nuttig is (92 %). Een meerderheid dacht dat 
de toestemming van de ouders geldig is voor zulk onderzoek (82,5 %) 
en 76,5 % dacht dat kinderen de kans moesten krijgen om instemming 
te geven op het moment dat zij de implicaties van opslag van en 
onderzoek op lichaamsmateriaal begrepen. Een kleine meerderheid 
schatte de leeftijd waarop jonge mensen opslag of onderzoek konden 
begrijpen tamelijk hoog: 16-18 jaar. Hoewel veel auteurs ervan 
overtuigd zijn dat volwassen donoren een brede toestemming kunnen 
geven voor eender welk toekomstig onderzoek, dacht slechts 47,6 van 
onze ondervraagden dat dit ook geldig was voor ouderlijke toestemming 
voor het gebruik van stalen van minderjarigen.  
Onze empirische studies hebben aangetoond dat er steun is voor 
genetisch onderzoek op lichaamsmateriaal van minderjarigen en dat het 
recht van ouders om toestemming te geven voor zulk onderzoek geldig 
is. Er is echter een sterke nadruk op het feit dat zulk onderzoek de 
kinderen niet zou belasten. Ook moeten minderjarigen betrokken 
worden bij beslissingen als zij ouder worden, maar men beseft dat het 
vermogen van kinderen om zulke beslissingen te nemen niet strikt 
overeenkomt met vaste leeftijdsgrenzen.  
Fase 3: Theorie  
In dit gedeelte hebben we drie thema’s die uit de eerste twee fases te 
voorschijn kwamen verder uitgewerkt en onderzocht en theoretisch 
onderbouwd. Deze thema’s zijn ‘risico’s en voordelen’, ‘toestemming’ en 
de ‘terugkoppeling van individuele onderzoeksresultaten’. In een eerste 
stuk onderzochten we of en hoe het idee van ‘minimaal risico’ kan 
toegepast worden op pediatrisch onderzoek op lichaamsmateriaal. De 
plicht tot solidariteit, die vaak genoemd wordt in de context van 
deelname aan biobanken, is gelimiteerd als de deelnemers minderjarig 
zijn, omdat deze een kwetsbare groep vormen. We argumenteren dat 
de belangrijkste kwesties te maken hebben met het feit dat onderzoek 
geen extra last voor de minderjarige mag zijn, en dat de waarden van 
een minderjarige moeten gerespecteerd worden. Ook is de vereiste van 
groepsvoordeel, een vereiste die vaak gehoord wordt in de context van 
klinische trials, moeilijk hard te maken in het kader van genetisch 
onderzoek, omdat de toekomstige toepassingen van zulk onderzoek 
moeilijk vast te leggen zijn bij de aanvang. De vereiste dat onderzoek 
op lichaamsmateriaal van kinderen kan gebeuren indien zulk onderzoek 
niet mogelijk is op lichaamsmateriaal van volwassenen lijkt dan 
eenduidiger. 
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Een tweede beschouwing heeft te maken met de reikwijdte van 
ouderlijke toestemming voor fundamenteel genetisch onderzoek. Deze 
reikwijdte heeft twee dimensies, een tijdelijke en een die te maken heeft 
met de inhoud van de toestemming. De tijdelijke reikwijdte is beperkt: 
jonge volwassenen hebben het recht om autonoom te beslissen over 
hun stalen als zij de competentie en maturiteit bereikt hebben waarop zij 
hiertoe bekwaam zijn. Met betrekking tot de inhoud van de toestemming 
is er een groeiende tendens om een brede toestemming te vragen voor 
toekomstig onderzoek als de deelnemers volwassenen zijn. Wij 
beargumenteren dat deze tendens niet direct vertaalbaar is naar het 
gebruik van lichaamsmateriaal van kinderen en dus naar ouderlijke 
toestemming. Kinderen hebben het recht hun eigen waarden en 
autonomie te ontwikkelen, en aangezien onderzoek en wetenschap niet 
helemaal waardevrij zijn moeten ze de kans krijgen om de toestemming 
die hun ouders gegevens hebben te herzien.  
Een derde overdenking heeft te maken met de kwestie van het 
terugkoppelen van individuele onderzoeksresultaten in pediatrische 
biobanken. Biobanken met lichaamsmateriaal van volwassenen hebben 
verschillende opties in deze context. Men kan beslissen geen 
individuele onderzoeksresultaten terug te koppelen, enkel resultaten 
terug te koppelen die klinisch relevant zijn en implicaties voor de 
gezondheid van de deelnemers kunnen hebben. Of men kan de keuze 
aan de deelnemer laten of deze al dan niet individuele 
onderzoeksresultaten wenst te ontvangen. De situatie is anders als de 
deelnemers kinderen zijn. Deze hebben niet autonoom beslist om deel 
te nemen aan het onderzoek en zijn kwetsbaarder. Er is dus een 
grotere plicht, van de kant van de onderzoekers, om relevante 
informatie terug te koppelen. Ook hebben ouders niet zomaar het recht 
om te beslissen om helemaal geen relevante informatie over hun 
kinderen te ontvangen. Ze mogen anderzijds ook geen toegang krijgen 
tot genetische informatie van hun kinderen die geen directe relevantie 
voor hun gezondheid heeft. 
Conclusie en aanbevelingen 
Gebaseerd op ons onderzoek in delen een en twee en op de reflecties 
uit deel drie hebben we aanbevelingen geformuleerd over de opslag en 
het gebruik van lichaamsmateriaal van minderjarigen voor genetisch 
onderzoek. Deze aanbevelingen kunnen gebruikt worden en verder 
uitgewerkt worden door professionele organisaties. Met betrekking tot 
risico’s en voordelen vinden we dat onderzoek op lichaamsmateriaal 
geen extra lasten mag vormen voor kinderen, zowel fysisch als 
emotioneel, en dat zulk onderzoek toegestaan is als het onmogelijk is 
hetzelfde onderzoek te doen op stalen van volwassenen. Met 
betrekking tot geïnformeerde toestemming stellen we dat toestemming 
door een wettelijke voogd of ouder nodig is en dat kinderen gradueel 
meer inspraak krijgen als zij ouder worden. Alle kinderen zouden 
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informatie moeten krijgen op hun niveau en er moet rekening gehouden 
worden met de instemming of weigering van een kind. Oudere 
minderjarigen zouden de kans moeten krijgen om zich terug te trekken 
en/of hernieuwde toestemming te geven, in zoverre als dat praktisch 
haalbaar is. Ouders en kinderen moeten op de hoogte gebracht worden 
van nieuw onderzoek op de stalen en moeten de mogelijkheid hebben 
om te weigeren deel te nemen. Met betrekking tot de terugkoppeling 
van individuele onderzoeksresultaten stellen we dat ouders niet mogen 
beslissen om geen informatie te krijgen in verband met te voorkomen of 
te behandelen ziektes die zich tijdens de minderjarigheid manifesteren. 
Ook mogen zij geen toegang krijgen tot alle genetische informatie en 
data over hun kinderen die het onderzoek zou voortbrengen. Biobank 
onderzoekers zouden moeten overwegen informatie over te voorkomen 
of te behandelen ziektes die zich tijdens de minderjarigheid 
manifesteren terug te koppelen naar ouders en minderjarigen. Ten 
slotte moet het ethisch comité dat toezicht houdt over onderzoek op 
stalen van minderjarigen specialisten in pediatrisch onderzoek, 
pediatrische genetica en pediatrische psychologie bevatten.
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